NON-PATHOGENIC STRAINS OF HIV-1

Abstract: The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular regions of the HIV-1 genome.

Description: NON-PATHOGENIC STRAINS OF HIV-1 The present invention relates to non-pathogenic strains of HIV-1 and to components, parts, fragments and derivatives thereof and to genetic sequences derived therefrom and their use in the development of diagnostic and therapeutic compositions for the treatment and prophylaxis of AIDS and AIDS-related disorders. The present invention also relates to a method for attenuating pathogenic strains of HIV-1 by mutagenizing particular regions of the HIV-1 genome. Bibliographic details of the publications referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography. Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. Genomic nucleotide sequences of HIV-1 strains referred to herein are represented by their corresponding DNA sequence. Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the PHLS Centre for Applied Microbiology and Research, European Collection of Animal Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4 OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession Number V941031169. Viral isolate "C54" was deposited at ECACC on 14 February, 1995 under Provisional Accession Number . A summary of particular deletion mutants of HIV-1 of the present invention referred to herein is given in Figure 11. Acquired Immune Deficiency Syndrome (AIDS) and AIDS related disorders are the clinical result of infection by Human Immunodeficiency Virus type I (HIV-1) (Barre- Sinoussi et al, 1983). Infection by HIV-1 is generally characterised by progressive immune system damage (Teeuwsen et al, 1990; Clerici et al, 1989) leading to opportunistic infections, malignancies or wasting syndrome that constitute clinically- defined AIDS (Busch et al, 1991; Klaslow et al, 1990). The high mortality rate of individuals infected with HIV-1 together with the social and economic consequences of the continuing HIV-1 epidemic has created an urgent need for a safe and effective treatment and/or prophylaxis against the devastating effects of AIDS. However, despite over a decade of high level scientific research into the pathogenesis of HIV-1 and the clinical manifestations of the disease, together with a detailed molecular analysis of the virus, there has been little success in the development of an effective vaccine. To date, the most effective therapy is treatment with zidovudine (AZT) which delays the onset of full blown AIDS and alleviates to some extent the symptoms of HIV-1 infection. However, AZT is not an innocuous compound and AZT, metabolic products thereof or impurities therein can cause a number of side effects which limit long term treatment with the drug. Furthermore, AZT resistant isolates have been reported during treatment. Clearly, therefore, a need exists to develop alternative strategies in preventing and treating HIV-1 infection. The initial phases of HIV-1 infection are summarised by Levy (1993) as involving attachment, fusion and nucleocapsid entry. These phases have been the traditional foci in research into development of antiviral strategies. The molecular events at the virus genomic level have also been the subject of intense scientific research with an aim being the development of a live attenuated vaccine as a possible approach for the treatment or prophylaxis of HIV-1 infection. There is a high variable rate of progression from initial HIV-1 infection to AIDS which reflects a rapidly changing pathogen and variable immune response of the host to infection (Sheppard et al, 1993). With regards to the latter, HIV-1 can be considered as a heterogenous group of viruses differing at the genetic level with concomitant variable pathogenicity. For example, HIV-1 strains can differ in their capacity to kill cells. Furthermore, it appears that HIV-1 strains evolve in a host after infection and that the evolution varies depending on the tissues infected by the virus. The major sites in the genome apparently responsible for biological and pathological variation are the highly variable envelope region (Cheng-Mayer et al, 1991; Shioda et α/, 1992; Hwang, et al 1991; Sullivan et al, 1993; Groenink et al, 1993) and the viral regulatory regions such as tat (Leguern et al, 1993). The genetic complexity of the HIV-1 group of viruses together with their variable pathogenicity, are major difficulties in the development of live vaccines, genetic vaccines or component vaccines. Notwithstanding the highly pathogenic nature of HIV-1, there are some reports of long term survival of subjects infected with the virus (Learmont et al, 1992; Levy, 1993; Sheppard et al, 1993; Lifson et al 1991). It is not always clear, however, whether a benign course following HIV-1 infection is due to host factors, viral factors or other unknown factors. There are reports that most infected people have at least laboratory evidence of progressive immune system damage in the form of CD4+ cell loss (Lang et al, 1989) and defective immune responses (Clerici et al, 1989). Although simian monkeys have been used as an in vivo model for HIV and Simian Immunodeficiency Virus (SIV) infection, a major handicap in AIDS research has been the absence of suitable in vivo models to study the pathogenesis of the disease and, in particular, to study the viruses involved in benign infection. The need for a suitable in vivo model is heightened by the fact that results obtained in vitro cannot necessarily be extrapolated to what occurs in vivo. This was clearly observed by Mosier et al (1993) where conflicting results were obtained in animals compared to cell cultures. Despite the absence of suitable in vivo models, considerable scientific research has been directed to attenuating HIV-1 strains by mutagenesis of the virus genome. Deletions in the we gene have been implicated in attenuated strains of SIV and their use in providing protective effects in monkeys (Daniel et al, 1992). . However, there are conflicting reports on the possible negative influence the nef gene product has on the rate or extent of virus replication (Terwilliger et α/, 1986; Luciw et α/, 1987; Niederman et al, 1989; Kim et al, 1989; Hammes et al, 1989). In fact, Kim et al (1989) found that nef did not affect HIV-1 replication or HIV-1 long terminal repeat (LTR)-driven CAT expression. Kestler III et al (1991) found that the we/ gene is required for full pathogenic potential in SIV. However, such is the complexity of the HIV-1 group of viruses and the variability of immune responses between individuals let alone different species, that it is far from clear whether nef deleted strains of HTV-1 would behave similarly to nef deleted strains of SIV-I. There is a need, therefore, in order to investigate the possibility of nef deleted HIV-1 strain as a vaccine candidate, to identify individuals infected with such modified viruses. Learmont et al (1992) reported that a cohort of five persons infected with blood products from a single HIV-1 infected donor have remained asymptomatic from up to about 10- 14 years after infection. Subsequently, a sixth person has been identified as being part of the cohort. Both the donor and recipients were HIV-1 seropositive but with no indications of clinical symptoms of HIV-1 related disease and CD4+ cell number and p 2 -microglobul_n levels have remained in the normal range. The identification of this cohort of benignly infected individuals provides a unique in vivo model in which the pathogenesis of HIV-1 infection can be studied at the clinical and molecular biological levels. However, it has not always possible using conventional isolation procedures to routinely and reproducibly isolate viral strains from the above mentioned donor or recipients which has frustrated efforts to investigate the cause of the asymptomatic individuals. In accordance with the present invention, methods have now been established to isolate viruses from the above individuals. It has been determined, in accordance with the present invention, that the six individuals of the cohort are infected by non-pathogenic strains of HIV-1. Furthermore, the non-pathogenic strains of HIV-1 carry one or more nucleotide mutations. The non-pathogenic strains of the present invention enable the generation of a range of therapeutic, diagnostic and targeting agents against HIV-1 infection. The present invention also enables the attenuation of previously pathogenic strains of HIV-1. Accordingly, one aspect of the present invention contemplates a non-pathogenic isolate of HIV-1 or a component, part, fragment or derivative thereof. In a related embodiment, there is provided a novel isolate of HIV-1 or a component, part, fragment or derivative thereof wherein said HIV-1 isolate is capable of stimulating in a human or primate subject an immune response such as a humoral immune response to at least one HIV-1 glycoprotein such as but not limited to gp41-45, gpl20 and/or gpl60 while not substantially reducing in said human or primate subject proliferative responses and cytokine production to a mitogen, alloantigen and/or recall antigen compared to a healthy, non-infected human or primate subject. Preferably, the cytokine is IL-2. Preferably, the mitogen is ConA or PHA and the recall antigen is influenza or tetanus toxoid. Preferably, the HIV-1 isolate is non-pathogenic. More particularly, the present invention relates to an isolated HIV-1 strain which: (i) is substantially non-pathogenic in human subjects; and (ii) carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one pathogenic HIV-1 -derived polypeptide or protein. Even more particularly, the present invention provides an isolated HIV-1 strain which: (i) is substantially non-pathogenic in human subjects; and (ii) carries a mutation in the nef gene and/or a long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome. Still even more particularly, the present invention is directed to an isolated virus which: (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1; (ii) is substantially non-pathogenic in human subjects; (iii) carries one or more deletion mutations in a region of its genome corresponding to a nef gene in said pathogenic strain of HIV-1; and (iv) optionally carries a mutation in one or both LTR regions. In a related embodiment, there is provided an isolated virus which: (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1; (ii) is substantially non-pathogenic in human subjects; .(iii) carries one or more deletion mutations in an LTR region of its genome; and (iv) optionally carries a mutation in a region corresponding to a nef gene in said pathogenic strain of HIV-1. In a further related embodiment, there is provided an isolated virus which: (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1; (ii) is substantially non-pathogenic in human subjects; and (iii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains nef coding sequences and LTR nucleotide sequences. In a particularly preferred embodiment, the present invention provides non-pathogenic HIV-1 isolate C18 deposited at the ECACC on 17 October, 1994 under Provisional Accession Number V94101706. In a related embodiment, the present invention provides non-pathogenic HIV-1 isolate C98 deposited at the ECACC on 31 October, 1994 under Provisional Accession Number V941031169. In another embodiment, the present invention provides non-pathogenic HIV-1 isolate C54 deposited at ECACC on 14 February, 1995 under Provisional Accession No. . Although pathogenicity is a relative term, it is used herein in relation to the capacity of a strain of HIV-1 to induce AIDS or AIDS-related disorders in an individual over time. Accordingly, a "non-pathogenic" strain of HIV-1 is a strain which, at the clinical level, does not lead to the development of AIDS, at least within the median time of 6-10 years following infection with HIV-1. At the laboratory level, a non-pathogenic strain of HIV-1 is considered not to alter CD4+ cell counts or p 2 -microglobulin concentrations. In addition, a non-pathogenic strain of HIV-1 may not alter CD8+ and CD3+ cell counts and would not alter lymphocyte counts. CD4+:CD8+ ratios also remain unchanged relative to normal non-infected individuals. Furthermore, generally, a non-pathogenic strain of HIV-1 does not induce p24 antigenaemia. A non-pathogenic HIV-1 of the present invention is generally still infectious but individuals infected with the virus remain free of symptoms for at least 6-10 years after infection. A laboratory classified non-pathogenic strain of HIV-1 may be determined at any time after infection. The term "non-pathogenic" is not to be considered as a strain that is never pathogenic under any conditions as this might depend on the host individual, the level of immune responsiveness in that individual and the extent or otherwise of other, for example, immune comprising disorders. Accordingly, a "non-pathogenic" HIV-1 isolate of the present invention may also be considered a "low virulent" strain of the virus. A non-pathogenic strain of HIV-1 as contemplated herein may be isolated from an asymptomatic individual or may be derived from a pathogenic strain by mutation. Although the present invention is not to be limited to any particular pathogenic strain of HIV-1, for reference purposes, an example of a pathogenic strain is HIV-1 NL4-3 strain as described by Myers et al (1992). The non-pathogenic nature of the HIV-1 of the present invention is conveniently evidenced by the cohort of seven individuals comprising one donor and six recipients which have remained free of symptoms or signs of HIV-1 infection for greater than the median time of 6-10 years. However, the individuals of the cohort are seropositive for HIV-1 following infection with the virus as determined by Western blot analysis and genetic analysis (e.g. using PCR techniques). A seropositive individual is one showing reactivity to at least one HIV-1 glycoprotein (such as but not limited to gp 41-45, gpl20, gpl60) and at least three other virus-specific bands. In accordance with the present invention, a non-pathogenic HIV-1 isolate is also a strain of HIV-1 which: (i) induces an immune response in a human or primate subject; and (ii) does not substantially reduce proliferative responses or cytokine production to a mitogen, alloantigen and/or recall antigen relative to a healthy, non-infected subject. Preferably, the immune response such as to a glycoprotein, for example gp41-45, gpl20 and/or gpl60. Preferably, the cytokine monitored is an interleukin, such as IL-2. Preferably, the recall antigen is influenza or tetanus toxoid. A non-pathogenic HIV-1 isolate is also one which: (iii) does not substantially alter proliferative responses or cytokine production to allorgeneic mononuclear cells. The genomes or complementary DNA therefrom of the non-pathogenic HIV-1 isolates of the present invention are capable of hybridising under medium stringency conditions to the corresponding genome or complementary DNA of a pathogenic strain of HIV-1 (e.g. HIV-1 strain NL4-3). The ability to hybridise to a pathogenic strain of HIV-1 only applies to a comparison of the entire genome/complementary DNA of a non-pathogenic strain or a fragment which includes genetic material corresponding to a region in the genome 3' of the nef gene in a pathogenic strain of HIV-1. For the purposes of reference only, a suitable genomic nucleotide sequence from a pathogenic HIV-1 strain is set forth in SEQ ID NO: 1 from HIV-1 strain NL4-3 (Myers et al, 1992): 1 TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAGAGATCCTTGATCTGTGG 51 ATCTACCACACACAAGGCTACTTCCCTGATTGGCAGAACTACACACCAGG 101 GCCAGGGATCAGATATCCACTGACCTTTGGATGGTGCTTCAAGTTAGTAC 151 CAGTTGAACCAGAGCAAGTAGAAGAGGCCAAATAAGGAGAGAAGAACAGC 201 TTGTTACACCCTATGAGCCAGCATGGGATGGAGGACCCGGAGGGAGAAGT 251 ATTAGTGTGGAAGTTTGACAGCCTCCTAGCATTTCGTCACATGGCCCGAG 301 AGCTGCATCCGGAGTACTACAAAGACTGCTGACATCGAGCTTTCTACAAG 351 GGACTTTCCGCTGGGGACTTTCCAGGGAGGTGTGGCCTGGGCGGGACTGG 401 GGAGTGGCGAGCCCTCAGATGCTACATATAAGCAGCTGCTTTTTGCCTGT 451 ACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTA 501 ACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTCA 551 AAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC 601 AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGG 651 GACTTGAAAGCGAAAGTAAAGCCAGAGGAGATCTCTCGACGCAGGACTCG 701 GCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTA 751 CGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGCGAG 801 AGCGTCGGTATTAAGCGGGGGAGAATTAGATAAATGGGAAAAAATTCGGT 851 TAAGGCCAGGGGGAAAGAAACAATATAAACTAAAACATATAGTATGGGCA 901 AGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTTTTAGAGACATC 951 AGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAG 1001 GATCAGAAGAACTTAGATCATTATATAATACAATAGCAGTCCTCTATTGT 1051 GTGCATCAAAGGATAGATGTAAAAGACACCAAGGAAGCCTTAGATAAGAT 1101 AGAGGAAGAGC-_AAACAAAAGTAAGAAAAAGGCΑCAGCAAGCAGCAGCTG 1151 ACACAGGAAACAACAGCCAGGTCAGCCAAAATTACCCTATAGTGCAGAAC 1201 CTCCAGGGGCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGC 1251 ATGGGTAAAAGTAGTAGAAGAGAAGGCTTTCAGCCCAGAAGTAATACCCA 1301 TGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAATACCATG 1351 CTAAACACAGTGGGGGGAC1ATC__AGCAGCCATGCAAATGTTAAAAGAGAC 1 01 CATCAATGAGGAAGCTGCAGAATGGGATAGATTGCATCCAGTGCATGCAG 1451 GGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCA 1501 GGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACACATAATCC 1551 ACCTATCCCAGTAGGAGAAATCTATAAAAGATGGATAATCCTGGGATTAA 1601 ATAAAATAGTAAGAATGTATAGCCCTACCAGCATTCTGGACATAAGACAA 1651 GGACCAAAGGAACCCTTTAGAGACTATGTAGACCGATTCTATAAAACTCT 1701 AAGAGCCGAGCAAGCTTCACAAGAGGTAAAAAATTGGATGACAGAAACCT 1751 TGTTGGTCCAAAATGCGAACCCAGATTGTAAGACTATTTTAAAAGCATTG 1801 GGACCAGGAGCGACACTAGAAGAAATGATGACAGCATGTCAGGGAGTGGG 1851 GGGACCCGGCCATAAAGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAA 1901 CAAATCCAGCTACCATAATGATACAGAAAGGCAATTTTAGGAACCAAAGA 1951 AAGACTGTTAAGTGTTTCAATTGTGGCAAAGAAGGGCACATAGCCAAAAA 2001 TTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGGAC 2051 ACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATC 2101 TGGCCTTCCCACAAGGGAAGGCCAGGGAATTTTCTTCAGAGCAGACCAGA 2151 GCCAACAGCCCCACCAGAAGAGAGCTTCAGGTTTGGGGAAGAGACAACAA 2201 CTCCCTCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAGCT 2251 TCCCTCAGATCACTCTTTGGCAGCGACCCCTCGTCACAATAAAGATAGGG 2301 GGGCAATTAAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATT 2351 AGAAGAAATGAATTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAA 2401 TTGGAGGTTTTATCAAAGTAGGACAGTATGATCAGATACTCATAGAAATC 2451 TGCGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAA 2501 CATAATTGGAAGAAATCTGTTGACTCAGATTGGCTGCACTTTAAATTTTC 2551 CCATTAGTCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGAT 2601 GGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATT 2651 AGTAGAAATTTGTACAGAAATGGAAAAGGAAGGAAAAATTTCAAAAATTG 2701 GGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAGAC 2751 AGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAAC 2801 TCAAGATTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAA 2851 AACAGAAAAAATCAGTAACAGTACTGGATGTGGGCGATGCATATTTTTCA 2901 GTTCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAG 2951 TATAAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCAC 3001 AGGGATGGAAAGGATCACCAGCΆATATTCCAGTGTAGCATGACAAAAATC 3051 TTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTCATCTATCAATACAT 3101 GGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAA 3151 AAATAGAGGAACTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCA 3201 GACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACT 3251 CCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAGGACA 3301 GCTGGACTGTCAATGACATACAGAAATTAGTGGGAAAATTGAATTGGGCA 3351 AGTCAGATTTATGCAGGGATTAAAGTAAGGCAATTATGTAAACTTCTTAG 3401 GGGAACCAAAGCACTAACAGAAGTAGTACCACTAACAGAAGAAGCAGAGC 3451 TAGAACTGGCAGAAAACAGGGAGATTCTAAAAGAACCGGTACATGGAGTG 3501 TATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCA 3551 AGGCCAATGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAA 3601 CAGGAAAATATGCAAGAATGAAGGGTGCCCACACTAATGATGTGAAACAA 3651 TTAACAGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGG 3701 AAAGACTCCTAAATTTAAATTACCCATACAAAAGGAAACATGGGAAGCAT 3751 GGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTC 3801 AATACCCCTCCCTTAGTGAAGTTATGGTACCAGTTAGAGAAAGAACCCAT 3851 AATAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCCAATAGGGAAACTA 3901 AATTAGGAAAAGCAGGATATGTAACTGACAGAGGAAGACAAAAAGTTGTC 3951 CCCCTAACGGACACAACAAATCAGAAGACTGAGTTACAAGCAATTCATCT 4001 AGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTGACAGACTCACAAT 4051 ATGCATTGGGAATCATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTA 4101 GTCAGTCAAATAATAGAGCAGTTAATAAAAAAGGAAAAAGTCTACCTGGC 4151 ATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATGGGT 4201 TGGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAG 4251 GCCCAAGAAGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAG 4301 TGATTTTAACCTACCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTG 4351 ATAAATGTCAGCTAAAAGGGGAAGCCATGCATGGACAAGTAGACTGTAGC 4401 CCAGGAATATGGCAGCTAGATTGTACACATTTAGAAGGAAAAGTTATCTT 4451 GGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTAATTCCAG 4501 CAGAGACAGGGCAAGAAACAGCATACTTCCTCTTAAAATTAGCAGGAAGA 4551 TGGCCAGTAAA_ACAGTACATACAGACAATGGCAGCAATTTCACCAGTAC 4601 TACAGTTAAGGCCGCCTGTTGGTGGGCGGGGATCAAGCAGGAATTTGGCA 4651 TTCCCTACAATCCCCAAAGTCAAGGAGTAATAGAATCTATGAATAAAGAA 4701 TTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGAC 4751 AGCAGTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGA 4801 TTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGAC 4851 ATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCG 4901 GGTTTATTACAGGGACAGCAGAGATCCAGTTTGGAAAGGACCAGCAAAGC 4951 TCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGACATA 5001 AAAGTAGTGCCAAGAAGAAAAGCAAAGATCATCAGGGATTATGGAAAACA 5051 GATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAACACA 5101 TGGAAAAGATTAGTAAAACACCATATGTATATTTCAAGGAAAGCTAAGGA 5151 CTGGTTTTATAGACATCACTATGAAAGTACTAATCCAAAAATAAGTTCAG 5201 AAGTACACATCCCACTAGGGGATGCTAAATTAGTAATAACAACATATTGG 5251 GGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCAT 5301 AGAATGGAGGAAAAAGAGATATAGCACACAAGTAGACCCTGACCTAGCAG 5351 ACCAACTAATTCATCTGCACTATTTTGATTGTTTTTCAGAATCTGCTATA 5401 AGAAATACCATATTAGGACGTATAGTTAGTCCTAGGTGTGAATATCAAGC 5451 AGGACATAACAAGGTAGGATCTCTACAGTACTTGGCACTAGCAGCATTAA 5501 TAAAACCAAAACAGATAAAGCCACCTTTGCCTAGTGTTAGGAAACTGACA 5551 GAGGACAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCA 5601 TACAATGAATGGACACTAGAGCTTTTAGAGGAACTTAAGAGTGAAGCTGT 5651 TAGACATTTTCCTAGGATATGGCTCCATAACTTAGGACAACATATCTATG 5701 AAACTTACGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTG 5751 CAACAACTGCTGTTTATCCATTTCAGAATTGGGTGTCGACATAGCAGAAT 5801 AGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGA 5851 CTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAA 5901 TTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATGACAA 5951 AAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGA 6001 GCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATCAAAGCAGTAAGT 6051 AGTACATGTAATGCAACCTATAATAGTAGCAATAGTAGCATTAGTAGTAG 6101 CAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGG 6151 AAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAATAGA 6201 AAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAGTATCAGCACTTG 6251 TGGAGATGGGGGTGGAAATGGGGCACCATGCTCCTTGGGATATTGATGAT 6301 CTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTG 6351 TGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCA 6401 TATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCAC 6451 AGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTA 6501 ACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGT 6551 TTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTCTGTGT 6601 TAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTA 6651 GCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAAT 6701 ATCAGCACAAGCATAAGAGATAAGGTGCAGAAAGAATATGCATTCTTTTA 6751 TAAACTTGATATAGTACCAATAGATAATACCAGCTATAGGTTGATAAGTT 6801 GTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCA 6851 ATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAA 6901 TAATAAGACGTTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTAC 6951 AATGTACACΑTGGAATC-AGGCCAGTAGTATCAACTCAACTGCTGTTAAAT 7001 GGCAGTCTAGCAGAAGAAGATGTAGTAATTAGATCTGCCAATTTCACAGA 7051 CAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATT 7101 GTACAAGACCCAACAACAATACAAGAAAAAGTATCCGTATCCAGAGGGGA 7151 CCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGC 7201 ACATTGTAACATTAGTAGAGCAAAATGGAATGCCACTTTAAAACAGATAG 7251 CTAGCAAATTAAGAGAACAATTTGGAAA AATAAAACAATAATCTTTAAG 7301 CAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGG 7351 AGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGT 7401 TTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGAC 7451 ACAATCACACTCCCATGCAGAATAAAACAATTTATAAACATGTGGCAGGA 7501 AGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTT 7551 CATCAAATATTACTGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC 7601 AATGGGTCCGAGATCTTCAGACCTGGAGGAGGCGATATGAGGGACAATTG 7651 GAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAG 7701 TAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCA 7751 GTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCAC 7801 TATGGGCTGCACGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGT 7851 CTGATATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAA 7901 CAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAACAGCTCCAGGCAAG 7951 AATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTT 8001 GGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCT 8051 AGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATAACATGACCTGGAT 8101 GGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAA 8151 TTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAA 8201 TTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCT 8251 GTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAA 8301 GAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATAT 8351 TCACCATTATCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAG 8401 GCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCA 8451 TTCGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCGGAGC 8501 CTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAAC 8551 GAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATT 8601 GGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTT 8651 AACTTGCTCAATGCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGT 8701 TATAGAAGTATTACAAGCAGCTTATAGAGCTATTCGCCACATACCTAGAA 8751 GAATAAGACAGGGCTTGGAAAGGATTTTGCTATAAGATGGGTGGCAAGTG 8801 GTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAATGAGAC 8851 GAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAA 8901 AAA<_ATGGAGC_AATCΑCAAGTAGC_AATACAGCAGCTAACAATGCTGCTTG 8951 TGCCTGGCTAGAAGCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACAC 9001 CTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGC 9051 CACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAG 9101 AAGACAAGATATCCTTGATCTGTGGATCTACCACACACAAGGCTACTTCC 9151 CTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACC 9201 TTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGA 9251 GGCCAATAAAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATG 9301 GAATGGATGACCCTGAGAGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGC 9351 CTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAA 9401 CTGCTGACATCGAGCTTGCTACAAGGGACTTTCCGCTGGGGACTTTCCAG 9451 GGAGGCGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGC 9501 ATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGA 9551 TCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCT 9601 CAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTG 9651 TGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAA 9701 TCTCTAGCA However, for the purposes of comparing the nucleotide sequences of non-pathogenic HIV-1 strains including the ability to hybridise to a reference strain, the present invention extends to a genomic nucleotide sequence from any pathogenic strain of HIV- 1. Accordingly, in a particularly preferred embodiment, there is provided a viral isolate which: (i) carries a genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1; and (ii) carries a deletion mutation in a region corresponding to the nef gene and/or in an LTR region. Generally, such an HIV-1 isolate is non-pathogenic as hereinbefore defined. In a related embodiment, there is provided an isolated virus which: (i) has a genome which is capable of hybridising under medium stringency conditions to complementary nucleic acid from a pathogenic strain of HIV-1; and (ii) carries one or more deletion mutations in a region of its genome corresponding to a region which contains «e/coding sequences and LTR nucleotide sequences. For the purposes of defining the level of stringency, reference can conveniently be made to Maniatis et al (1982) at pages 387-389 which is herein incorporated by reference where the washing steps disclosed are considered high stringency. A low stringency is defined herein as being in 1-3X SSC/0.1-0.5% w/v SDS at 37-50°C for 2-3 hours. Depending on the source and concentration of nucleic acid involved in the hybridisation, alternative conditions of stringency may be employed such as medium stringent conditions which are considered herein to be 0.1-1X SSC/0.25-0.5% w/v SDS at > 45°C for 2-3 hours or high stringent conditions considered herein to be 0.1-1X SSC/0.1% w/v SDS at 60°C for 1-3 hours. In a particularly preferred embodiment of the present invention, the non-pathogenic strain of HIV-1 carries a mutation in the nef ' gene and or LTR region of the genome. A "mutation" is considered herein to include a single or multiple nucleotide substitution, deletion and/or addition. Most preferred mutations are single or multiple deletions of at least one, most preferably at least ten and even more preferably at least twenty contiguous nucleotides from a region corresponding to the nef gene and/or the LTR region. When the non-pathogenic virus carries a mutation in the LTR region, this generally occurs 5' of the Spl sites. According to a preferred aspect of the present invention, there is provided a viral isolate which: (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gpl20 and/or gpl60; (ii) is substantially non-pathogenic in human subjects; and (iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the nef gene and or LTR region of a pathogenic strain of HIV-1. In another embodiment, there is provided a viral isolate which: (i) is capable of inducing an immune response to at least one of gag, pol and or env; (ii) is substantially non-pathogenic in human subjects; and (iii) carries a deletion mutation of at least ten nucleotides in a region corresponding to the nef gene and/or LTR region of a pathogenic strain of HIV-1. Preferably, in respect of the latter embodiment, the immune response is an antibody or a cell mediated response. In a most preferred embodiment, the immune response is a humoral immune response. The nucleotide sequence of the we/ gene in HIV-1 NL4-3 is defined in SEQ ID NO: 650: ATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTGCTGTAAGGGAAAGAAT GAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATCTCGAGACCTAGAAAAAC ATGGAGCAATCΑCAAGTAGCAATACAGCAGCTAACAATGCTGCTTGTGCCTGGCTAGAA GCACAAGAGGAGGAAGAGGTGGGTTTTCCAGTCACACCTCAGGTACCTTTAAGACCAAT GACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAG GGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACACACAA GGCTACTTCCCTGATTGGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGAC CTTTGGATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGGTAGAAGAGGCCAATA AAGGAGAGAACACCAGCTTGTTACACCCTGTGAGCCTGCATGGAATGGATGACCCTGAG AGAGAAGTGTTAGAGTGGAGGTTTGACAGCCGCCTAGCATTTCATCACGTGGCCCGAGA GCTGCATCCGGAGTACTTCAAGAACTGCTGA The present invention extends to any or all single or multiple nucleotide deletions to a contiguous series of at least ten nucleotides from the nef gene which render the strain avirulent. The deletions may encompass the entire gene or parts thereof and may represent a single deletion or two or more deletions. Put in alternative terms, the non- pathogenic HIV-1 isolates of the present invention comprise a nucleotide sequence at the corresponding nef gene region non-identifiable to SEQ ID NO: 650, said non-identity comprising at least 5%, more preferably at least 10% and even more preferably at least 20% variation thereon. In a preferred embodiment, therefore, the present invention contemplates a viral isolate which: (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gpl20 and/or gρl60; (ii) carries a genome or a part or fragment thereof capable of hybridising under medium stringency conditions to a nucleotide sequence as set forth in SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from another pathogenic strain of HIV-1; (iii) carries a deletion of at least ten nucleotides in a region corresponding to the nef gene in HIV-1 NL4-3; and wherein said deletion encompasses one or more of the following decanucleotides from the we/gene of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1: ATGGGTGGCA(SEQ ID NO: 2) TGGGTGGCAA(SEQ ID NO: 3); GGGTGGCAAG(SEQ ID NO: 4) GGTGGCAAGT(SEQ ID NO: 5) ; GTGGCAAGTG(SEQ ID NO: 6) TGGCAAGTGG(SEQ ID NO: 7); GGCAAGTGGT(SEQ CAAGTGGTCA(SEQ AGTGGTCAAA(SEQ TGGTCAAAAA(SEQ GTCAAAAAGT(SEQ CAAAAAGTAG(SEQ AAAAGTAGTG(SEQ AAGTAGTGTG(SEQ GTAGTGTGAT(SEQ AGTGTGATTG(SEQ TGTGATTGGA(SEQ TGATTGGATG(SEQ ATTGGATGGC(SEQ TGGATGGCCT(SEQ GATGGCCTGC(SEQ TGGCCTGCTG(SEQ GCCTGCTGTA(SEQ CTGCTGTAAG(SEQ GCTGTAAGGG(SEQ TGTAAGGGAA(SEQ TAAGGGAAAG(SEQ AGGGAAAGA (SEQ GGAAAGAATG(SEQ AAAGAATGAG(SEQ AGAATGAGAC(SEQ AATGAGACGA(SEQ TGAGACGAGC(SEQ AGACGAGCTG(SEQ ACGAGCTGAG(SEQ GAGCTGAGCC(SEQ GCTGAGCCAG(SEQ TGAGCCAGCA(SEQ AGCCAGCAGC(SEQ CCAGCAGCAG(SEQ AGCAGCAGAT(SEQ CAGCAGATGG(SEQ GCAGATGGGG(SEQ AGATGGGGTG(SEQ ATGGGGTGGG(SEQ ID NO: 84) ; TGGGGTGGGA(SEQ ID NO: 85) ; GGGGTGGGAG(SEQ ID NO: 86); GGGTGGGAGC(SEQ ID NO: 87) ; GGTGGGAGCA(SEQ ID NO: 88) ; GTGGGAGCAG(SEQ ID NO: 89) ; TGGGAGCAGT(SEQ ID NO: 90) ; GGGAGCAGTA(SEQ ID NO: 91) ; GGAGCAGTAT(SEQ ID NO: 92) ; GAGCAGTATC(SEQ ID NO: 93) ; AGCAGTATCT(SEQ ID NO: 94) ; GCAGTATCTC(SEQ ID NO: 95) ; CAGTATCTCG(SEQ ID NO: 96); AGTATCTCGA(SEQ ID NO: 97) ; GTATCTCGAG(SEQ ID NO: 98); TATCTCGAGA(SEQ ID NO: 99) ; ATCTCGAGAC(SEQ ID NO: 100 TCTCGAGACC(SEQ ID NO: 101) CTCGAGACCT(SEQ ID NO: 102 TCGAGACCTA(SEQ ID NO: 103) CGAGACCTAG(SEQ ID NO: 104 GAGACCTAGA(SEQ ID NO: 105) AGACCTAGAA(SEQ ID NO: 106 GACCTAGAAA(SEQ ID NO: 107) ACCTAGAAAA(SEQ ID NO: 108 CCTAGAAAAA(SEQ ID NO: 109) CTAGAAAAAC(SEQ ID NO: 110 TAGAAAAACA(SEQ ID NO: 111) AGAAAAACAT(SEQ ID NO: 112 GAAAAACATG(SEQ ID NO: 113) AAAAACATGG(SEQ ID NO: 114 AAAACATGGA(SEQ ID NO: 115) AAACATGGAG(SEQ ID NO: 116 AACATGGAGC(SEQ ID NO: 117) ACATGGAGCA(SEQ ID NO: 118 CATGGAGCAA(SEQ ID NO: 119) ATGGAGCAAT(SEQ ID NO: 120 TGGAGCAATC(SEQ ID NO: 121) GGAGCAATCA(SEQ ID NO: 122 GAGCAATCAC(SEQ ID NO: 123) AGCAATCACA(SEQ ID NO: 124 GCAATCACAA(SEQ ID NO: 125) CAATCACAAG(SEQ ID NO: 126 AATCACAAGT(SEQ ID NO: 127) ATCACAAGTA(SEQ ID NO: 128 TCACAAGTAG(SEQ ID NO: 129) CACAAGTAGC(SEQ ID NO: 130 ACAAGTAGCA(SEQ ID NO: 131) CAAGTAGCAA(SEQ ID NO: 132 AAGTAGCAAT(SEQ ID NO: 133) AGTAGCAATA(SEQ ID NO: 134 GTAGCAATAC(SEQ ID NO: 135) TAGCAATACA(SEQ ID NO: 136 AGCAATACAG(SEQ ID NO: 137) GCAATACAGC(SEQ ID NO: 138 CAATACAGCA(SEQ ID NO: 139) AATACAGCAG(SEQ ID NO: 140 ATACAGCAGC(SEQ ID NO: 141) TACAGCAGCT(SEQ ID NO: 142 ACAGCAGCT (SEQ ID NO: 143) CAGCAGCTAA(SEQ ID NO: 144 AGCAGCTAAC(SEQ ID NO: 145) GCAGCTAACA(SEQ ID NO: 146 CAGCTAACAA(SEQ ID NO: 147) AGCTAACAAT(SEQ ID NO: 148 GCTAACAATG(SEQ ID NO: 149) CTAACAATGC(SEQ ID NO: 150 TAACAATGCT(SEQ ID NO: 151) AACAATGCTG(SEQ ID NO: 152 ACAATGCTGC(SEQ ID NO: 153) CAATGCTGCT(SEQ ID NO: 154 AATGCTGCTT(SEQ ID NO: 155) ATGCTGCTTG(SEQ ID NO: 156 TGCTGCTTGT(SEQ ID NO: 157) GCTGCTTGTG(SEQ ID NO: 158 CTGCTTGTGC(SEQ ID NO: 159) ATGACTTACA(SEQ ID NO: 236 GACTTACAAG(SEQ ID NO: 238 CTTACAAGGC(SEQ ID NO: 240 TACAAGGCAG(SEQ ID NO: 242 CAAGGCAGCT(SEQ ID NO: 244 AGGCAGCTGT(SEQ ID NO: 246 GCAGCTGTAG(SEQ ID NO: 248 AGCTGTAGAT(SEQ ID NO: 250 CTGTAGATCT(SEQ ID NO: 252 GTAGATCTTA(SEQ ID NO: 254 AGATCTTAGC(SEQ ID NO: 256 ATCTTAGCCA(SEQ ID NO: 258 CTTAGCCACT(SEQ ID NO: 260 TAGCCACTTT(SEQ ID NO: 262 GCCACTTTTT(SEQ ID NO: 264 CACTTTTTAA(SEQ ID NO: 266 CTTTTTAAAA(SEQ ID NO: 268 TTTTAAAAGA(SEQ ID NO: 270 TTAAAAGAAA(SEQ ID NO: 272 AAAAGAAAAG(SEQ ID NO: 274 AAGAAAAGGG(SEQ ID NO: 276 GAAAAGGGGG(SEQ ID NO: 278 AAAGGGGGGA(SEQ ID NO: 280 AGGGGGGACT(SEQ ID NO: 282 GGGGGACTGG(SEQ ID NO: 284 GGGACTGGAA(SEQ ID NO: 286 GACTGGAAGG(SEQ ID NO: 288 CTGGAAGGGC(SEQ ID NO: 290 GGAAGGGCTA(SEQ ID NO: 292 AAGGGCTAAT(SEQ ID NO: 294 GGGCTAATTC(SEQ ID NO: 296 GCTAATTCAC(SEQ ID NO: 298 TAATTCACTC(SEQ ID NO: 300 ATTCACTCCC(SEQ ID NO: 302 TCACTCCCAA(SEQ ID NO: 304 ACTCCCAAAG(SEQ ID NO: 306 TCCCAAAGAA(SEQ ID NO: 308 CCAAAGAAGA(SEQ ID NO: 310 AAAGAAGACA(SEQ ID NO: 312 AAGAAGACAA(SEQ AGAAGACAAG(SEQ ID NO: 314 GAAGACAAGA(SEQ AAGACAAGAT(SEQ ID NO: 316 AGACAAGATA(SEQ GACAAGATAT(SEQ ID NO: 318 ACAAGATATC(SEQ CAAGATATCC(SEQ ID NO: 320 AAGATATCCT(SEQ AGATATCCTT(SEQ ID NO: 322 GATATCCTTG(SEQ ATATCCTTGA(SEQ ID NO: 324 TATCCTTGAT(SEQ ATCCTTGATC(SEQ ID NO: 326 TCCTTGATCT(SEQ CCTTGATCTG(SEQ ID NO: 328 CTTGATCTGT(SEQ TTGATCTGTG(SEQ ID NO: 330 TGATCTGTGG(SEQ GATCTGTGGA(SEQ ID NO: 332 ATCTGTGGAT(SEQ TCTGTGGATC(SEQ ID NO: 334 CTGTGGATCT(SEQ TGTGGATCTA(SEQ ID NO: 336 GTGGATCTAC(SEQ TGGATCTACC(SEQ ID NO: 338 GGATCTACCA(SEQ GATCTACCAC(SEQ ID NO: 340 ATCTACCACA(SEQ TCTACCACAC(SEQ ID NO: 342 CTACCACACA(SEQ TACCACACAC(SEQ ID NO: 344 ACCACACACA(SEQ CCACACACAA(SEQ ID NO: 346 CACACACAAG(SEQ ACACACAAGG(SEQ ID NO: 348 CACACAAGGC(SEQ ACACAAGGCT(SEQ ID NO: 350 CACAAGGCT (SEQ ACAAGGCTAC(SEQ ID NO: 352 CAAGGCTACT(SEQ AAGGCTACTT(SEQ ID NO: 354 AGGCTACTTC(SEQ GGCTACTTCC(SEQ ID NO: 356 GCTACTTCCC(SEQ CTACTTCCCT(SEQ ID NO: 358 TACTTCCCTG(SEQ ACTTCCCTGA(SEQ ID NO: 360 CTTCCCTGAT(SEQ TTCCCTGATT(SEQ ID NO: 362 TCCCTGATTG(SEQ CCCTGATTGG(SEQ ID NO: 364 CCTGATTGGC(SEQ CTGATTGGCA(SEQ ID NO: 366 TGATTGGCAG(SEQ GATTGGCAGA(SEQ ID NO: 368 ATTGGCAGAA(SEQ TTGGCAGAAC(SEQ ID NO: 370 TGGCAGAACT(SEQ GGCAGAACTA(SEQ ID NO: 372 GCAGAACTAC(SEQ CAGAACTACA(SEQ ID NO: 374 AGAACTACAC(SEQ GAACTACACA(SEQ ID NO: 376 AACTACACAC(SEQ ACTACACACC(SEQ ID NO: 378 CTACACACCA(SEQ TACACACCAG(SEQ ID NO: 380 ACACACCAGG(SEQ CACACCAGGG(SEQ ID NO: 382 ACACCAGGGC(SEQ CACCAGGGCC(SEQ ID NO: 384 ACCAGGGCCA(SEQ CCAGGGCCAG(SEQ ID NO: 386 CAGGGCCAGG(SEQ AGGGCCAGGG(SEQ GGCCAGGGGT(SEQ CCAGGGGTCA(SEQ AGGGGTCAGA(SEQ GGGTCAGATA(SEQ GTCAGATATC(SEQ CAGATATCCA(SEQ GATATCCACT(SEQ TATCCACTGA(SEQ TCCACTGACC(SEQ CACTGACCTT(SEQ CTGACCTTTG(SEQ GACCTTTGGA(SEQ CCTTTGGATG(SEQ TTTGGATGGT(SEQ TGGATGGTGC(SEQ GATGGTGCTA(SEQ TGGTGCTACA(SEQ GTGCTACAAG(SEQ GCTACAAGCT(SEQ TACAAGCTAG(SEQ CAAGCTAGTA(SEQ AGCTAGTACC(SEQ CTAGTACCAG(SEQ AGTACCAGTT(SEQ TACCAGTTGA(SEQ CCAGTTGAGC(SEQ AGTTGAGCCA(SEQ TTGAGCCAGA(SEQ GAGCCAGAT (SEQ GCCAGATAAG(SEQ CAGATAAGGT(SEQ GATAAGGTAG(SEQ TAAGGTAGA (SEQ AGGTAGAAGA(SEQ GTAGAAGAGG(SEQ AGAAGAGGCC(SEQ AAGAGGCCAA(SEQ GAGGCCAATA(SEQ ID NO: 464 AGGCCAATAA(SEQ ID NO: 465) GGCCAATAAA(SEQ ID NO: 466 GCCAATAAAG(SEQ ID NO: 467) CCAATAAAGG(SEQ ID NO: 468 CAATAAAGGA(SEQ ID NO: 469) AATAAAGGAG(SEQ ID NO: 470 ATAAAGGAGA(SEQ ID NO: 471) TAAAGGAGAG(SEQ ID NO: 472 AAAGGAGAGA(SEQ ID NO: 473) AAGGAGAGAA(SEQ ID NO: 474 AGGAGAGAAC(SEQ ID NO: 475) GGAGAGAACA(SEQ ID NO: 476 GAGAGAACAC(SEQ ID NO: 477) AGAGAACACC(SEQ ID NO: 478 GAGAACACCA(SEQ ID NO: 479) AGAACACCAG(SEQ ID NO: 480 GAACACCAGC(SEQ ID NO: 481) AACACCAGCT(SEQ ID NO: 482 ACACCAGCTT(SEQ ID NO: 483) CACCAGCTTG(SEQ ID NO: 484 ACCAGCTTGT(SEQ ID NO: 485) CCAGCTTGTT(SEQ ID NO: 486 CAGCTTGTTA(SEQ ID NO: 487) AGCTTGTTAC(SEQ ID NO: 488 GCTTGTTACA(SEQ ID NO: 489) CTTGTTACAC(SEQ ID NO: 490 TTGTTACACC(SEQ ID NO: 491) TGTTACACCC(SEQ ID NO: 492 GTTACACCCT(SEQ ID NO: 493) TTACACCCTG(SEQ ID NO: 494 TACACCCTGT(SEQ ID NO: 495) ACACCCTGTG(SEQ ID NO: 496 CACCCTGTGA(SEQ ID NO: 497) ACCCTGTGAG(SEQ ID NO: 498 CCCTGTGAGC(SEQ ID NO: 499) CCTGTGAGCC(SEQ ID NO: 500 CTGTGAGCCT(SEQ ID NO: 501) TGTGAGCCTG(SEQ ID NO: 502 GTGAGCCTGC(SEQ ID NO: 503) TGAGCCTGCA(SEQ ID NO: 504 GAGCCTGCAT(SEQ ID NO: 505) AGCCTGCATG(SEQ ID NO: 506 GCCTGCATGG(SEQ ID NO: 507) CCTGCATGGA(SEQ ID NO: 508 CTGCATGGAA(SEQ ID NO: 509) TGCATGGAAT(SEQ ID NO: 510 GCATGGAATG(SEQ ID NO: 511) CATGGAATGG(SEQ ID NO: 512 ATGGAATGGA(SEQ ID NO: 513) TGGAATGGAT(SEQ ID NO: 514 GGAATGGATG(SEQ ID NO: 515) GAATGGATGA(SEQ ID NO: 516 AATGGATGAC(SEQ ID NO: 517) ATGGATGACC(SEQ ID NO: 518 TGGATGACCC(SEQ ID NO: 519) GGATGACCCT(SEQ ID NO: 520 GATGACCCTG(SEQ ID NO: 521) ATGACCCTGA(SEQ ID NO: 522 TGACCCTGAG(SEQ ID NO: 523) GACCCTGAGA(SEQ ID NO: 524 ACCCTGAGAG(SEQ ID NO: 525) CCCTGAGAGA(SEQ ID NO: 526 CCTGAGAGAG(SEQ ID NO: 527) CTGAGAGAGA(SEQ ID NO: 528 TGAGAGAGAA(SEQ ID NO: 529) GAGAGAGAAG(SEQ ID NO: 530 AGAGAGAAGT(SEQ ID NO: 531) GAGAGAAGTG(SEQ ID NO: 532 AGAGAAGTGT(SEQ ID NO: 533) GAGAAGTGTT(SEQ ID NO: 534 AGAAGTGTTA(SEQ ID NO: 535) GAAGTGTTAG(SEQ ID NO: 536 AAGTGTTAGA(SEQ ID NO: 537) AGTGTTAGAG(SEQ ID NO: 538 GTGTTAGAGT(SEQ ID NO: 539) TGTTAGAGTG(SEQ GTTAGAGTGG(SEQ TTAGAGTGGA(SEQ TAGAGTGGAG(SEQ AGAGTGGAGG(SEQ GAGTGGAGGT(SEQ AGTGGAGGTT(SEQ GTGGAGGTTT(SEQ TGGAGGTTTG(SEQ GGAGGTTTGA(SEQ GAGGTTTGAC(SEQ AGGTTTGACA(SEQ GGTTTGACAG(SEQ GTTTGACAGC(SEQ TTTGACAGCC(SEQ TTGACAGCCG(SEQ TGACAGCCGC(SEQ GACAGCCGCC(SEQ ACAGCCGCCT(SEQ CAGCCGCCTA(SEQ AGCCGCCTAG(SEQ GCCGCCTAGC(SEQ CCGCCTAGCA(SEQ CGCCTAGCAT(SEQ GCCTAGCATT(SEQ CCTAGCATTT(SEQ CTAGCATTTC(SEQ TAGCATTTCA(SEQ AGCATTTCAT(SEQ GCATTTCATC(SEQ CATTTCATCA(SEQ ATTTCATCAC(SEQ TTTCATCACG(SEQ TTCATCACGT(SEQ TCATCACGTG(SEQ CATCACGTGG(SEQ ATCACGTGGC(SEQ TCACGTGGCC(SEQ CACGTGGCCC(SEQ ACGTGGCCCG(SEQ CGTGGCCCGA(SEQ GTGGCCCGAG(SEQ TGGCCCGAGA(SEQ GGCCCGAGAG(SEQ GCCCGAGAGC(SEQ CCCGAGAGCT(SEQ CCGAGAGCTG(SEQ CGAGAGCTGC(SEQ GAGAGCTGC (SEQ AGAGCTGCAT(SEQ GAGCTGCATC(SEQ AGCTGCATCC(SEQ GCTGCATCCG(SEQ CTGCATCCGG(SEQ TGCATCCGGA(SEQ GCATCCGGAG(SEQ CATCCGGAGT(SEQ ATCCGGAGTA(SEQ TCCGGAGTAC(SEQ CCGGAGTACT(SEQ CGGAGTACTT(SEQ GGAGTACTTC(SEQ GAGTACTTCA(SEQ AGTACTTCAA(SEQ GTACTTCAAG(SEQ TACTTCAAGA(SEQ ACTTCAAGAA(SEQ CTTCAAGAAC(SEQ TTCAAGAACT(SEQ TCAAGAACTG(SEQ CAAGAACTGC(SEQ AAGAACTGCT(SEQ AGAACTGCTG(SEQ GAACTGCTGA(SEQ Generally, the subject HIV-1 isolate is non-pathogenic as hereinbefore defined. Additionally, reference herein to "a deletion" includes reference to a contiguous or non¬ contiguous series of two or more deletions. The non-pathogenic isolate may carry a single decanucleotide deletion or may carry more than one decanucleotide deletion. Where it carries multiple deletions these may all correspond to a contiguous sequence or be from different parts of the nef gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above. It is emphasised that the present invention extends to analogous sequences from other pathogenic strains of HIV-1 which might carry nef genes with a slightly altered sequence relative to HIV-1 strain NL4-3. In a most preferred embodiment of the present invention, there is provided a non- pathogenic strain of HIV-1 carrying a nucleotide sequence in its genome as set forth in SEQ ID No. 614: GAAGAGATTTGGGAGAACATGACCTGGATGCAGTGGGAAAAAGAAATTCACAATCACAC AAAATAC_ATATACTCCTTACTTGAAAAATCGC_AGAACCAAC_AAGAAAAGAATGAACAAG AACTATTGGAATTGGATCAATGGGCAAGTTTGTGGAATTGGTTTGACATAACAAAATGG CTGTGGTATATAAAAATATTCATAATGGTAGTAGGAGGCTTGATAGGTTTAAGAATAGT TTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCGTTTC AGACCCTCCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATCGAAGAAGAAGGT GGAGAGAGAGACAGAGACAGATCCACTCGATTAGTACACGGATTCTTAGCACTTTTCTG GGACGACCTGAGGAGCCTGTGCCTCTTCCTCTACCACCACTTGAGAGACTTACTCTTGA TTGTAACAAGGATTGTGGAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATATTGG TGGAACCTCCTAAAGTATTGGAGCCAGGAACTGCAGAAGAGTGCTGTTATCTTGCTCAA TGCCACCGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTTTAGAAGTATTACAAAGAG CTTATAGAGCTATCCTCCACATACCTAGAAGAATAAGACAGGGCCTCGAAATGGCTTTG CTATAAAATGGGTGGCAAGTGAGCAAAAAGTAGTGTAGTCAGATAGCATGCATCATAAG GGGTGGGGGCCAACAACTAACAATGCTGATCGTGCCTGGCTAGAAGCACAAGAGAAGGA AGAAGCGGGTTTTCCAGTCAAACCTCAGGTAGCTGTAGATCTTAGCCACTTTTTAAAAG AAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATACACAGTGCTGC AAACTATTACCAGTGGAGTCAGCGAAGATAGAAGAGGCCAATGGAGGAGAAAACCACAG ATTGTTCTGTTGGGGACTTTCCATCCGTTGGGGACTTTCCAAGGCGGCGTGGCCTGGGT GACTAGTTCCGGTGGGGACTTTCCAAGAAGGCGCGGCCTGGGCGGGACTGGGGAGTGGC GAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGCTGTTACTGGGTCTCTCGGGTT AGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTC AATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGT ATCTAGA; andor SEQ ID NO: 615: GAAACAATTTGGGATAACATGACCTGGATGCAGTGGGAAAGAGAAATTGACAATTACAC AAACATAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAAAATGAACTAG AATTATTGGAATTGGATAAATGGGCAAATTTGTGGAATTGGTTTAGTATATCAAACTGG CTATGGTATATAAAATTATTCATAATGGTAGTAGGAGGCTTGGTAGGTTTAAGAATAGT TTTTACTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATACTCACCATTGTCGTTTC AGACCCACCTCCCAACCCCGAAGGGACCCGACAGGCCAGAAGGAATCGAAGAAGAAGGT GGAGAGAGAGACAGAGGCAGCTCCACTCGATTAGTGCACGGATTCTTAGCACTTTTCTG GGACGACCTGAGGAGTCTGTGCCTCTTCAGCTACCACCACTTGAGAGACTTACTCTTGA TTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGATGGGAAGCCCTCAAATACTGG TGGAATCTCCTGCAGTATTGGAGGCAGGAACTACAGAAGAGTGCTGTTAGCTTGTTCAA TGGCACGGCCATAGCAGTAGCTGAGGGGACAGATAGAGTTATAGAAGCTTTACGAAGGG CTTATAGAGCTATTCTCCACATACCTAGAAGAATAAGACAGGGCTTAGAAAGGGCTTTG CTATAAAATGGGTGGCAAGTGGTCAGAAAGTAGTGTGGTTAGAAGGCATGTACCTTTAA GACAAGGCAGCTATAGATCTTAGCCGCTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCT AATTCACTCACAGAGAAGATCAGTTGAACCAGAAGAAGATAGAAGAGGCCATGAAGAAG AAAACAACAGATTGTTCCGTTTGTTCCGTTGGGGACTTTCCAGGAGACGTGGCCTGAGT GATAAGCCGCTGGGGACTTTCCGAAGAGGCGTGACGGGACTTTCCAAGGCGACGTGGCC TGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTGCATATAAGCAGCTGCTTTCTGC CTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAG GGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCC CGTCTGTTGTGTGACTCTGGTATCTAGA. The present invention, however, extends to HIV-1 isolates which are non-pathogenic; carry genomes capable of hybridising under low stringency conditions to SEQ ID NO: 614 or SEQ ID NO: 615; and which do not direct the synthesis of a full length nef gene product. In a further embodiment the present invention contemplates a viral isolate which: (i) is reactive to antibodies to a glycoprotein from HIV-1 such as at least one of gp41-45, gρl20 and or gρl60; (ii) carries a genome or a part or fragment thereof capable of hybridising under medium stringency conditions to a nucleotide sequence as set forth in SEQ ID NO: 1 or a complementary form thereof or an analogous sequence from .mother pathogenic strain of HIV-1; (iii) carries a deletion of at least ten nucleotides in a region corresponding to the LTR region in HIV-1 NL4-3; and wherein said deletion encompasses one or more of the following decanucleotides from the LTR region of HIV-1 NL4-3 or corresponding sequences from another pathogenic strain of HIV-1: CTGTTGTGTG (SEQ ID NO: 782) TGTTGTGTGA (SEQ ID NO: 783) GTTGTGTGAC (SEQ ID NO: 784) TTGTGTGACT (SEQ ID NO: 785) TGTGTGACTC (SEQ ID NO: 786) GTGTGACTCT (SEQ ID NO: 787) TGTGTGACTC (SEQ ID NO: 788) GTGTGACTCT (SEQ ID NO: 789) TGTGACTCTG (SEQ ID NO: 790) GTGACTCTGG (SEQ ID NO: 791) TGACTCTGGT (SEQ ID NO: 792) GACTCTGGTA (SEQ ID NO: 793) ACTCTGGTAA (SEQ ID NO: 794) CTCTGGTAAC (SEQ ID NO: 795) TCTGGTAACT (SEQ ID NO: 796) CTGGTAACTA (SEQ ID NO: 797) TGGTAACTAG (SEQ ID NO: 798) GGTAACTAGA (SEQ ID NO: 799) The non-pathogenic isolate may carry a single decanucleotide deletion in the LTR region or may carry multiple deletions in the same region or in the LTR region and another region such as the nef gene. In particular, the mutation may be in the LTR/we/ overlap region. Where it carries multiple deletions, these may correspond to a contiguous sequence or be from different parts of the LTR region and or nef gene. Furthermore, the terminal end portions of a deletion may lie within a decanucleotide as defined above. Yet another aspect of the present invention provides an infectious molecular clone comprising genetic sequences derived from the non-pathogenic HIV-I isolates as hereinbefore described and includes genetic sequences encoding major structural proteins such as gag, env and pol. Infectious molecular clones are particularly useful as genetic compositions capable of "infecting" host cells without need of viral coat. The infectious molecular clones of the present invention may also be derived from pathogenic HIV-1 strains rendered non-pathogenic as hereindescribed. According to this latter embodiment, there is contemplated a method of attenuating a pathogenic strain of HIV-1, said method comprising inducing a mutation in the nef gene and or an LTR region to generate a non-pathogenic HIV-1 strain as hereinbefore described. Preferred mutations are deletions of at least ten nucleotides such as one or more of the decanucleotides as hereinbefore described. The mutations may also constitute substitutions and/or insertions of heterologous nucleic acid molecules in the nef and or LTR regions such as the incorporation of a sense (i.e. co-suppression) antisense or ribozyme molecule (see below). In still yet another embodiment of the present invention, there is provided an isolated, non-pathogenic strain of HIV-1 comprising a deletion in its genome of at least 10 nucleotide within the region of nucleotide 8787 and 9709 and more particularly within the region 8800 and 9700 and even more preferably within the region 8800 and 9410, using the nucleotide numbering of HIV-1 NL4-3. In one embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3): nucleotide (i) 8830-8862; (ii) 9009-9035; (iii) 9019-9029; and (iv) 9033-9049. In another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4-3): and In yet another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4- 3): nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. In still yet another embodiment, the deletion of at least 10 nucleotides is from within a region selected from the list consisting of (using the nucleotide numbers of HIV-1 NL4- 3): nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. The above embodiments including any combinations thereof or functional equivalents thereof. Most preferred variants of HIV-1 are defined in Table 3. Reference herein to the non-pathogenic HIV-1 strains of the present invention includes reference to components, parts, fragments and derivatives thereof including both genetic and non-genetic material. Furthermore, the non-pathogenic HIV-1 strains may be in isolated form or resident in peripheral blood mononuclear cells (PBMCs) or other like cells where the genome of the HIV-1 strains is integrated as DNA from said HIV-1 strains such as proviral DNA. In addition, the present invention extends to recombinant virus such as from (or resident in) prokaryotes or eukaryotes as well as in the form of infectious molecular clones. Accordingly, the present invention provides for the non-pathogenic HIV-1 isolate, genomic material therefrom, complementary proviral DNA, molecular infectious clones, recombinant viral particles or genetic sequences therefrom or cells expressing same or blood cells carrying proviral DNA or to any mutants, derivatives, components, fragments, parts, homologues or analogues of the foregoing. The non-pathogenic HIV-1 strains of the present invention are particularly useful in the development of therapeutic compositions, therapeutic molecules and/or diagnostic reagents. With regards to the former, the non-pathogenic HIV-1 strain may be considered as a live attenuated vaccine where individuals carrying DNA derived from said non-pathogenic HIV-1 strain such as proviral DNA in target cells are protected from infection by a corresponding pathogenic strain. The term "vaccine" is used in its broadest sense as a therapeutic composition or molecule which prevents or reduces HIV-1 infection or risk of infection or which ameliorates the symptoms of infection. It may involve the stimulation of an immune response or may involve blocking HIV-1 cells receptors and or the use of genetic compositions, for example, to introduce ribozymes or antisense molecules to HIV-1 directed genetic sequences or to prepare infectious molecular clones. For convenience, all such compositions are referred hereinafter to "therapeutic compositions". Accordingly, the present invention contemplates a method for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic HIV-1 as hereinbefore defined in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non- pathogenic HIV-1. More particularly, the present invention contemplates a method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. By "productive infection" as used in the specification and claims herein is meant the infection of a cell or cells by a pathogenic strain of HIV-1 which leads ultimately to the symptomology of AIDS or AIDS related diseases. A cell infected productively produces pathogenic virions. By definition, infection of an individual by a non-pathogenic strain of HIV-1 would not lead to productive infection. Non pathogenic HIV-1 strains generally replicate to a sufficient extent to protect cells against challenge by virulent or pathogenic strains. The methods of the present invention are applicable prophylactically (i.e. to prevent de novo infection) or therapeutically (i.e. to reduce or slow disease progression). The present invention further provides a method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non-pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying proviral DNA from said non-pathogenic HIV-1. The term "vaccinating" should not be taken as limiting the invention to the prevention of HIV-1 infection by solely immunological means. The term "vaccinating" includes any means of preventing productive infection of an individual by pathogenic HIV-1. As an alternative to the above methods, a therapeutic composition as hereinbefore defined is administered. The non-pathogenic isolate may be administered inter alia as an isolated viral preparation or via infected blood cells. Another aspect of the invention provides a therapeutic composition for inhibiting or reducing the risk of infection by a pathogenic strain of HIV-1 said therapeutic composition comprising a non-pathogenic strain of HIV-1 or genetic sequences derived therefrom as hereinbefore described and optionally one or more pharmaceutically acceptable carriers and/or diluents. The therapeutic composition of the present invention is generally suitable for intravenous, intraperitoneal, intramuscular, intramucosal (e.g. nasal spray, respiratory spray) or other forms of parenteral administration. The therapeutic composition might also be administered via an implant or rectally or orally. In addition to the mutations contemplated above, the non-pathogenic HIV-1 strain may also contain one or more other mutations to further reduce the risk of reversion to virulence and/or to insert a genetic sequence capable of providing directly or indirectly an identifiable signal, having further anti-HIV-1 properties and or immunostimulatory or cell regulatory properties. For example, the non-pathogenic HIV-1 isolate in the therapeutic composition may comprise additional genetic material capable of directing expression of antisense nucleotide sequences to inhibit expression of one or more proteins encoded by a pathogenic strain of HIV-1. Alternatively, sense co-suppression may be employed. Preferred sense or antisense molecules would reduce expression of the nef gene or affect normal functioning of the LTR region. According to this embodiment, the non-pathogenic HIV-1 strain may be considered as a targeting agent to introduce genetic constructs capable of reducing expression of one or more HIV-1 proteins or polypeptides. In this embodiment there is provided a viral isolate which: (i) is genetically or immunologically related to a pathogenic strain of HIV-1; (ii) is substantially non-pathogenic in human subjects; (iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and (iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down-regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1. Preferred proteins or polypeptides targeted for reduced expression are those encoded by one or more of the following: gag, pol, env, tat, rev, vpu, vpr, vz/and/or nef genes. The most preferred protein or polypeptide targeted for reduced expression is the product of the nef gene. Alternatively, the target nucleotide sequence does not encode a polypeptide or protein but is required for other functions such as integration or excision from the human genome or expression of genes on the viral genome. An example of such a nucleotide sequence is the LTR region. Accordingly, the present invention extends to disruption to the function of such regions. The above aspect relates to use of antisense technology. The present invention extends, however, to use of ribozymes and/or co-suppression to achieve the same results. In an alternative embodiment, or in addition to, the second (or optionally a third) nucleotide sequence encodes an antiviral agent (e.g. interferon) and/or an immune enhancing agent. The identification of deletions z ' wter alia in the nef gene and/or LTR region in asymptomatic subjects provides a unique opportunity to study the in vivo effects of attenuated HIV-1 strains carrying one or more mutations in selected genetic regions. In particular, the present invention provides a means for designing therapeutic compositions directed to inhibiting expression of a nef gene and/or LTR region in a pathogenic HIV-1 strain (such as contemplated above) as well as developing a therapeutic regimem aimed at inhibiting the activity of the nef gene product for the function of the LTR region. According to this latter embodiment, the present invention provides a therapeutic composition comprising a molecule capable of inhibiting the intracellular activity of the nef gene product and/or LTR region, said composition further comprising one or more pharmaceutically acceptable carriers and/or diluents. The molecule contemplated by the above aspect of the subject invention may be a protein, polypeptide, peptide, chemical compound, sugar moiety or derivative of the nef gene product. The molecule will need to be capable of entering an infected cell. Where the molecule is a protein, polypeptide or peptide, it may be encoded by the second nucleotide sequence on the targeting vector as contemplated above. Alternatively, the molecule may be a nucleic acid molecule capable of targeting the nef gene or LTR region. The deletion mutants of the present invention may result in a modified nef gene product either having no readily discemable activity or having activity different to the naturally occurring nef protein. In any event, if a mutant nef gene product is produced, it will generally have a lower molecular weight than the naturally occurring we/protein and will have a different overall amino acid sequence. This provides, therefore, for a means for diagnosing individuals with benign HIV-1 infection by, for example, assaying for a modified nef protein or screening for a modified nef gene sequence. Alternatively, benign HIV-1 infection may be detected by assaying for a modified LTR region such as an altered nucleotide sequence. According to one embodiment, there is provided a method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising contacting a biological sample from said individual with an effective amount of an antibody specific to a nef protein from a non-pathogenic strain of HIV-1 (as hereinbefore defined) for a time and under conditions sufficient to form an antibody-modified nef protein complex and then detecting said complex. The presence of said complex is indicative of a modified nef gene product and of the non- pathogenicity of the strain of HIV-1. The biological sample is a sample likely to contain the modified nef gene product such as tissue extract or cell extract of an infected cell. However, where the modified we/gene product is capable of permeation or transport out of the cell, suitable biological fluid would include serum, whole blood, lymph and mucosal secretion amongst other fluids. Many variations in the subject assay are possible and are contemplated herein. For example, an assay could be based on the inability for a nef specific antibody to bind to a modified we/protein. For the purposes of the present invention the term "contacting" including "mixing". The presence of a modified we/molecule in biological fluid can be detected using a wide range of immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These include both single-site and two-site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays and include ELISA and RIA techniques. Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, and by way of example only, in a typical forward assay, a modified nef product-specific antibody is immobilised onto a solid substrate to form a first complex and the sample to be tested for modified nef product brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-modified nef product secondary complex, a second modified nef protein antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a tertiary complex of antibody- modified nef product-antibody. Any unreacted material is washed away, and the presence of the tertiary complex is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparison with a control sample containing known amounts of hapten. Variations of the forward assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent. The antibodies used above may be monoclonal or polyclonal. The solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier. By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, produces an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecule in this type of assay re either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes). In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to one skilled in the art. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production,upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product. Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that the foregoing can be used to label a modified nef product and to use same directly in the detection of, for example, circulatory antibodies specific to said modified nef product. Alternatively, genetic assays may be conducted to screen for abberations in the nef gene and/or LTR region. Such a genetic assay may be by Southern or Northern blot analysis, PCR analysis or the like using oligonucleotides specific to a deleted region of a we/gene and/or LTR region. According to this embodiment there is provided a method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining directly or indirectly the presence of a deletion mutation in the genome of said HIV-1 wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV- 1. The deletion mutation may result in the genome being unable to synthesise a polypeptide or protein from a pathogenic strain of HIV-1 or may direct the synthesis of a truncated form of said polypeptide or protein. The mutation may also lead to altered expression of a polypeptide detectable by, for example, decreased synthesis of a particular protein, such as the nef gene product. Alternatively, the deletion mutation affects the LTR region or a regulatory region of the HIV-1 genome. In either case, affected viruses may also be detected by, for example, observing low viral copy numbers such as low viral loads. Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3. Preferably, said non-pathogenic HTV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (i) 8830-8862; and Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (vii) 9105-9224; and (viii) 9271-9370. Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. Preferably, said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. The above nucleotide numbers are based on the nucleotide numbering in the NL4-3 genome. Particularly preferred oligonucleotides are based on the deleted regions of the nef gene and/or LTR region such as but not limited to one or more oligonucleotides based on SEQ ID NO: 2 to SEQ ID NO: 613 and or SEQ ID NO: 652 to SEQ ID NO: 799. The present invention further extends to kits for the diagnosis of infection by pathogenic strains of HIV-1 or for determining the pathogenicity of infecting virus. The kits would be in compartmental form each comprising one or more suitable reagents for conducting the assay. The present invention is further described by the following non-limiting Figures and Examples. In the Figures: Figure 1 is a representation showing the alignment of the nucleotide sequences from donor D36 peripheral blood mononuclear cell (PBMC) [D36P] and non-pathogenic HIV- 1 from recipient C18 HIV StV [C18S], C18 mY MBC [C18M] and C98 HIV [C98H] and C54 PBMC [C54P] with the equivalent region of HIV-1 NL4-3. Sequences labelled PBMC are from patient PBMC, those labelled HIV are from virus isolated from patient PBMC and grown in culture. Numbering for HIV-1 NL4-3 is as per Myer et al (1992) where nucleotide 1 is the first nucleotide of the complete proviral DNA sequence. D36P, C18S, C18M, C98H and C54P are numbered from the start of the region sequenced. Identity with NL4-3 sequence is shown by (*). Deleted nucleotides are shown by (-). Spaces introduced to maximise alignment are shown by (,). Features in NL4-3 are marked by overlining the sequence, features in D36 and C18 are marked by underlining the sequence. Figure 2 shows the alignment of encoded amino acid sequences of (a) tat exon 3 and (b) rev exon 3 from HIV-1 NL4-3, D36 PBMC, C18 HIV StV and C98 HIV. In-phase termination codons (*) and NL4-3 encoded amino acid numbers are shown. Figure 3 is a representation showing the alignment of C-terminal envelope glycoprotein gp41 amino acid sequences encoded by D36 PMBC, C18 HIV StV , C18 and C98 HIV. Numbering is that of the amino acid sequence of the mature envelope glycoprotein of HIV NL4-3. Termination in shown by (#). Figure 4 is a representation showing alignment of amino acid sequences encoded by the we/genes of HIV-1 NL4-3, D36 PBMC, C18 HIV StV , C18 HIV^-, and C98 HIV. In phase termination codons are shown by (#). Identical amino acids are shown by (*). Residues underlined are those immediately before a deletion. Figure 5 shows a duplication of NFΛB and Spl sequences in D36 PBMC, C18 HIV StV , C18 HIV j ^c and C98 HIV demonstrated by alignment of their low homology region sequences with the NFΛ_B-Spl region of HIV-1 NL4-3. Nucleotide numbering according to Figure 1. Identity with NL4-3 sequence shown by (*) and NFA_B and Spl sites in NL4-3 overlined. Position of neflUTR region sequence deletion shown by (Δ). Figure 6 is a graphical representation showing replication of C18 and C98 viral isolates and D36 PBMCs from asymptomatic patients in PHA-stimulated PBMCs. Figure 7 is a graphical representation showing replication of viral isolates from asymptomatic patients in non-PHA stimulated PBMCs. 228200 is an Australian isolate of HIV-1 described by Kiernan, R. et al (1990). Its characteristics include being T cell trophic, with fast kinetics, high producer of HIV-1 and or SI phenotype. Figure 8 is a graphical representation of cell surface receptor expression for syncytia- inducing (SI)/ non-syncytia-inducing (NSI)/asymptomatic patient isolates. 228200 is defined in the legend to Figure 7. 243925 is a viral isolate of HIV-1 which is monocyte/macrophage trophic and exhibits NSI phenotype (Dr Karen Coats-Fryer, PhD thesis entitled "Viral determinants of HIV-1 syncytium formation", the University of Melbourne, Parkville, Victoria, Australia. Figure 9 is a representation of the nucleotide sequence of C18 HIV-l^-. (SEQ ID NO: 800). Figure 10(a) - (g) are graphical representations showing clinical immunology of cohort; (a) CD3; (b)(i) CD4 (ii) CD4%; (c)(i) CD8; (ii) CD8%; (d) lymphocyte count; (e) CD4/CD8 ratio; (f) β-2-microglobulin; and (g) Kaplan-Meier estimates of time to disease progression (Cox & Oakes, 1989). Figure 11 is a schematic representation of the deletion mutants of the present invention. A summary of the SEQ ID Nos. used in the subject specification is shown below: SEQ ID NO: DESCRIPTION 1 Nucleotide sequence of HIV-1 strain NL4-3 genome 2-613 Decanucleotides of nef gene from HIV-1 strain NL4-3 614 Partial nucleotide sequence of D36 HIV-1 isolate 615 Partial nucleotide sequence of C18 HIV-l^c isolate 616-625 PCR primers shown in Table 1 626-633 Sequence primers shown in Table 2 634 Amino acid residues 15-27 of HIV-1 NL4-3 nef protein 635 HIV-1 NL4-3 tat exons (Figure 2) 636 HIV-1 D36 tat exons (Figure 2) 637 HIV-1 C18 tat exons (Figure 2) 638 HIV-1 NL4-3 rev exons (Figure 2) 639 HIV-1 D36 rev exons (Figure 2) 640 HIV-1 C18 rev exons (Figure 2) 641 HIV-1 NL4-3 C-terminal of gp41 (Figure 3) 642 HIV-1 D36 C-terminal of gp41 (Figure 3) 643 HIV-1 C18 C-terminal of gp41 (Figure 3) 644 HIV-1 NL4-3 nef gene (Figure 4) 645 HIV-1 D36 nef gene (Figure 4) 646 HIV-1 C18 nef gene (Figure 4) 647 HIV-1 NL4-3 NFKB/SP1 sequence (Figure 5) 648 HIV-1 D36 NFKB/SP1 sequence (Figure 5) 649 FflV-1 C18 NFKB/SP1 sequence (Figure 5) 650 Nucleotide sequence of we/gene from HIV-1 strain NL4-3 651 Nucleotide sequence of ewv and we/ regions of NL4-3 652-799 Decanucleotides of LTR region from HIV-1 strain NL4-3 800 Nucleotide sequence of C18 HlV-l^ jg -. EXAMPLE 1 Source Material For the purposes of the following examples, a non-pathogenic HIV-1 strain was isolated from a recipient of HIV-1 infected blood. The recipient is designated "C18". Other recipients are defined as "C54" and "C98". The donor is identified herein as "D36". The place of isolation may be indicated after the abbreviation of "HIV". For example, St Vincents Hospital, Sydney (HIV StV ) or Macfarlane Burnet Centre of Medical Research, Melbourne (HIVJ^ ). Exemplary viral isolates referred to herein as "C18" and "C98" were deposited at the PHLS Centre for Applied Microbiology and Research, European Collection of Animal Cell Cultures (ECACC), Division of Biologies, Porton Down, Salisbury, Wiltshire SP4 OJG. C18 was deposited on 17 October, 1994 under Provisional Accession Number V94101706 and C98 was deposited on 31 October, 1994 under Provisional Accession Number V941031169. Figure 11 is a summary of the deletion mutants of the present invention. Viruses were isolated by the following procedures: 1. Infected peripheral blood mononuclear cells (PBMCs) were co-cultured with HIV-1 seronegative donor PBMCs. A convenient source of seronegaitve donor PBMCs is a blood bank. The supernatants and cells are harvested every 7 days and fresh medium added with CD8 depleted PBMCs. CD8 depletion promotes the ability to isolate HIV-1. The culture and procedure is continued for up to approximately 5 weeks; 2. The infected PBMCs are purified from whole blood and these cells are cultured alone for up to 5 weeks. PMBCs alone are used because the virus is more likely to be monocytotropic. Fresh medium is added weekly and supernatant fluid is harvested at this time; 3. Supernatant fluids are harvested every approximately 7 days, fresh medium and fresh HIV-1 seronegative CD8 depleted PBMCs are added at this time; 4. HIV-1 seronegative PBMCs are pretreated with with M-CSF for approximately 72 hours prior to the addition of infected PBMCs. M-CSF has been shown to enhance HIV-1 replication in monocytes (Gendelman et al, 1988); or 5. The supernatant fluid is harvested from the cultures of step 4 every approximately 7 days, fresh medium added together with HIV-1 seronegative stimulated CD8 depleted PBMCs. The virus is isolated from the infected PBMCs. EXAMPLE 2 DNA Preparation and PCR Amplification Non-pathogenic HIV-1 (e.g. strain C18) infected peripheral blood mononuclear cells (PBMC) were harvested 4 days after infection of phytohaemagglutinin (PHA) stimulated HIV-1 negative donor PBMC cultured by the method of Neate et al (1987) and washed in phosphate buffered saline (PBS). PBMC from Donor D36 and Recipients C18, C54 and C98 were prepared by Ficoll isopaque centrifugation of buffy coat cells and washed with PBS. Approximately 10 7 cells were lysed in lml lysis solution (0.45% v/v NP40, 0.45% v/v Tween 20, lOmM Tris-HCl pH 8.3, 40mM KC1 2.5 mM MgCl 2 ) and digested with 60μg/ml proteinase K (Boehringer Mannheim) at 55°C for 1 hour followed by 100°C for 10 minutes. Lysates were stored at -20°C. All polymerase chain reaction (PCR) primers (Table 1) and sequencing primers (Table 2) were synthesised using an Applied Biosystems model 391 DNA synthesiser using phosphoramidite chemistry. Strict physical separation was maintained for sample, PCR reagent mix and PCR reaction preparations as well as amplification and analysis. Final reaction mixes (50μl) contained 2 μl neat or diluted cell lysate, 0.2μM each primer, 200mM dNTPs and 1.25 units Taq polymerase (Boehringer Mannheim) in PCR buffer, (1 OmM Tris-HCl pH8.3, 50mM KC1, lOOμg/ml gelatine) adjusted to the optimum MgCl 2 concentration for the primer pair (1.5-3. OmM). Aliquoted reagent mix was overlaid with 50μl mineral oil prior to addition of DNA template lysate. After template denaturation at 94°C for 3 min amplification was achieved with 30 cycles of 94°C, 1 min; 55°C, 1 min; 72°C, 2 mins. A final elongation reaction was conducted at 72°C for 7 minutes. For double PCR amplification 2 μl of first round product was added to the second reagent mix and amplified as before. PCR amplified DNA was checked for quality, quantity and fragment size by agarose gel electrophoresis in Tris-Acetate-EDTA buffer (Sambrook et al, 1989) stained in ethidium bromide and viewed by UV transillumination. EXAMPLE 3 DNA Sequence Analysis The DNA sequence of PCR amplified HIV-1 regions was determined by the dideoxynucleotide method (Sanger et al, 1997) using Sequenase T7 polymerase (United States Biochemicals). PCR amplified DNA was purified by PCR Magic prep resin chromatography (Promega). Approximately 2 to 7 μg purified DNA plus lOng specific primer (Table 2) were denatured by boiling for 3 mins and snap frozen to -20°C. The initial labelling reaction was for 3 minutes at 22°C (room temperature) with 35 SdNTP (500Ci/mmol; Dupont) followed by dideoxynucleotide termination reactions at 37°C for 5 minutes. NP40, to 0.45% v/v, was included in denaturation and reaction mixes (Bachman et al, 1990). Sequencing reaction products were denatured in formamide and resolved on a 6% w/v polyacrylamide gel containing 8M urea, fixed in 10% v/v acetic acid, 10% v/v methanol and dried. Following autoradiography on XK1 film (Kodak) the gel sequences were read assembled, translated to protein and aligned using the PC/GENE suite of programs (IntelliGenetics, USA). TABLE 1 PCR PRIMERS 1. Sequence is presented from 5' to 3' of the primer. 2. Position is according to the numbering of HIV NL4-3 in Myers et al (1992). 3. SEQ ID NOs are given in parentheses. TABLE 2 SEQUENCING PRIMERS 1. Sequence is presented from 5' to 3' of the primer. 2. Position is according to the numbering of HIV NL4-3 in Myers et al (1992). 3. SEQ ID NOs are given in parentheses. EXAMPLE 4 Cells and Cell Culture Peripheral blood was obtained from HIV-1 sero-negative volunteers and mononuclear cells prepared by centrifugation on a Ficoll Hypaque density gradient (Peper et al, 1968). PBMC were activated with phytohemagglutinin (PHA; 10μg/10 6 cells) for 48 h at 37°C washed and then cultured in RPMI 1640 medium containing 10% v/v heat inactivated foetal calf serum, 15mM HEPES, 0.1% v/v sodium bicarbonate, 25μg/ml polybrene (Sigma), 10% v/v interleukin 2 (Boehringer Mannheim) and 1:1000 anti-interferon (Miles) (IL-2 medium). Non-PHA stimulated cells were prepared in a similar manner except they were cultured in medium lacking PHA and IL-2. EXAMPLE 5 Antipeptide-antisera Antibodies specific for HIV-1 Nef were raised against a peptide corresponding to the predicted amino acid residues 15-27 (AVRERMRRAEPAA SEQ ID NO: 634) of Nef encoded by the HIV-1 clone pNL4.3 (Kemp et al, 1988). The peptide was conjugated to keyhole limpet hemocyanin (KLH; Calbiochem, Behring Diagnostics, CA) via glutaraldehyde and this complex used to immunise sheep (0.5mg peptide conjugate/sheep). Antibodies to the peptide were purified by affinity chromatography. Reactivity of the antibodies with recombinant HIV-1 Nef 25 and 27 was demonstrated by immunoblotting. EXAMPLE 6 Reactivity of anti-Nef s- 27) w ^ H^ C18-infected Cells in Immunoblotting Seven days post-infection HIV-1 C18-infected PBMCs and mock - infected cells were washed in PBS then lysed (0.5% w/v NP-40, 0.5% w/v sodium deoxycholate, 50mM NaCl, 25mM Tris-HCl, lOmM EDTA, 0.01% w/v sodium azide and lOmM phenylmethylsulphonylfluoride). After nuclei were spun out lysates were electrophoresed in a 13% w/v SDS-polyacrylamide gel (SDS-PAGE) and subsequently transferred to Hybond-C nitrocellulose (Amersham, Buckinghamshire, England) for 1 h at 100 V using a Bio-Rad protein transfer cell (Bio-Rad, Richmond, Ca). Membranes were pre-incubated with 1% w/v BSA/PBS for 2 h at room temperature and then reacted with affiiiity purified sheep anti-Nef, 15 _ 27) , diluted 1 : 100, overnight at room temperature. After three washes in 1% w/v BSA PBS, the blots were incubated with donkey anti- sheep Ig conjugated to biotin (Amersham, diluted 1 :500) for 1 h at room temperature. After extensive washing as described above the membranes were incubated with streptavidin-conjugated horse radish peroxidase (Amersham; diluted 1:500 for 1 h at room temperature. All dilutions were made with 1% w/v BSA in PBS. After further washing the membrane was developed with phenylenediamine substrate (Dako, Dapopatts, Denmark). The antibody preparation used in the immunoblotting experiments was free of detectable antibodies to the immunogenic carrier protein and coupling reagent. EXAMPLE 7 Analysis by Polymerase Chain Reaction Amplification A 5' fragment defined by primers Cl-1 and Cl-2 containing the 5' LTR and part of the gag gene was amplified. DNA from HIV-1 C18 infected PBMC gave an amplified fragment (amplimer) of about 1.9 kb compared with 2. lkb for pHXB2 control template, implying a deletion of about 200bp from HIV C18. Further amplification of this fragment with primers defining the U3 region of the LTR (Cl-1 and LTR-3') gave amplimers of about 300 bp for HIV-1 C18 infected PBMC DNA compared with 340bp for C18 and D36 PBMC DNA and 484 bp for pHXB2 control. This implies the loss of approximately 140 to 180bp from the U3 region of these proviral DNAs. To analyse the nef-gene-3' LTR region, the nested primer pairs SK68-C1-6 and KS-2- LTR-3' were used in a double PCR. Amplimers of approximately 830bp were obtained for HIV-1 C18 infected PBMC DNA as well as for PBMC DNA from Donor D36 and Recipients C18, C54 and C98 compared with approximately 1230bp for pHXB2 DNA. These results suggest that about 400bp of DNA have been deleted from the Donor and Recipient proviral DNAs. In comparison, amplification of the polymerase gene region by double PCR with the nested primer pairs RT5'-v3-RT3'-v2 and RT5'-v2-RT3'-vl gave a fragment (approximately 2.1 kb) the same size as the molecular clone pHXB2 fragment for HIV-1 C18 infected PBMC DNA, suggesting that deletions from this region were unlikely. EXAMPLE 8 Nucleotide Sequence of the nef-3 'LTR Region PCR amplification experiments indicated an approximately 200bp nucleotide deletion from both the nef gene and LTR regions of Donor D36 PBMC and Recipient Cl 8 HIV-1 proviral DNA. To further analyse these regions, the DNA sequence was determined for the PCR amplified we/-3 '-LTR region of D36 PBMC, C18 isolates HIV^c and HIV Stv as well as isolate C98 HIV infected PBMC proviral DNA. The 3' region was amplified with outer primers (SK68-C16) and inner primers (SK68-LTR 3' or KS2-C16) and sequenced directly using a number of internal sequencing primers based on the HIV-1 NL4-3 nucleotide sequence (Table 2). Alignment of the nucleotide sequences of the amplified 3' region of donor D36 PBMC and recipient C18 isolates HlV^r- and HIV StV and C98 HIV (Fig 1) showed a number of nucleotide sequences changes, including deletions, relative to the nucleotide sequence of wild-type infectious HIV-1 (HIV-1 NL4-3). In the region of alignment, D36 PBMC lacked 291 nucleotides, C18 HIV StV differed in size by 388 nucleotides (comprising deletions of 397 nucleotides and an insertion of 9 nucleotides), C18 HIV^-. differed by 456 nucleotides and C98 HIV lacked 158 nucleotides compared with HIV-1 NL4-3. The overall identity with HIV-1 NL4-3 nucleotide sequence of D36 PBMC, C18 HIV Stv , HlV j ^r and C98 HIV nucleotide sequences, including deletions, was 73% (1157/1596), 67% (1459/1592), 62% (982/1592) and 79% (1105/1399), respectively. The D36 PBMC sequence differed from HIV-1 NL4-3 in a number of features. A change in the wild type tat termination codon from TAG to TCG (Ser) extended the third tat exon (which starts at splice acceptor 10) by a further 15 amino acids to terminate at a conserved TAG (Fig 1). The resulting C-terminal peptide is rich in charged amino acids (8/15) (Fig 2a). The wild type rev termination codon has also changed (TAG to GAG, Glu) and the third rev exon is extended for 14 codons to terminate at a conserved TAG (Fig 2b). The encoded extra amino acids are mainly polar (11/14) and charged in nature (Fig 2b). The sequence also encodes the C-terminal 237 amino acids of Env gp41 (Fig 3) terminating at the normal termination codon. The D36 PBMC Env amino acid sequence has 85% identity with the HIV NL4-3 sequence, increasing to 89% if similarities are included. There are significant differences from HIV-1 NL4-3 downstream of the ewv (gp41) gene. A change in the fifth nef codon, from TGG (Tip) to TGA (Fig 1), introduces an early termination in the D36 PBMC nef gene. The encoded Nef protein is identical to the N- terminal 4 amino acids of NL4-3 Nef (Fig 4). Following the early termination there are deletions of 33, 47, 93 and 91 nucleotides and a region of low sequence homology, compared with HIV NL4-3, prior to the wild type we/termination codon site (HIV NL4- 3 nts 9405-9407). As well as removing a significant part of the nef gene, these deletions also bring into phase a further 6 termination codons. While the polypurine tract (plus strand primer binding site) and the first 38 nucleotides of the LTR U3 region are perfectly conserved, downstream U3 region sequences are disrupted by the 93 and 91 nucleotide deletions and the low homology region. The resulting U3 region lacks recognition sequences for the transcription factors c-myb, USF and TCFlα as well as one of the suggested NF-AT sites (Gaynor et al, 1992). Downstream from the 91 nucleotide deletion, a 59 nucleotide region of low homology contains two extra NFKB enhancer sites 19 nucleotides upstream of the usual site of a pair of NFKB sites, the upstream one of which is altered in its 5'-half in D36. Sequences further downstream are highly conserved with respect to HIV-1 NL4-3, including the position and number of Spl basal promoter sites, TATA box, TAR and polyadenylation signal sequences. Similar to D36 PBMC, the C18 HIV StV and HIV j ^c sequences show the tat third exon to be extended by 15 codons. All but two codons (altered by point mutations) are identical to those of D36 PBMC (Fig 2a). The rev third exon of both C18 isolates is also extended (Fig 2b) but by only three codons, identical to the first three codons of the D36 PBMC rev extension. The same 237 amino acid coding region of Env gp41 is found in both the C18 HIV DNA sequences (Fig 3) and shows 85% identify, increasing to 88% if similarities are included, with the same region of the NL4-3 Env gp41. It is in the nef gene and LTR regions that the major differences from wild-type HIV-1 arise, just as in D36 PBMC. The nef gene of C18 HIV StV encodes 24 amino acids with 9 of the 10 N-teπninal being identical to the NL4-3 Nef protein (Fig 4). Thereafter, deletions of 177 and 11 nucleotides cause a frameshift and termination at the 25th codon (Fig 1). Downstream deletions of 120, 82 and 7 nucleotides cause further loss of wild type nef gene sequence and bring into phase a further three termination codons. The nef gene of C18 HIV^-. encodes only 7 amino acids with only the initiator methionine identical to the NL4-3 Nef protein. This loss of identity and early termination is brought about by a 250 nucleotide deletion after the fifth nucleotide of the nef gene. Downstream deletions of 120 and 86 nucleotides cause further loss of wild-type nef gene sequences. In both C18 isolates there is perfect conservation of the polypurine tract and 29/31 nucleotides at the 5' end of the U3 region immediately before the 120 nucleotide deletion (Fig 1). This deletion together with the downstream 82 and 7 nucleotide deletions in HIV StV and 86 nucleotide deletion in HIV^-. and the low homology region cause the loss of the 5' half of the NRT-1 site (Yamamoto et al 1992) and the downstream NFAT site. A third NFKB site is present 31 (HIV stV ) and 33 (HIVJ^JBJ-) nucleotides upstream of the expected pair of NFKB sites which are themselves separated by 13 nucleotides instead of the 4 nucleotides in HIV-1 NL4-3. The 5'-most Spl site sequence is slightly altered but sequences downstream including the other 2 Spl sites, the TATA box, TAR and polyadenylation signal sequences are identical to HIV-1 NL4-3 sequence. The three sequences, D36 PBMC, C18 HIV StV and C18 HIV^-. show a number of similarities consistent with the transmission of virus from person D36 to person C18 as well as a number of differences indicating post-transmission divergence of sequence. All three have tat open reading frames (ORFs) extended by 15 codons. All three have extended rev ORFs. The new rev termination codon in both C18 HIV-1 isolates, three codons downstream of the NL4-3 rev termination codon, has a point mutation in D36 PBMC to make a Glu codon so that it continues for a further 11 codons (Fig 2b) to terminate at a conserved TGA. The partial Env gp41 amino acid sequences are more closely related to each other (86% identity or 90% including similarities) than to HIV NL4-3 (85% and 89%, respectively). The nucleotide sequence of the nef and LTR region of the HIV-1 isolate from recipient C98 (C98 HIV) is 90.3% identical (1264/1399) to the HIV NL4-3 sequence, ignoring deletions. Similar to the D36 PBMC and C18 MV StV and HIV,^-. isolates the C98 HIV sequence shows the third exon of tot to be extended by 15 codons with all but one being identical to the D36 PBMC tot extension. Also, the rev gene is extended by 3 codons, 2 of which are identical to the first 2 codons of the D36 PBMC rev extension. The sequence also encodes the C-terminal 223 amino acids of Env gp41 terminating at the normal termination codon. The C98 HIV Env amino acid sequence has 89% identity with HIV NL4-3 Env sequence, increasing to 92% of similarities are included. As with the D36 PBMC and the C98 HIV isolate sequences it is the nef gene and LTR regions that major differences from the HIV NL4-3 sequence arise. The nef gene open reading frame of C98 HIV is much longer than in D36 PBMC, C18 HIV StV and HlV j ^ jg -., encoding 85 amino acids compared with 206 amino acids for NL4-3. Sixty eight of those 85 amino acids are identical to the N-terminal sequence of NL4-3 Nef. The single, small deletion (16 nucleotides) in the C98 HIV we/alone regions (Table 3) occurs after nef codon 82 causing a frameshift and termination after a further 3 codons at the start of the highly conserved polypurine tract sequence immediately before the 3'- LTR. The we LTR region has two deletions totalling 142 nucleotides. The 5'-most deletion of 42 nucleotides includes the splice acceptor 12 sequence. The NRT-1, dyad symmetry and myb response element sequences are all intact. However, the downstream 100 nucleotide deletion includes sequences from the 3' end of the 5'-NF-AT and all of the 3' NF-AT sequences as well as the USF transcription factor recognition sequence. The downstream low homology region of 77 nucleotides lacks the TCF-lα sequence but has two additional NFKB sites 13 nucleotides apart and 26 nucleotides upstream of the 3'-half-remmant of the normal 5'-NFKB site. Sequence downstream, including the 3'- NFKB site, the 3 Spl sites, TATA box TAR and polyadenylation signal sequences are all highly conserved. The main feature of the sequences is the series of deletions, with respect to HIV NL4-3, in the we/gene-3'-LTR region. These can be grouped into two regions namely the nef- alone region, that part of the nef gene upstream of the LTR, and the nefϊLTK region, where the nef ' gene and LTR U3 regions overlap. The deletions in these regions of each of the sequences start and end at the same or similar positions (Table 3). The deletions are larger in C18 HIV StV and C18 HIV^-. sequences where totals of 397 and 456 nucleotides have been deleted (relative to NL4-3) compared to 291 nucleotides, from D36 and 158 nucleotides from C98 HIV. In the we/alone region the two deletions in Cl 8 HIV StV and the single deletion in Cl 8 HIV MBC occupy the same region as the three deletions in D36 PBMC. Similarly, the we LTR region in the three deletions in the Cl 8 HIV StV , the two deletions in the Cl 8 HIV^-. and the D36 PBMC sequences occupy the same region. These findings indicate that mutant virus was transmitted from D36 to C18 after which further deletions and rearrangements occurred. Similarly, the sequence of C98 HIV in the we LTR region indicates two deletions occupying the same region as the we LTR deletions in D36 and the C18 sequences. However, the size (only 16 nucleotides) and the position of the deletion in the we/alone region of C98 HIV are distinct from those of the D36 PBMC and C18 sequences. The timing of transmission of virus by transfusion was that recipient C18 was transfused approximately 19 months after C98. Consistent with the relative timing of transmission and the sequence similarities and differences is the suggestion that at the time of transmission to C98, the D36 sequence had deletions in the we/LTR region but not in we/alone region. After transmission to C98, the C98 virus developed further deletions and rearrangements, including the deletion in the we/alone region. The D36 virus evolved so that at the time of transmission to C18, further deletions and rearrangements had occurred including deletion of sequence from the we/alone region distinct from the C98 HIV we/alone region deletion. After transmission to C18, further deletions and rearrangements occurred in the Cl 8 virus giving rise to at least two sequences (HIV Stv "d fflV MBc) * The we/alone deletion region may be a mutation or recombination "hotspot" as it includes sequences that were found to be variably duplicated in 28 out of 54 Nef protein sequences derived from 8 of 12 patients analysed in a study (Shugars et al 1993). The sequence between the we/alone and the we LTR region deletions is highly conserved and is important in provirus integration into the infected cell genome and interacts with a number of cellular proteins. It is interesting that the sequence equivalent to NL4-3 nucleotides 9209 to 9225 is retained in D36 and C98 HIV but lost in the Cl 8 HIV sequences. This includes part of a sequence of dyad symmetry (9210 to 9231) and is a significant part of the binding site for NRT-1 (Yamamoto et al 1991) which has been shown to have a negative regulatory effect on HIV-1 expression. The presence of this sequence in D36 and C98 HIV and its absence from the C18 isolates may coπelate with the inability to isolate virus from D36 PBMC and the poor replication of C98 HIV but the ability to isolate HIV-1 from C18 PBMC. The deletion of sequence equivalent to nucleotides 9281 to 9395 of NL4-3 causes the loss of some transcription factor binding sites including NFAT and USF from the D36, C18 HIV and C98 HIV sequences. A further similarity between the D36, C18 HIV StV , C18 HIV MBC and C98 HIV sequences is a region of low homology to HIV-1 NL4-3 extending downstream of the we LTR deleted region to the NFKB enhancer/Spl promoter site region. This low homology region in fact consists of incomplete duplications of part of the NFKB/Spl region (Fig 5) resulting in D36 and C98 HIV having 2 extra NFKB sites upstream of an altered 5' NFKB site while the C18 sequences have one extra NFKB site and altered spacing between the 5' and 3' wild type NFKB sites due to an insertion of 9 nucleotides. For the C18 and C98 HIV-1 isolates virus replication was assessed in PHA-stimulated and non-stimulated PBMCs (Figs 6 and 7). In PHA-stimulated PBMCs we also studied cell surface CD4 and IL-2R expression (Fig 8). In comparison with HIV-1 wild type SI and NSI isolates clearly both C18 HIV^-. and C98 viruses are replication competent, though C98 HIV replicates more poorly than C18 HIV^-. and are of the NSI phenotype when syncytium formation and CD4 and IL-2R surface expression are taken into account. Additionally, and more surprisingly, these two viruses replicated almost as efficiently in non-PHA stimulated PBMCs when compared to a typical local wild type SI isolate (HIV-1 228200, Fig 7). When protein expression was assessed for C18 HIV^c and C98 HIV MBC although structural proteins were identified, no typical Nef protein was seen in infected cells. However, analysis of cell lysates prepared from PBMC infected with C18 HIV^-. or PBMC infected with C98 HIV j ^ j - (which were subsequently stimulated by UV irradiation, see Valerie et al, 1988) by Western immunoblotting using two antibodies specific for the N-terminal region of Nef showed the presence of smaller proteins of 19 kDa and 21 kDa, respectively. These proteins were not observed in mock-injected control PBMC lysates and were not observed when the infected-cell lysates were probed were probed with antibodies reactive with the C-terminus of Nef. Thus, although the C18 and C98 HIV isolates are replication competent in vitro they clearly replicate differently using different conditions for cell activation and from the known functions of HIV-1 Nef protein and the LTR show that the major deletion in the nef gene and/or the LTR is at least in part responsible for the outcome of infection, implicating the importance of Nef and/or the LTR in the clinical outcome of infection in vivo. EXAMPLE 9 Determination of Degree of Relatedness Between Viruses To determine the degree of relatedness between viruses such as between mutants or between mutants and a wild-type virus and to ascertain putative infected patients, the method of Delwart et al was employed. EXAMPLE 10 Immune responsiveness of subjects infected by non-pathogenic HIV-1 isolate In this example, the donor and recipients of the cohort were tissue typed and assessed for basic cellular immune responses. Proliferative responses and IL-2 production to the mitogens ConA and PHA, to allogeneic mononuclear cells (irradiated pooled mononuclear cells from 20 random donors) and to recall antigens (e.g. influenza and tetanus toxoid) were within normal ranges. While at the immunogenetic level, HLA typing failed to identify a consistently common allele or haplotype within the group. The conservation of CD4+ counts observed in the cohort, the relative integrity of their immune system and the varied HLA types of the donor and recipients further supports the fact that the symptomless condition of the cohort members is due to a non- pathogenic strain of HIV-1 or a strain of low virulence. Accordingly, this provides a screening procedure for subjects putatively infected by a non-pathogenic HIV-1 isolate where such subjects are seropositive for HIV-1 (e.g. have antibodies to an HIV-1 glycoprotein) yet have normal proliferative responses and cytokine production to mitogens, allogeneic mononuclear cells and to recall antigens. EXAMPLE 11 Clinical Immunology of Cohort To establish that the donor and the recipients belonging to the cohort exhibit normal immunological profiles, members of the cohort were assayed for CD3, CD4, CD8, lymphocyte count, CD4/CD8 ratio and β-2-microglobulin over time since seroconversion. Parameters considered normal in non-infected individuals range as follows: The results are shown in Figures 10(a)-(g) and clearly show that the immunological profiles of cohort members are substantially normal further highlighting the non- pathogenicity of the HIV-1 isolates of the present invention. Figure 10(g) shows a graph of the Kaplan-Meier (Ox and Oates, 1989) estimates of time to disease progression (AIDS or CD4 > 250). The results demonstrate that the difference is large in spite of the conservative bias, with a median time to progression of 6.2 years in the main database. An exact logrank test (Cytel Software Corporation, 1989, StatXact: Statistical Software for Exact Nonparametric Inference. Cambridge, Massachusetts.) was performed, demonstrating that the difference between the groups was highly statistically significant (logrank statistic 11.8, pO.OOOl). Table 3 Deletions and their sizes in the nef-alone and the ne/ΪLTR regions of the Long-Term Asymptomatic HIV-1 Sequences Sequence we/alone Region Region we LTR Region Region Total Deletion Deletion Deletion (nt) (nt) (nt) D36 PBMC 8830-8862 (33) 9112-9204 (93) 8882-8928 (47) 9281-9371 (91) 184 291 9009-9035 (27) 107 C18 HIV St V 8830-9006 (177) 9105-9224 (120) t- 9019-9029 (11) 188 9281-9362 (82) 202 390 V C I S HIV BC 8792-9041 (250) 250 9105-9224 (120) 9281-9366 (86) 206 456 C98 HIV 9033-9048 (16) 16 9148-9189 (42) 9271-9370 (100) 142 158 C54 PBMC incomplete 9281-9375 (95) 95 95 + Sequence numbering relates to the equivalent position in HIV-1 NL4-3. Numbers in brackets are the deletion sizes in nucleotides (nt). The nef ORF starts at nt 8787and the 3'-LTR starts at nt 9074 in HIV-1 NL4-3. EXAMPLE 12 Sequencing of isolate HIV-1 C18 MBC The genome of variant HIV-1 designated C18 HIV-l j ^c was amplified by the polymerase chain reaction (PCR) as 7 overlapping fragments using the sets of inner and outer oligonucleotide primers, designed using the programme PCRPLAN (IntelliGenetics), listed in Table 5 and either UlTma (Applied Biosystems) or a mixture of KlenTaq and Pfu (KlenTaq LA, Ab Peptides Inc) polymerases (for faithful amplification of long fragments). The resulting fragments were cloned into the Smal site of the plasmid vector pGEM7Zf+. Insert-contaiiiing clones representing each region of the full length variant HIV-1 were sequenced by a nested deletion strategy (Gou & Wu, 1982) and cycle sequencing with Taq polymerase and dye labelled primers complimentary to the T7 or SP6 sites within the cloning vector. Nucleotide sequences were entered and collated by ASSEMGEL and SEQIN (IntelliGenetics) and SEQED (Applied Biosystems) and translated to the encoded amino acid sequences using TRANSL (IntelliGenetics) programmes. Sequence alignments used NALIGN, CLUSTAL (IntelliGenetics) and SEQED programmes. The full length sequence (Fig 9; SEQ ID NO:800) of isolate HIV-1 is 9207 nucleotides long which is 506 nucleotides shorter than the HIV NL4-3 sequence. This size difference is comprised of 126 nucleotides of insertions and 632 nucleotides of deletions, see Table 6. The most extensive differences between the HIV-1 Clβ^-. sequence and HIV-1 NL4-3 are in the U3 region of the LTR and in the nef gene, as hereinafter described. The 5' LTR has deletions of 120 and 87 nucleotides and a region of low sequence homology, which is the result of an imperfect duplication of the downstream NFKB and Spl response sequences. These result in the loss of sequence from a number sites important in the regulation of transcription of HIV-1 genes, including the negative response element (NRE) and the response elements for a number of transcription factors including NF-AT, NRT-1, USF and TCF-lα. Furthermore, the low homology region contains an extra NFKB and Spl sites as well as an insertion of 9 nucleotides between the usual NFKB sites. Downstream of the NFKB sites the sequence of the LTR has a high level of homology (96.2%) with the same region of HIV NL4-3. The gag gene contains 3 insertions, which represent direct repetitions of adjacent sequences. The first is a perfect repeat of 15 nucleotides after the equivalent of nucleotide 1134 of HIV-1 NL4-3 and adds 5 amino acids to the C-terminus region of pl7 gag . The remaining 2 insertions are imperfect and perfect repeats of 30 and 6 nucleotides, respectively, after the equivalent of HIV NL4-3 nucleotides 2163 and 2232, respectively. These encode an extra 12 amino acids in the C-terminus region of pl5 gag just downstream of the gag to pol frameshift sequences. The variation in sequence length of the gag gene at these two positions is unusual. The homology of the encoded amino acid sequence of HIV-1 018^-. and HIV NL4-3 for the gag pl7, p24, and pl5 proteins is 87.1%, 93.5% and 94.3%, respectively. In the pol ORF, the encoded proteins have high homology with the NL4-3 sequences being 95.5% overall comprising plO protease 92.9%, p66 reverse transcriptase 95.4% and p34 integrase 95.8%. The amino acid sequence of the p61 RT lacks the mutations associated with resistance to the nucleoside (AZT, ddl, ddC)and non-nucleoside (Nevirapine) analogue drugs used in the treatment of HIV-1 -infected persons. The vi/gene encodes a 192 amino acid protein with 88.0% homology with that of HIV-1 NL4-3. The vpr gene encodes a 96 amino acid protein with 89.6% homology with that of HIV-1 NL4-3. There are 2 insertions and 1 deletion of sequences in the vpu gene. The insertions of 3 and 9 nucleotides are after the equivalent of nucleotide 6071 and 6234, respectively, of HIV-1 NL4-3. These add 1 amino acid after amino acid 3, and 3 amino acids after amino acid 59 of the encoded Vpu protein. The deletion of 12 nucleotides after the equivalent of HIV-1 NL4-3 nucleotide 6261 deletes 4 amino acids from the C-terminal region of Vpu as well as from the signal peptide of the ewv polyprotein, which is encoded by an overlapping reading frame. Amino acid sequence homology of HIV-1 C18 MBC V P U w * NL4-3 is 85.2%. The sequence encoding the ewv gpl20 has 9 insertions totalling 45 nucleotides (encoding 15 amino acids) and the deletion of a total of 18 nucleotides (encoding 6 amino acids). These are listed in Table 6. All of these events (insertions and deletions) are at positions in the ewv gene. This is within the ewv V3 coding region, immediately upstream of the sequence encoding the so called V3 tip (or loop) amino acid sequence, Gly Pro Gly Arg. The V3 region sequence is that of a typical clade B subtype (North America, Europe and Australia) being identical to the clade B consensus sequence (based on 186 ewv sequences) at 29/35 positions. The type of amino acid at positions 11 and 28 of the V3 loop region (where position 1 is the Cys at amino acid 266 of the ewv gpl20) is predictive of the viral non-syncytium / syncytium forming phenotype (Fouchier et al, 1992). The HIV-1 Clδ j ^-. ewv gene encoded amino acid sequence has Ser at position 11 and Ile at position 28 of the V3 loop region. The lack of a positively charged amino acid at both positions is strongly indicative of a non-syncytium viral phenotype. The overall amino acid sequence homology with HIV-1 NL4-3 (ignoring deletions and insertions) is 86.1%, comprising 85.5% for the gpl20 region and 87.6% for the gp41 region. Both the tat and rev second exon open reading frames (ORF) are longer than in HIV-1 NL4-3. A change of the tat termination codon from TAG to TCG extends the tat ORF to a downstream in phase termination codon extending the encoded tat amino acid sequence by 15 residues, compared with the 86 amino acid long NL4-3 tat protein, to a total length of 101 amino acids. However, this is the usual length of the HIV-1 tat protein. Similarly, the normal rev termination codon is changed from TAG to GAG. This extends the rev ORF to an in-phase teπnination codon 3 codons downstream so that the encoded Rev protein is 119 amino acids long instead of the usual 116. As mentioned above the most extensive differences between the sequences of the isolate HIV-1 C18MBC and HIV-1 NL4-3 are in the nef gene and the LTR region. While the nef gene overlaps the 3' LTR, these differences are found in both the nef alone and the nef I LTR overlap regions. The HIV C18 MBC -encoded nef protein is only 24 amino acids long compared with the normal length of 206 amino acids. This severe shortening of the nef protein is due to the deletion of 188 nucleotides (the 177 and 11 nucleotide deletions) from the we/alone region which also brings into phase a termination codon, TAG, at the resulting 25th codon. Downstream there is further loss of potential nef gene sequences by the 120 and 87 nucleotide deletions situated in the nef I LTR overlap region. The resulting 24 amino acid nef protein is identical to the N-terminus of the HIV-1 NL4-3 nef at 9 of the first 10 positions. Thereafter, homology is lost completely. Some sequences used in the generation of mature mRNAs are altered or lost in Clδ j ^ g -.. The dinucleotide immediately after the splice donor site 2 (SD2) at nts 4818-4819 (NL4- 3 equivalent nts 4963-4964)is changed from the conserved GT to GC. It is expected that this change would lead to loss of function of this site as a splice donor. Splice donor 2 is used in the processing of HIV-1 transcripts to some of the mRNAs that encode Tat, Rev and nef proteins. Similarly the splice acceptor site 7 (SA7) sequence at nts 6477-6478 (NL4-3 equivalent nts 6602-6603) is changed from the conserved AG dinucleotide to TC. This change is expected to lead to loss of function of this site as a splice acceptor. While this SA site is used in HIV-1 mRNA processing it is not a major site and is not used in the production of the regulatory proteins (Tat, Rev or nef) mRNAs. The splice donor 12 site is absent from the C18 MBC sequence (NL43 equivalent nts 9161-9162) as it is within the first deletion region in the nef I LTR overlap region which occurs at nt 8797 and results in the loss of NL43 nucleotides 9105 to 9224. It is significant that the SA12 site is absent from the sequence of all of the cohort virus isolates so far obtained as well as from the sequence of D36 PBMC, however, the C54 PBMC sequence does contain the SA12 site. SA12 is not used in the processing of mRNAs that encode the viral regulatory proteins. Normally SA12 is used in splicing in conjunction with SD1, 2, 3 and 4 and the resulting spliced RNA is probably not a mRNA but may have a regulatory role involving binding to cellular proteins (Smith et al, 1992). An interesting feature of the sequence of the HIV-1 Clδ j ^-. isolate is the deletion and rearrangement of sequence from the 5' -LTR U3 region and the deletion of sequence from the nef gene (both nef alone and nef I 3' LTR regions). These being the only features of the sequence distinct from disease-causing HIV-1. The lack of AIDS or AIDS-like symptoms in the patient C18 is attributed to the effects of the loss of LTR sequence and / or the loss of nef coding sequences and their role in the pathogenesis of AIDS. TABLE 4 Primers used to Amplify Overlapping regions of HTV-1 Clδ j y jjj c Primer Direction Primer Sequence Coordinate Length (nt) 30 TGrSAAGGGCT.-ATTTACTCCCAAAAAAGAC 25 AATCGTTCTAGCTCCCTGCTTGCCC 30 AA ~~ - ~ 3-3TGGAAGGGCT_--.TTTACTCCC 31 CCTCTAGACCGCTTAATACTGACGCTCTCGC 23 TCTCTCGACGCAGGACTCGGC 30 CTGTTTTCTGCCAGTTCTAGCTCTGCTTCT 26 TTTCCCGGGCGGCGACTGGTGAGTAC 32 CCC ΓAGACΓTGCCCAATTCAA I- CCCAC 39 CC_ACACCAGAC-_____-C__ΓC___^^ 39 • _~CΓA_A_A*-_ ~ TCCACA~-~A^^ 39 CCATCCTGATAAATGGACAσraαΛCCCATfiCTA^^ 37 TGGCCCAAACATTATGTACCTCTGCATCATATGC 30 AGCAGGACATAACAAGGTAGGATCTCTACA 28 GGATCTGTCTCTGTC CTCTCTCCACCT Underlined sequences depict added restriction enzyme site + and - orientations refer to sense and antisense strands of the double stranded DNA sequence TABLE 5 Sequence Deletions and Insertions in HIV-1 C18 MBC . Compared with HIV-1 NL43 EXAMPLE 13 Macrophage Isolates of HIV-1 C18 and HIV-1 C98 HIV-1 has been isolated from the macrophages of patients C18 and C98. Patient monocytes were prepared as follows. Whole blood was spun at 2000rpm for 10 minutes. Plasma was removed into a separate tube and the remaining cells were diluted 1:2 in PBS " (magnesium and calcium free phosphate buffered saline). This was underlaid with 10 ml of Ficoll Isopaque and spun at 2000rpm for 20 minutes. Cells were collected from the interphase and washed three times with PBS " . These cells were then seeded into a 6 well Costar tray at a concentration of 1.0 x 10 7 /ml and allowed to adhere for 1 hour. Any non-adherent cells were removed by aspiration. Donor HIV-1 negative macrophages for use in co-cultivation were prepared as follows. Peripheral blood mononuclear cells were purified from whole blood using Ficoll Isopaque density gradient. These cells were seeded at a concentration of 2.0 x 10 6 /ml in teflon. PBMC were cultured in the presence of 3μg/ml of PHA and lOOOU/ml of M-CSF 3 days prior to co-culture. On day of co-culture, donor PBMC were CD8 depleted. Dyna beads coated with anti- CD8 were used for this purpose. Dyna beads were washed once in PBS " and then applied to a magnet for 3 minutes. Supernatant was removed and the beads were then resuspended in 250μl of RF-10. Aliquots of 2.0 x 10 8 patient cells were then added to 250μl (3 beads : 1 CD8 T-cell) of Dyna beads and allowed to incubate for 30 minutes on ice with occasional mixing. After 30 minutes the cell suspension was placed onto a magnet for 3 minutes. The supernatant was then removed placed into a second tube containing 142 μl (1 bead : 1 CD8 T-cell) of Dyna beads. This suspension was placed on ice for an additional 30 minutes with occasional mixing. After 30 minutes cell suspension was placed onto a magnet for 3 minutes. Supernatant was removed and washed once in RF-10. For co-culture, CD8 depleted PBMC were then added to patient monocytes. Half media changes were done every 7 days for a period of 21 days. Aliquots of 2.5 ml of medium was removed from these cultures and replaced with CD8 depleted donor PBMC in Iscoves containing 10% HuS (Human serum), 5% v/v FCS and 5% w/v IL-2 and lOOOU/ml of M-CSF. Harvested supernatants were spun at 1400 rpm for 10 minutes and stored as lml aliquots. Cell pellets were lysed in 200μl of lysis buffer for PCR analysis. Infection was quantitated using a p24 EIA Kit. Cells were harvested from the co-cultures and used to prepare DNA as described above. The nef I 3'-LTR region of both virus isolates was amplified by PCR using the above described primer sets and conditions (Example 12). The resulting amplimers were cloned into the plasmid vector pT7T3U19 and the nucleotide sequence determined by the Taq cycle sequencing method with dye-labelled primers. The C18 macrophage sequence has 3 deletions starting and finishing at positions within 3 nucleotides of the same deletions in Clδ j ^-.. The encoded nef protein is 3 amino acids long compared with 7 amino acids for Clδ j ^ .. The low homology region of the LTR U 3 region of C18 macrophage is very similar in sequence to 018^-. and similarly it has one extra upstream NFKB site. On the other hand, the sequence of C98 macrophage has a number of differences from the C98 isolate. While it has exactly the same first deletion of 16 nucleotides just upstream of the polypurine tract (PPT), in the we/alone region, and exactly the same second deletion (position and size) it has an extra deletion of 18 nucleotides at NL4-3 equivalent nucleotides 9206 to 9223. The final deletion is in approximately the same position as in the C98 isolate but is 5 nucleotides longer. The encoded we/protein is 34 amino acids long compared with 86 amino acids for the C98 isolate. The low homology region is very similar to the C98 isolate, having the same 2 extra upstream NFKB sites and completely lacking the normal 5 '-NFKB site. EXAMPLE 14 Construction and Use of an Infectious Molecular Clone Molecular biological techniques can be used to construct a molecular clone of, for example, HIV-1 Two schemes may be used. In the first scheme genomic DNA, extracted from either the CD4 positive PBMC of the patient C18 or donor PBMC that have been infected with the isolate HIV-1 Clβ^-. , is used as the template for polymerase chain reaction amplification, using thermostable polymerase of high transcriptional fidelity (eg UlTma polymerase or KlenTaq/Pfii polymerase mixture), of long (6 to 7 kb) overlapping fragments representing the 5'- and 3 '-parts of the HIV-1 d-MB C P ro viral genome of total length 9207nts. The amplified fragments may then be ligated together after digestion with a restriction enzyme that cleaves at a unique site common to the overlapping region of the amplified fragments, for example the unique Bgl I or Nco I sites. Ligation of this full length proviral DNA into a plasmid vector will allow its propagation in E coli and the subsequent preparation of large (mg) quantities of this molecularly cloned proviral DNA. In the second scheme donor PBMC that have been infected with the isolate HIV-1 Clδ j ^ jgf - are used as a source of non-integrated proviral DNA which can be extracted from the infected cells by the Hirt extraction method (Hirt, 1967). Circular proviral DNA molecules may be linearised by digestion with a restriction enzyme that cleaves at a unique position in the genome (eg the Bgl I or Nco I sites). The resilting linearised molecules can be ligated into a plasmid or, more usually, a bacteriophage lambda (λ) based vector (eg Charon 4a, λWES) after modification of the end to provide blunt or cohesive ends compatible with the vector. Transformation or transduction of E coli with the recombinant plasmid or bacteriophage material, respectively allows the propagation of the proviral DNA. Clones of E coli containing proviral DNA may be selected and DNA prepared. Molecular clones of retro viral genomes prepared in this way are often permuted. Rearrangement to the functional arrangement of sequences is achieved by restriction enzyme cleavage and religation of fragments to reconstruct the coπectly permuted proviral genome. The molecularly cloned DNA products of both schemes can be used to prepare variant proviral genomes that may be used as the basis of a biologically attenuated HIV-1 vaccine strain. Similarly, they may be modified to contain extra DNA sequences in the we/alone deletion region that may deliver sequences that may be of therapeutic advantage (eg antisense or ribozyme sequences). Infectious virus particles of HIV-1 018^-. , or modified virus, can be produced by transfection of human cells (eg HeLa cells) which will produce, and release to the culture medium, virus particles of HIV-1 CIS^ QQ , or modified virus. These virus particles can be used to infect a variety of CD4 positive cells for further propagation or experimentation. EXAMPLE 15 In vivo Primate Model Following construction of infectious molecular clones of the mutant HIV-1 strains, studies are then undertaken in primates to establish attenuation, immunogenicity and vaccine prophylactic efficacy. All studies compare mutant clones of HIV-1 with isogenic wild-type (WT) virus. Initial studies are performed using the macaque ( nemistrinά) model of HIV-1 infection. Macaque-infectious WT HIV-1 and mutant clones are compared with respect to duration of viremia, anatomic sites of replication, and cellular and humoral immune responses. Where the mutant HIV-1 clones induce an immune response in the macques infected, challenge studies with WT virus are also performed. Studies are performed in a limited number of chimpanzees, generally in parallel with the macaque studies. Relevant mutations are engineered into WT HIV-1 clones previously shown to produce chronic infection in chimps, and the course of chimp infection with mutant clones compared with historical controls. If infection is established, WT challenge studies is also performed. Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features. BIBLIOGRAPHY BACHMANN B, LUKE W AND HUNSMANN G (1990). Nucl Acids Res 18: 1309. BARRE-SINOUSSI F, CHERMANN JC, REY F, et al (1983) Science 220: 868-871. BUSCH MP, EL AMAD Z, SHEPPARD HW, ASCHER MS, LANG W (1991) NEngl JMed 325: 733-735. CHENG-MAYER C, SHIODA T, LEVY JA (1991) J Virol 65: 6931-6941. CLERICI M, STOCKS NI, ZAJAC RA, et al (1989) J Clin Invest 84: 1892-1899. COX and OAKES (1989) Survival Analysis, Chapman & Hall. DANIEL MD, KIRCHHOFF F, CZAJAK SC, SEHGAL P AND DESROSIERS RC (1992). Science 258: 1938-1941. DELWART EL, et al (1993) Science 262: 1257-1261. FOUCHER RAM, et al (1992) J. Virol. 66: 3183-3187. GAYNOR R (1992). AIDS 6m 347-363. GOU L-H and WU R. (1982) Nucleic Acids Research 10: 2065-2084. GREENWAY et al (1994) Virology 198: 245-256. GROENINK M, FOUCHIER RAM, BROERSEN S, et al (1993) Science 260: 1513- 1515. HAMMES SR, DIXON EP, MALIM MH, CULLEN BR and GREENE WC, (1989) Proc Natl Acad Sci USA 86: 9549-9553. HIRT B. (1967) J Mol Biol 26: 365-369. HWANG SS, BOYLE TJ, LYERLY HK, CULLEN BR (1991) Science 253: 71-74. KASLOW RA, DUQUESNOY R, VAN RADEN M, KINGSLEY L, MARRARI M. (1990) E wcet 335: 927-930. KEMP BE, RYLATT DB, BUNDESEN PG, DOHERTY RR, MCPHEE DA, STAPLETON D, COTTIS LE, WILSON K, JOHN MA, KHAN JM, DINH DP, MILES S & HILL YARD CJ (1988). Science 241: 1352-1354. KESTLER HW, RINGLER DJ, MORI K, PANICALI DL, SEHGAL PK, DANIEL MD & DESROSIERS RC (1991). Cell 65: 651-662. KIERNAN R, et al (1990) AIDS Res. Hum. Retroviruses 6: 743-752. KIM S, IKEUCHI K, BYRN R, GROOPMAN J and BALTIMORE D (1989) Proc Natl Acad Sci USA 86: 9544-9548. LANG W, PERKINS H, ANDERSON RE, ROYCE R, JEWELL N. WILKELSTEIN W. (1989) JAcquir Immune Defic Syndr 2: 63-69. LEARMONT J, TINDALL B, EVANS L, CUNNINGHAM A, CUNNINGHAM P, WELLS J, PENNY R, KALDOR J AND COOPER DA. (1992). Z wcet 340: 863-867. LEGUERN M, SHIODA T, LEVY JA, CHENG-MAYER C. (1993) Virology 195; 441- 447. LEVY JA, (1993) AIDS 7; 1401-1410. LIFSON AR, BUCHBINDER SP, SHEPPARD HW, et al (1991) J infect Dis 163: 959-965. LUCIW PA, CHENG-MAYER C and LEVY JA (1987) Proc Natl Acad Sci USA 84: 1434-1438. MANIATIS T et al (1982). Molecular cloning. A Laboratory Manual, 1st edition Pub. Cold Spring Harbor Laboratory Press. MOSIER DE, GULIZIA RJ, MACISAAC PD, TORBETT BE, LEVY JA (1993) Science 260: 689-692. MYERS A, KORBAR B, BERZOFSKY JA, SMITH RF & PAVLAKIS SA eds (1992; 1993). Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Pub Theoretical Biology and Biophysics Group. Los Alamos National Laboratory, Los Alamos, NM USA. NEATE EV, HEALY DS, PRINGLE RC, GUST ID, AND JOWLETT JMB (1987). Aust NZJ Med 17: 461 -466. NIEDERMAN TMJ, THIELAN BJ, and RATNER L. (1989) Proc Natl Acad Sci USA 86: 1128-1132. PEPER RJ, TINA WZ, & MICHELSON MM (1968). J Lab Clin Med 72: 842-846. SANGER F, NICKLEN S AND COULSON AR (1977). Proc Natl Acad Sci USA 4: 5463-67. SHEPPARD HW, LANG W, ASCHER MS, VITTINGHOF E and WINKELSTEIN W. (1993) AIDS 7: 1159-1166. SHIODA T, LEVY JA, CHENG-MAYER C (1992) Proc Natl Acad Sci USA 89: 9434-9438. SHUGARS DC, SMITH MS, GLUECK DH, NANTERMET PV, SEILLIER- MOISEIWITSCH F AND SWANSTROM R (1993). J Virol 67: 4639-4650. SMITH J, AZAD AA, and DEACON NJ (1992) J Gen Virol 73: 1825-1828. SULLIVAN N, THALI M, FURMAN C, HO DD, SODROSKI J (1993) J Virol 67: 3674-3679. TEEUWSEN VJP, SIEBELINK KHJ, DE WOLF F, GOUDSMIT J, UYTDEHAAG FGCM, OSTERHAUS ADME (1990) AIDS 4: 77-81. TERSMETTE M, DE GOEDE REY, BERT JM, et al (1988) J Virol 62: 2026-2032. TERWILLIGER E, SODROSKI JG, ROSEN CA, and HASELTINE WA, (1986) J Virol 60: 754-760. YAMANOTO K MORI S, OKAMOTO T, SHINOTOHNO K AND KYOGOKU Y (1991). Nucl Acids Res 22: 6107-6112. YANISCH-PERRON C, VIEIRA J, and MESSING J Gewe 13: 103-119. SEQUENCE LISTING (1) GENERAL INFORMATION: (i)(a) APPLICANT: (Other than US) THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH LIMITED and AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION) (b) INVENTORS/APPLICANTS (US only): DEACON, N; LEARMONT, J; McPHEE, D; CROWE, S and COOPER, D. (ii) TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1 (iii) NUMBER OF SEQUENCES: 800 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: DAVIES COLLISON CAVE (B) STREET: 1 LITTLE COLLINS STREET (C) CITY: MELBOURNE (D) STATE: VICTORIA (E) COUNTRY: AUSTRALIA (F) ZIP: 3000 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICAΗON DATA: (A) APPLICAΗON NUMBER: PCT INTERNAΗONAL (B) FILING DATE: 14-FEB-1995 (vii) PRIOR APPLICAΗON DATA: (A) APPLICAΗON NUMBER: PM3864 (AU) (B) FILING DATE: 14-FEB-1994 (A) APPLICAΗON NUMBER: PM4002 (AU) (B) FILING DATE: 21-FEB-1994 (A) APPLICAΗON NUMBER: PN0284 (AU) (B) FILING DATE: 23-DEC-1994 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: HUGHES, Dr E JOHN L (C) REFERENCE/DOCKET NUMBER: EJH/EK (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: +61 3 254 2777 (B) TELEFAX: +61 3 254 2770 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9709 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: TCGTCACAAT AAAGATAGGG ATACAGTATT AGAAGAAATG TTGGAGGTTT TATCAAAGTA AAGCTATAGG TACAGTATTA TGACTCAGAT TGGCTGCACT AATTAAAGCC AGGAATGGAT TAAAAGCATT AGTAGAAATT GGCCTGAAAA TCCATACAAT GGAGAAAATT AGTAGATTTC AATTAGGAAT ACCACATCCT TGGGCGATGC ATATTTTTCA CCATACCTAG TATAAACAAT AGGGATGGAA AGGATCACCA TTAGAAAACA AAATCCAGAC CTGACTTAGA AATAGGGCAG GGTGGGGATT TACCACACCA GTTATGAACT CCATCCTGAT GCTGGACTGT CAATGACATA ATGCAGGGAT TAAAGTAAGG AAGTAGTACC ACTAACAGAA AAGAACCGGT ACATGGAGTG AGCAGGGGCA AGGCCAATGG CAGGAAAATA TGCAAGAATG CAGTACAAAA AATAGCCACA TACCCATACA AAAGGAAACA TTCCTGAGTG GGAGTTTGTC AAGAACCCAT AATAGGAGCA AATTAGGAAA AGCAGGATAT ACACAACAAA TCAGAAGACT TAGAAGTAAA CATAGTGACA ATAAGAGTGA ATCAGAGTTA TCTACCTGGC ATGGGTACCA TGGTCAGTGC TGGAATCAGG AACATGAGAA ATATCACAGT TAGTAGCAAA AGAAATAGTA ATGGACAAGT AGACTGTAGC AAGTTATCTT GGTAGCAGTT CAGAGACAGG GCAAGAAACA AAACAGTACA TACAGACAAT GGTGGGCGGG GATCAAGCAG TAGAATCTAT GAATAAAGAA ATCTTAAGAC AGCAGTACAA TTGGGGGGTA CAGTGCAGGG AAGAATTACA AAAACAAATT GAGATCCAGT TTGGAAAGGA TACAAGATAA TAGTGACATA ATGGAAAACA GATGGCAGGT (2) INFORMATION FOR SEQ ID N0:2: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISTICS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: (C) STRANDEDNESS: single (D) TOPOLOGY: linear GTGGCAAGTG (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:7: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:2: (i) SEQUENCE CHARACTERISΗCS: ATGGGTGGCA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMATION FOR SEQ ID NO:3: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:7: (C) STRANDEDNESS: single (D) TOPOLOGY: linear TGGCAAGTGG (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:8: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:3: (i) SEQUENCE CHARACTERISΗCS: TGGGTGGCAA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMATION FOR SEQ ID NO:4: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:8: (C) STRANDEDNESS: single (D) TOPOLOGY: linear GGCAAGTGGT (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:9: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: GGGTGGCAAG (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMATION FOR SEQ ID NO:5: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:9: (Q STRANDEDNESS: single (D) TOPOLOGY: linear GCAAGTGGTC (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:10: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:5: (i) SEQUENCE CHARACTERISΗCS: GGTGGCAAGT (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMATION FOR SEQ ID NO:6: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:10: (C) STRANDEDNESS: single CAAGTGGTCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 11 : (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l 5 : (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTCAAAAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 16: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:ll: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGTGGTCAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 12: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 16: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTCAAAAAGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:17: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:12: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGTGGTCAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:13: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 17: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCAAAAAGTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:18: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGGTCAAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:14: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAAAAAGTAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:19: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGTCAAAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:15: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAAAAGTAGT (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:20: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GTAGTGTGAT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:25: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAAGTAGTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:21: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TAGTGTGATT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:26: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAGTAGTGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:22: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTGTGATTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:27: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:22: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGTAOTGTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:23: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:27: (i) SEQUENCE CHARACTΕRISTTCS: (A) LENGTH: 10 base pairs GTGTGATTGG (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO ~ 8: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGTAGTGTGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:24: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGTGATTGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO_29: (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:33: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTGGATGGCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:34: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGATTGGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:30: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGATGGCCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:35: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:30: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGATTGGATG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:31: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGATGGCCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:36: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATTGGATGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:32: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:36: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATGGCCTGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:37: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATTGGATGGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:33: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:37: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATGGCCTGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:38: (ii) MOLECULE TYPE: DNA (i) SEQUENCE O-AF-ACTERISTICS: (A) LENGTH: 10 base pairs CTGCTGTAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:43: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:38: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGCCTGCTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:39: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:43: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGCTGTAAGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:44: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGCCTGCTGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:40: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTGTAAGGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:45: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCCTGCTGTA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:41: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTGTAAGGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:46: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCTGCTGTAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:42: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGTAAGGGAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:47: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:52: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:47: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTAAGGGAAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:48: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGAAAGAATG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:53: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:48: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAAGGGAAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:49: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:53: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GAAAGAATGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:54: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:49: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGGGAAAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:50: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:54: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAAGAATGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:55: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:50: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGGGAAAGAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:51: (xi) SEQUENCE DESCRIPTION: SEQ tt> NO:55: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAGAATGAGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:56: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: (B) TYPE: nucleic acid ( STRANDEDNESS: single GGGAAAGAAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAATGAGAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:57: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GAGACGAGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:62: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:57: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAATGAGACG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:58: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AGACGAGCTG (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ff> NO:63: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:58: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AATGAGACGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:59: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:63: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GACGAGCTGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:64: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:59: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATGAGACGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:60: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:64: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACGAGCTGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:65: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:60: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGAGACGAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:61: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CGAGCTGAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:66: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:70: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGAGCCAGCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:71: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGCTGAGCC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:67: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGCCAGCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:72: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:67: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCTGAGCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:68: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:72: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCCAGCAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:73: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRJPΗON: SEQ ID NO:68: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTGAGCCAG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:69: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:73: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCAGCAGCA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:74: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:69: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGAGCCAGC (C) STOANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:70: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ED NO:74: CCAGCAGCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:75: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCAGATGGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:80: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:75: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGCAGCAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:76: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCAGATGGGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:81: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:76: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCAGCAGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:77: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGATGGGGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:82: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:77: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCAGCAGATG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:78: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:82: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGATGGGGTG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:83: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGCAGATGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:79: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:83: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATGGGGTGG (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:84: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGTGGGAGCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:89. (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATGGGGTGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:85: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:89: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GTGGGAGCAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:90: Oi) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:85: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGGGTGGGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:86: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:90: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGGGAGCAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:91: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: (B) TYPE: nucleic acid (O STRANDEDNESS: single GGGGTGGGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:87: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:91: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGGAGCAGTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:92: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:87: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGGTGGGAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:88: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:92: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGAGCAGTAT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:93: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:97: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGTATCTCGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:98: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:93: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGCAGTATC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:94: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTATCTCGAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:99: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCAGTATCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:95: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:99: (A) LENGTH: 10 base paire (B) TYPE: nucleic acid TATCTCGAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:100: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:95: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCAGTATCTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:96: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt ) NO: 100: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATCTCGAGAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:101: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:96: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGTATCTCG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:97: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:101: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTCGAGACC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:102: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AGACCTAGAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:107: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTCGAGACCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:103: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GACCTAGAAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:108: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TCGAGACCTA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:104: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:108: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACCTAGAAAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO: 109: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CGAGACCTAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:105: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CCTAGAAAAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:l 10: (it) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:105: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGACCTAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO: 106: (xi) SEQUENCE DESCRIPTION: SEQ TD NO: 110: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTAGAAAAAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:lll: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 116: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l ll: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAGAAAAACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:l 12: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:l 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AAACATGGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 117: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:112: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAAAAACAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO: 113: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO: 117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AACATGGAGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:l 18: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO.113: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAAAAACATG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:114: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:118: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACATGGAGCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:l 19: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:114: (B) TYPE: nucleic acid (Q STRANDEDNESS: single AAAAACATGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:l 15: (xi) SEQUENCE DESCRIPTION: SEQ ID O:119: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CATGGAGCAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 120: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:115: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAACATGGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATGGAGCAAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:121: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCAATCACAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 126: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:121: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGAGCAATC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO: 122: (xi) SEQUENCE DESCRIPΗON: SEQ E> NO:126: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAATCACAAG (B) TYPE: nucleic acid ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO: 127: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO: 122: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGAGCAATCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO: 123: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AATCACAAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO: 128: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:123: (B) TYPE: nucleic acid (Q STRANDEDNESS: single GAGCAATCAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:124: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ATCACAAGTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:129: (Li) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:124: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCAATCACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt> NO:125: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCACAAGTAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:130: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:134: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGTAGCAATA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:135: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO: 130: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACAAGTAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:131: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTAGCAATAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:136: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO: 131: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACAAGTAGCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:132: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAGCAATACA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO: 137: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt> NO:132: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAAGTAGCAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO: 133: fii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTTON: SEQ ID NO: 137: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCAATACAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:138: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:133: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGTAGCAAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO: 134: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:138: GCAATACAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 139: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:143: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACAGCAGCTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:144: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 139: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAATACAGCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:140: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 144: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGCAGCTAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:145: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:140: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AATACAGCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 141: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:145: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCAGCTAAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO: 146: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:141: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATACAGCAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 142: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:146: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCAGCTAACA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:147: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO: 142: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TACAGCAGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO: 143: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 147: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGCTAACAA (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO: 148: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AACAATGCTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 153: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCTAACAAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:149: (xi) SEQUENCE DESCRffΗON: SEQ ID NO: 153: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACAATGCTGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 154: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:149: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCTAACAATG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:150: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:154: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAATGCTGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 155: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO: 150: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTAACAATGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:151: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:155: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AATGCTGCTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 156: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAACAATGCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO: 152: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ATGCTGCTTG (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt ) NO: 157: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTTGTGCCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 162: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:157: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGCTGCTTGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:158: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTGTGCCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:163: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:158: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTGCTTGTG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 159: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTGTGCCTGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 164: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:159: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGCTTGTGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:160: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 164: (A) LENGTH: 10 base paiis (B) TYPE: nucleic acid TGTGCCTGGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:165: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO: 160: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGCTTGTGCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:161: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: . (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:165: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGCCTGGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 166: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGGCTAGAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 171: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:166: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGCCTGGCTA (D) ' TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO: 167: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:171: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGCTAGAAGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 172: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 167: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCCTGGCTAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:168: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:172: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTAGAAGCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 173: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:168: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCTGGCTAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:169: (xi) SEQUENCE DESCRffTTON: SEQ TD NO: 173: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTAGAAGCAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt> NO:174: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO: 169: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTGGCTAGAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO: 170: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:174: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TAGAAGCACA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:175: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:170: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 180: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 175: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAAGCACAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO: 176: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CACAAGAGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 181: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO: 176: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAAGCACAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt> NO:177: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l 81: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACAAGAGGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:182: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:177: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGCACAAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO: 178: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO: 182: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAAGAGGAGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:183: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:178: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCACAAGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO: 179: (xi) SEQUENCE DESCRffTTON: SEQ TD NO: 183: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAGAGGAGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:184: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCACAAGAGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 184: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAGGAGGAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO: 185: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGGAAGAGGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 190: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO: 185: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGGAGGAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO: 186: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 190: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGAAGAGGTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:191: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGGAGGAAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:187: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:191: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GAAGAGGTGG (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO: 192: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:187: (B) TYPE: nucleic acid (Q STRANDEDNESS: single GGAGGAAGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:188: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:192: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AAGAGGTGGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 193: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:188: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGGAAGAGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO: 189: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 193: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGGTGGGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO: 194: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 198: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGGTTTTCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO: 199: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO: 194: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGGTGGGTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:195: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:199: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGTTTTCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:200: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:195: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGTGGGTTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:196: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTTTTCCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:201 : (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:196: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTGGGTTTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:197: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:201: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTTTTCCAGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:202: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:197: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGGGTTTTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:198: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:202: TTTTCCAGTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:203: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:207: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGTCACACC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:208: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:203: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTCCAGTCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:204: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:208: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGTCACACCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt ) NO:209: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTCCAGTCAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:205: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:209: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTCACACCTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:210: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:205: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCCAGTCACA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:206: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:210: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCACACCTCA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:211: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:206: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCAGTCACAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:207: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:211: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACACCTCAG (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:212: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:216: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTCAGGTACC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:217: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:212: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACACCTCAGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:213: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TCAGGTACCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:218: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:213: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CACCTCAGGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:214: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CAGGTACCTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:219: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACCTCAGGTA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:215: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:219: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGGTACCTTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi ) NO_220: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:215: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCTCAGGTAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:216: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO.220: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGTACCTTTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO-221: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:225: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTTAAGACC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:226: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:221: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTACCTTTAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:222: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:226: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTAAGACCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:227: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:222: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TACCTTTAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:223: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID N0.227: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTAAGACCAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:228: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:223: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCTTTAAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:224: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:228: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAAGACCAAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:229: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:224: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTTTAAGAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:225: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:229: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGACCAATG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:230: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAATGACTTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:235: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:230: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGACCAATGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:231: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:235: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AATGACTTAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:236: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:231: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GACCAATGAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ K> NO:232: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:236: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ATGACTTACA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:237: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:232: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACCAATGACT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:233: (xi) SEQUENCE DESCRIPTION: SEQ K> NO:237: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGACTTACAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:238: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: . (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233: (B) TYPE: nucleic acid (Q STRANDEDNESS: single CCAATGACTT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:234: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GACTTACAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:239: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:234: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:244: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACTTACAAGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:240: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:244: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAAGGCAGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:245: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:240: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTTACAAGGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:241: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:245: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAGGCAGCTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:246: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:241: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTACAAGGCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:242: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:246: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGGCAGCTGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:247: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:242: (B) TYPE: nucleic acid (C> STRANDEDNESS: single TACAAGGCAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:243: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:247: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGCAGCTGTA (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:248: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:243. (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACAAGGCAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID N0:248: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCAGCTGTAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:249: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:253: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGTAGATCTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:254: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTTON: SEQ ID NO:249: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CAGCTGTAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:250: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:254: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GTAGATCTTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:255: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:250: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCTGTAGAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:251: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:255: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TAGATCTTAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO-256: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:251: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCTGTAGATC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO-252: (xi) SEQUENCE DESCRIPTION: SEQ ID NO-256: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGATCTTAGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:257: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:2S2: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTGTAGATCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:253: (xi) SEQUENCE DESCRIPTION: SEQ ID N0:257: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATCTTAGCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:258: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:262: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAGCCACTTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:263: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:258: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATCTTAGCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:259: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (XI) SEQUENCE DESCRIPTION: SEQ ID NO:263: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCCACTΠT ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:264: (ii) MOLECULE TYPE: DNA (I) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:259: (A) LENGTH: 10 base pairs (Et) TYPE: nucleic acid TCTTAGCCAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:260: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (XI) SEQUENCE DESCRIPTION: SEQ ID NO:264: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCACTΠTT (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) N0.265: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACIERISTTCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO.260: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTAGCCACT (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO-261: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt> NO:265: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCACTΠTTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:266: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:261: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTAGCCACTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO_262: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:266: CACTTTTTAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:267: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:271 : (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTAAAAGAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:272: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:267: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACTTTTTAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:268: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:272: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTAAAAGAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:273: , (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:268: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTTTTAAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:269: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:273: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAAAAGAAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:274: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (XI) SEQUENCE DESCRIPTION: SEQ TD NO:269: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTΠTAAAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:270: (ii) MOLECULE TYPE: DNA (I) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:274: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAAAGAAAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:275: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:270: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTTAAAAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID N0.271: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:275: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAAGAAAAGG (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:276: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:280: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAAGGGGGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:281: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:276: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGAAAAGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:277: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:281: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AAGGGGGGAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:282: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:277: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAAAAGGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:278: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:282: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGGGGGGACT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:283: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:278: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAAAAGGGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:279: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:283: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGGGGGACTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:284: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:279: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAAGGGGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:280: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:284: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGGGGACTGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO_285: - I l l - (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:289: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACTGGAAGGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:290: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:285: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGGACTGGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:286: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:290: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGGAAGGGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:291: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:286: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGACTGGAA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:287: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:291: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGAAGGGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:292: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:287: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGACTGGAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:288: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:292: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGAAGGGCTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:293: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:288: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GACTGGAAGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:289: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTTON: SEQ TD NO:293: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAAGGGCTAA ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:294: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTAATTCAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:299: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:294: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGGGCTAAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:295: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:299: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTAATTCACT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:300: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:295: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGGGCTAATT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:296: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:300: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TAATTCACTC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:301: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:296: (B) TYPE: nucleic acid ( STRANDEDNESS: single GGGCTAATTC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:297: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:301: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AATTCACTCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ K> NO:302: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:297: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGCTAATTCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:298: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:302: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ATTCACTCCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:303: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:298: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:308. (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:303: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTCACTCCCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:304: (xi) SEQUENCE DESCRffTTON: SEQ ID NO:308: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TCCCAAAGAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:309: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:304: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TCACTCCCAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:305: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO.309: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CCCAAAGAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO.310: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:305: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CACTCCCAAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:306: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:310: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CCAAAGAAGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:311: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:306: (B) TYPE: nucleic acid (Q STRANDEDNESS: single ACTCCCAAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:307: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:311: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAAAGAAGAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:312: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:307: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTCCCAAAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:312: ■ (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAGAAGACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:313: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:317: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGACAAGATA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:318: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTTON: SEQ ID NO:313: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGAAGACAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:314: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:318: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GACAAGATAT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:319: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:314: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAAGACAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) N0.315: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:319: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACAAGATATC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:320: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:315: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAAGACAAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:316: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:320: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAAGATATCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:321: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:316: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGACAAGAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:317: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:321: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGATATCCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:322: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:326: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATCCTTGATC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:327: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTΕRISTTCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:322: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGATATCCTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:323: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:327: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCCTTGATCT (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:328: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:323: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATATCCTTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:324: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:328: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTTGATCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi ) NO:329: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:324: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATATCCTTGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:325: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO_329: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTGATCTGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:330: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ED NO:325: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TATCCTTGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:326: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTTON: SEQ ffi) NO.330: TTGATCTGTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:331: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:335: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGTGGATCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:336: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:331: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGATCTGTGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:332: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:336: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTGGATCTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) N0.337: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:332: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATCTGTGGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID N0.333: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:337: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGGATCTAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:338: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:333: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATCTGTGGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:334: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:338: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGATCTACC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:339: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:334: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTGTGGATC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:335: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:339: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGATCTACCA (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:340: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:344: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TACCACACAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:345: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:340: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GATCTACCAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:341: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:345: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ACCACACACA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:346: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTTCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt> NO:341: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATCTACCACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:342: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:346: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CCACACACAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:347: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:342: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TCTACCACAC (D) TOPOLOGY: linear (ϋ) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:343: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:347: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CACACACAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:348: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ TD NO:343: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTACCACACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:344: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:348: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ACACACAAGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:349: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:353: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAAGGCTACT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:354: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:349: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACACAAGGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:350: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:354: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGGCTACTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:355: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:350: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACACAAGGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:351: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:355: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGCTACTTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:356: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:351: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACAAGGCTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:352: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:356: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGCTACTTCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:357: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ TD NO:352: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACAAGGCTAC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:353: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:357: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTACTTCCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:358: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTCCCTGATT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:363: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:358: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTACTTCCCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:359: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:363: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TCCCTGATTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:364: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:359: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TACTTCCCTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO.360: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:364: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CCCTGATTGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ff> NO:365: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:360: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACTTCCCTGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:361: (xi) SEQUENCE DESCRffTlON: SEQ TD NO:365: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CCTGATTGGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:366: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:361: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTTCCCTGAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:362: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:366: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTGATTGGCA (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:367: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:362: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:372: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:367: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGATTGGCAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:368: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:372: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GGCAGAACTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:373: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:368: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GATTGGCAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:369: (xi) SEQUENCE DESCRIPTION: SEQ ID N0.373: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCAGAACTAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:374: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:369: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATTGGCAGAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO.370: (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:374: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAGAACTACA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:375: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:370: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTGGCAGAAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO:371: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:375: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AGAACTACAC (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD N0.376: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ TD NO:371: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGCAGAACT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:376: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAACTACACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:377: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:381: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACACACCAGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:382: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ED NO:377: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AACTACACAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:378: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:382: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CACACCAGGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:383: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:378: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACTACACACC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:379: (xi) SEQUENCE DESCRIPTION: SEQ tt ) NO:383: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ACACCAGGGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:384: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:379: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTACACACCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:380: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:384: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CACCAGGGCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:385: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:380: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TACACACCAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ED NO:381: (xi) SEQUENCE DESCRIPTION: SEQ ID N0:385: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCAGGGCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:386: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:390: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGCCAGGGGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:391: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:386: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCAGGGCCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:387: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:391: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCAGGGGTC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:392: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:387: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGGGCCAGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:388: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:392: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCAGGGGTCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:393: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:388: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGGCCAGGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:389: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:393: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGGGGTCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:394: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ TD NO:389: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGCCAGGGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:390: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:394: AGGGGTCAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:395: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:399: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCAGATATCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:400: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:395: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGGTCAGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:396: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:400: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGATATCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO.401: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ tt) NO:396: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGTCAGATA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:397: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:401: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGATATCCAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO.402: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:397: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTCAGATAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:398: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:402: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATATCCACT (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO.403: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO :398: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTCAGATATC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:399: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:403: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATATCCACTG (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:404: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:408: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CACTGACCTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:409: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:404: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TATCCACTGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:405: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:409: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACTGACCTTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:410: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:405: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATCCACTGAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:406: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:410: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTGACCTTTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:411: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:406: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TCCACTGACC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO:407: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:411: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGACCTTTGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:412: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:407: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCACTGACCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:408: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:412: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GACCTTTGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:413: (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:4I7: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTGGATGGTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:418: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:413: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCTTTGGAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:414: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:418: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGATGGTGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:419: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:414: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTTTGGATG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:415: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:419: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGATGGTGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:420: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:415: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTTGGATGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:416: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:420: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATGGTGCTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:421: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:416: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTGGATGGT ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:417: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: - (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:421: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATGGTGCTAC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:422: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTACAAGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:427: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:422: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGTGCTACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:423: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:427: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTACAAGCTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:428: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:423: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGTGCTACAA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:424: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:428: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TACAAGCTAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:429: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:424: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTGCTACAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:425: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:429: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACAAGCTAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:430: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:425: (Et) TYPE: nucleic acid (C) STRANDEDNESS: single TGCTACAAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:426: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:430: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CAAGCTAGTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:431: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:426: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:436: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:431: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGCTAGTAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:432: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:436: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTACCAGTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:437: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:432: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCTAGTACC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:433: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:437: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GTACCAGTTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:438: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:433: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCTAGTACCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:434: (xi) SEQUENCE DESCRffTTON: SEQ tt) NO:438: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TACCAGTTGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:439: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:434: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTAGTACCAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:435: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:439: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ACCAGTTGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:440: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:435: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAGTACCAGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:440: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCAGTTGAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:441: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:445: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGAGCCAGAT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:446: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:441: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CAGTTGAGCC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:442: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:446: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GAGCCAGATA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:447: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:442: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGTTGAGCCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:443: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:447: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGCCAGATAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:448: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:443: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTTGAGCCAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:444: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:448: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCCAGATAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:449: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:444: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTGAGCCAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:445: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:449: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCAGATAAGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:450: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:454: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAAGGTAGAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:455: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ED NO:450: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAGATAAGGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:451: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:455: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGGTAGAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:4S6: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:451: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGATAAGGTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:452: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:456: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGTAGAAGA (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:457: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:452: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATAAGGTAG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:453: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:457: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTAGAAGAG ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:458: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:453: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATAAGGTAGA ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:454: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:458: GTAGAAGAGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:459: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:463' (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGGCCAAT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:464: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:459: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAGAAGAGGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:460: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:464: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGGCCAATA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:465: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:460: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAAGAGGCC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:461: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:465: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGCCAATAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:466: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ TD NO:461: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAAGAGGCCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:462: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:466: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGCCAATAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:467: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:462: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGAGGCCAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:463: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:467: (A) LENGTH: 10 base pairs (Et) TYPE: nucleic acid GCCAATAAAG (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:468: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:472: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TAAAGGAGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:473: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:468: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCAATAAAGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:469: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:473: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AAAGGAGAGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:474: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ED NO:469: (B) TYPE: nucleic acid ( STRANDEDNESS: single CAATAAAGGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:470: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:474: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AAGGAGAGAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:475: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:470: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AATAAAGGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:471: (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:475: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AGGAGAGAAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:476: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:471: (B) TYPE: nucleic acid (Q STRANDEDNESS: single ATAAAGGAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:472: (xi) SEQUENCE DESCRIPΗON: SEQ ED NO:476: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGAGAGAACA (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:477: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:481: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAACACCAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:482: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:477: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGAGAACAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:478: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:482: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AACACCAGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:483: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:478: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGAACACC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:479: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:483: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACACCAGCTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:484: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:479: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGAACACCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:480: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:484: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACCAGCTTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:485: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO.480: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAACACCAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:481: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:485: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCAGCTTGT ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:486: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTTGTTACAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:491: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:486- (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCAGCTTGTT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:487: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:491: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTGTTACACC (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:492: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:487: (B) TYPE: nucleic acid (Q STRANDEDNESS: single CAGCTTGTTA (D) TOPOLOGY: linear fti) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:488: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:492: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGTTACACCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:493: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ID NO:488: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCTTGTTAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:489: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:493: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GTTACACCCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO.494: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS. (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:489: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCTTGTTACA ~ >) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:490: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:494: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTACACCCTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) " FORMATION FOR SEQ ID NO:495: (ii) MOLECULE TYPE: DNA 0) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:490: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:500: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:495: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TACACCCTGT (P) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:496: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:500: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CCTGTGAGCC (B) TYPE: nucleic acid ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:501: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:496: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACACCCTGTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID N0.497: (xi) SEQUENCE DESCRIPΗON: SEQ JD NO:501: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTGTGAGCCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:502: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:497: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CACCCTGTGA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:498: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:502: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TGTGAGCCTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:503: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt ) NO:498: (B) TYPE: nucleic acid ( STRANDEDNESS: single ACCCTGTGAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:499: (xi) SEQUENCE DESCRffTTON: SEQ tt) NO:503: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GTGAGCCTGC (B) TYPE: nucleic acid ( STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:504: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ TD NO:499: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCCTGTGAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID N0:504: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGAGCCTGCA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:505: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:509: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTGCATGGAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:510: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:505: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGCCTGCAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:506: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:510: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGCATGGAAT (B) TYPE: nucleic acid (Q STRANDEDNESS: single 0-) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:511: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:506: (B) TYPE: nucleic acid (Q STRANDEDNESS: single AGCCTGCATG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:507: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:511: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCATGGAATG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:512: (Li) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:507: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCCTGCATGG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO:508: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:512: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CATGGAATGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:513: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:508: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCTGCATGGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:509: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:513: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATGGAATGGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:514: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:518: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATGGATGACC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:519. (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:514: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGAATGGAT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:515: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:519: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGATGACCC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:520: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:515: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGAATGGATG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:516: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:520: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGATGACCCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:521: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:516: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAATGGATGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:517: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ tt> NO:521: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GATGACCCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:522: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:517: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AATGGATGAC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:518: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:522: ATGACCCTGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:523: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:527: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTGAGAGAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:528: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:523: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGACCCTGAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:524: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:528: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGAGAGAGA (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:529: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:524: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GACCCTGAGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:525: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:529: (A) LENGTH: 10 base paire (B) TYPE: nucleic acid TGAGAGAGAA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:530: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:525: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCCTGAGAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:526: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:530: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGAGAGAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:531: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:526: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCCTGAGAGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:527: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ED NO:531: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGAGAAGT (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:532: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:536: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GAAGTGTTAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:537: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:532: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGAGAAGTG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:533: (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:537: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AAGTGTTAGA (B) TYPE: nucleic acid (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:538: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ tt> NO:533: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAGAAGTGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:534: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:538: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTGTTAGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:539: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:534: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGAAGTGTT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ff> NO:535: (xi) SEQUENCE DESCRIPTION: SEQ ~ 5 NO:539: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GTGTTAGAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:540: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ BD NO:535: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGAAGTGTTA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ED NO:536: (xi) SEQUENCE DESCRIPTION: SEQ ID NO.540: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGTTAGAGTG (B) TYPE: nucleic acid ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ DD NO:541: (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:545: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGTGGAGGT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:546: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:541: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTTAGAGTGG (C) STRANDEDNESS: single ~ >) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:542: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:546: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGTGGAGGTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:547: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:542: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTAGAGTGGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:543: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:547: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGGAGGTTT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:548: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:543: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAGAGTGGAG (C) STRANDEDNESS: single ~ )) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:544: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ED NO:548: (A) LENGTH: 10 base pairs 0_) TYPE: nucleic acid TGGAGGTTTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:549: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ED NO:544: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGTGGAGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:545: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:549: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGAGGTTTGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:550: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TTTGACAGCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:555: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:550: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGGTTTGAC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:551: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:555: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTGACAGCCG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:556: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ID NO:551: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGGTTTGACA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:552: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:556: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGACAGCCGC (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:557: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:552: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGTTTGACAG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:553: (xi) SEQUENCE DESCRffTlON: SEQ tt) NO:557: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GACAGCCGCC (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:558: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:553: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTTTGACAGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:554: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:558: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACAGCCGCCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:559: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ID NO:554: (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:564: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:559: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CAGCCGCCTA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:560: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:S64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GCCTAGCATT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:565: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:560: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCCGCCTAG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:561: (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:565: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CCTAGCATTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:566: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ TD NO:561: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCCGCCTAGC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:562: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:566: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTAGCATTTC (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:567: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:562: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCGCCTAGCA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:563: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:567: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TAGCATTTCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:568: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:563: (B) TYPE: nucleic acid (Q STRANDEDNESS: single CGCCTAGCAT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:568: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCATTTCAT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:569: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:573: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTCATCACGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:574: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ TD NO:569: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GCATTTCATC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:570: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:574: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TCATCACGTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:575: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:570: (B) TYPE: nucleic acid (C).STRANDEDNESS: single CATTTCATCA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:571: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:575: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CATCACGTGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:576: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:571: (B) TYPE: nucleic acid ( STRANDEDNESS: single ATTTCATCAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:572: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:576: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs ATCACGTGGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ED NO:577: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:572: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTTCATCACG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ED NO:573: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:577: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCACGTGGCC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:578: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:582: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGCCCGAGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:583: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:578: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CACGTGGCCC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:579: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:583: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGCCCGAGAG ( STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:584: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:579: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACGTGGCCCG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:580: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:584: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCCGAGAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:585: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO.580: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CGTGGCCCGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt ) NO:581: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ tt) NO:585: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCCGAGAGCT ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATTON FOR SEQ tt ) NO:586: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:581: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGGCCCGAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:582: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESOUPTTON: SEQ ffi) NO:586: CCGAGAGCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:587: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:591: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCTGCATCC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:592: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:587: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CGAGAGCTGC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:588: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:592: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTGCATCCG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt ) NO:593. (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:588: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGAGCTGCA (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:589: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTTON: SEQ ffi) NO:593: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGCATCCGG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:594: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:589: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGAGCTGCAT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:590: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ DD NO:594: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGCATCCGGA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:595: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:590: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAGCTGCATC ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:591: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CI-ARACrERISlTCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:595: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCATCCGGAG (ii) MOLECULE TYPE: DNA (2) nMFORMATION FOR SEQ ID NO:596: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:600: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CGGAGTACTT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:601: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:596: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CATCCGGAGT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:597: (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:601: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GGAGTACTTC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:602: (ϋ) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:597: (B) TYPE: nucleic acid (Q STRANDEDNESS: single ATCCGGAGTA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:598: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:602: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GAGTACTTCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:603: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:598: (B) TYPE: nucleic acid (Q STRANDEDNESS: single TCCGGAGTAC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi ) NO:599: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:603: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTACTTCAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:604: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:599: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCGGAGTACT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:600: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:604: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GTACTTCAAG (B) TYPE: nucleic acid ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:605: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (B) TYPE: nucleic acid (C) STRANDEDNESS: single (C) STRANDEDNESS: single 05) TOPOLOGY: linear (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:609: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:605: TCAAGAACTG TACTTCAAGA (2) INFORMAΗON FOR SEQ ID NO:610: (2) INFORMAΗON FOR SEQ ID NO:606: (i) SEQUENCE CHARACTERISΗCS: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (B) TYPE: nucleic acid (C) STRANDEDNESS: single (C) STRANDEDNESS: single 05) TOPOLOGY: linear (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:610: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:606: CAAGAACTGC ACTTCAAGAA (2) ~ - ~ 5RMAT-ON FOR SEQ TD NO:611: (2) INFORMATION FOR SEQ ID NO:607: (i) SEQUENCE CHARACTERISΗCS: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (B) TYPE: nucleic acid (C) STRANDEDNESS: single (Q STRANDEDNESS: single 05) TOPOLOGY: linear 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ ID NO:611: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:607: AAGAACTGCT CTTCAAGAAC (2) INFORMAΗON FOR SEQ TD NO:612: (2) INFORMAΗON FOR SEQ ID NO:608: (i) SEQUENCE CHARACTERISΗCS: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (B) TYPE: nucleic acid (C) STRANDEDNESS: single (C) STRANDEDNESS: single 05) TOPOLOGY: linear (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:612: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:608: AGAACTGCTG TTCAAGAACT (2) INFORMATION FOR SEQ ffi) NO:613: (i) SEQUENCE CHARACTERISTICS: (2) INFORMAΗON FOR SEQ E) NO:609: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (i) SEQUENCE CHARACTERISΗCS: (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:613: GAACTGCTGA (2) INFORMATION FOR SEQ ID NO:614: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1305 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 614: GAAGAGATTT GGGAGAACAT GACCTGGATG CAGTGGGAAA AAGAAATTCA CAATCACACA 60 AAATACATAT ACTCCTTACT TGAAAAATCG CAGAACCAAC AAGAAAAGAA TGAACAAGAA 120 CTATTGGAAT TGGATCAATG GGCAAGTTTG TGGAATTGGT TTGACATAAC AAAATGGCTG 180 TGGTATATAA AAATATTCAT AATGGTAGTA GGAGGCTTGA TAGGTTTAAG AATAGTTTTT 240 GCTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATACT CACCATTGTC GTTTCAGACC 300 CTCCTCCCAA CCCCGAGGGG ACCCGACAGG CCCGAAGGAA TCGAAGAAGA AGGTGGAGAG 360 AGAGACAGAG ACAGATCCAC TCGATTAGTA CACGGATTCT TAGCACTTTT CTGGGACGAC 420 CTGAGGAGCC TGTGCCTCTT CCTCTACCAC CACTTGAGAG ACTTACTCTT GATTGTAACA 480 AGGATTGTGG AACTTCTGGG ACGCAGGGGA TGGGAAGCCC TCAAATATTG GTGGAACCTC 540 CTAAAGTATT GGAGCCAGGA ACTGCAGAAG AGTGCTGTTA TCTTGCTCAA TGCCACCGCC 600 ATAGCAGTAG CTGAGGGGAC AGATAGAGTT TTAGAAGTAT TACAAAGAGC TTATAGAGCT 660 ATCCTCCACA TACCTAGAAG AATAAGACAG GGCCTCGAAA TGGCTTTGCT ATAAAATGGG 720 TGGCAAGTGA GCAAAAAGTA GTGTAGTCAG ATAGCATGCA TCATAAGGGG TGGGGGCCAA 780 CAACTAACAA TGCTGATCGT GCCTGGCTAG AAGCACAAGA GAAGGAAGAA GCGGGTTTTC 840 CAGTCAAACC TCAGGTAGCT GTAGATCTTA GCCACTTTTT AAAAGAAAAG GGGGGACTGG 900 AAGGGCTAAT TCACTCCCAA AGAAGACAAG ATACACAGTG CTGCAAACTA TTACCAGTGG 960 AGTCAGCGAA GATAGAAGAG GCCAATGGAG GAGAAAACCA CAGATTGTTC TGTTGGGGAC 1020 TTTCCATCCG TTGGGGACTT TCCAAGGCGG CGTGGCCTGG GTGACTAGTT CCGGTGGGGA 1080 CTTTCCAAGA AGGCGCGGCC TGGGCGGGAC TGGGGAGTGG CGAGCCCTCA GATGCTGCAT 1140 ATAAGCAGCT GCTTTCTGCT GTTACTGGGT CTCTCGGGTT AGACCAGATC TGAGCCTGGG 1200 AGCTCTCTGG CTAACTAGGG AACCCACTGC TTAAGCCTCA ATAAAGCTTG CCTTGAGTGC 1260 TTCAAGTAGT GTGTGCCCGT CTGTTGTGTG ACTCTGGTAT CTAGA 1305 (2) INFORMATION FOR SEQ ID NO:615: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1208 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:615: GAAACAATTT GGGATAACAT GACCTGGATG CAGTGGGAAA GAGAAATTGA CAATTACACA 60 AACATAATAT ACACCTTAAT TGAAGAATCG CAGAACCAAC AAGAAAAAAA TGAACTAGAA 120 TTATTGGAAT TGGATAAATG GGCAAATTTG TGGAATTGGT TTAGTATATC AAACTGGCTA 180 TGGTATATAA AATTATTCAT AATGGTAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT 240 ACTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATACT CACCATTGTC GTTTCAGACC 300 CACCTCCCAA CCCCGAAGGG ACCCGACAGG CCAGAAGGAA TCGAAGAAGA AGGTGGAGAG 360 AGAGACAGAG GCAGCTCCAC TCGATTAGTG CACGGATTCT TAGCACTTTT CTGGGACGAC 420 CTGAGGAGTC TGTGCCTCTT CAGCTACCAC CACTTGAGAG ACTTACTCTT GATTGTAACG 480 AGGATTGTGG AACTTCTGGG ACGCAGGGGA TGGGAAGCCC TCAAATACTG GTGGAATCTC 540 CTGCAGTATT GGAGGCAGGA ACTACAGAAG AGTGCTGTTA GCTTGTTCAA TGGCACGGCC 600 ATAGCAGTAG CTGAGGGGAC AGATAGAGTT ATAGAAGCTT TACGAAGGGC TTATAGAGCT 660 ATTCTCCACA TACCTAGAAG AATAAGACAG GGCTTAGAAA GGGCTTTGCT ATAAAATGGG 720 TGGCAAGTGG TCAGAAAGTA GTGTGGTTAG AAGGCATGTA CCTTTAAGAC AAGGCAGCTA 780 TAGATCTTAG CCGCTTTTTA AAAGAAAAGG GGGGACTGGA AGGGCTAATT CACTCACAGA 840 GAAGATCAGT TGAACCAGAA GAAGATAGAA GAGGCCATGA AGAAGAAAAC AACAGATTGT 900 TCCGTTTGTT CCGTTGGGGA CTTTCCAGGA GACGTGGCCT GAGTGATAAG CCGCTGGGGA 960 CTTTCCGAAG AGGCGTGACG GGACTTTCCA AGGCGACGTG GCCTGGGCGG GACTGGGGAG 1020 TGGCGAGCCC TCAGATGCTG CATATAAGCA GCTGCTTTCT GCCTGTACTG GGTCTCTCTG 1080 GTTAGACCAG ATCTGAGCCT GGGAGCTCTC TGGCTAACTA GGGAACCCAC TGCTTAAGCC 1140 TCAATAAAGC TTGCCTTGAG TGCTTCAAGT AGTGTGTGCC CGTCTGTTGT GTGACTCTGG 1200 TATCTAGA 1208 (2) INFORMATION FOR SEQ ID NO:616: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:616: TGGAAGGGCT AATTTGGT 18 (2) INFORMAΗON FOR SEQ ID NO:617: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:617: ATCTTCCCTA AAAAATTAGC CTGTC 25 (2) INFORMAΗON FOR SEQ ID NO:618: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:618: AGGCTCAGAT CTGGTCTAAC 20 (2) INFORMAΗON FOR SEQ TD NO:619: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ED NO:619: AGCAGCAGGA AGCACTATGG 20 (2) INFORMAΗON FOR SEQ ID NO:620: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ ID NO:620: TGCTAGAGAT TTTCCACAC 19 (2) INFORMAΗON FOR SEQ TD NO:621: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:621: AGTGAATAGA GTTAGGCAGG 20 (2) INFORMATION FOR SEQ ID NO:622: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ ID NO:622: GTAAGACAGT ATGATCAGAT A 21 (2) INFORMAΗON FOR SEQ TD NO:623: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:623: TTGTAGGGAA TTCCAAATTC C 21 (2) INFORMATION FOR SEQ ID NO:624: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:624: CAGGATCCTA CACCTGTCAA CATAAT 26 (2) INFORMAΗON FOR SEQ ID NO:625: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ TD NO:625: GGGAATTCCT TATTCCTGCT TG 22 (2) INFORMAΗON FOR SEQ ffi) NO:626: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ TD NO:626: CCAGAAGTTC CACAATCC 18 (2) INFORMAΗON FOR SEQ TD NO:627: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:627: TTCTTCTAGG TATGTGGAG 19 (2) INFORMATION FOR SEQ ID NO:628: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:628: AGTGAATTAG CCCTTCCAG 19 (2) INFORMAΗON FOR SEQ ID NO:629: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:629: TGCTAGAGAT TTTCCACAC 19 (2) INFORMAΗON FOR SEQ ID NO:630: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:630: TGCTCTGGAA AACTCAT 17 (2) INFORMAΗON FOR SEQ ED NO:631: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:631: CTTTCTATAG TGAATAGAG 19 (2) INFORMATION FOR SEQ ID NO:632: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 632: TATTGGAGTC AGGAACT 17 (2) INFORMATION FOR SEQ ID NO:633: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:633: GGTCTAACCA GAGAGAC 17 (2) INFORMATION FOR SEQ ID NO:634: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:634: Ala Val Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO:635: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (O- STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 635: Pro Thr Ser Gin Ser Arg Gly Asp Pro Thr Gly Pro Lys Glu Lys 1 5 10 15 Lys Lys Val Glu Arg Glu Thr Glu Thr Asp Pro Phe Asp Thr 20 25 30 Asp Pro His 35 (2) INFORMATION FOR SEQ ID NO:636: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:636: Pro Ser Ser Gin Pro Arg Gly Asp Pro Thr Gly Pro Lys Glu Ser Lys 1 5 10 15 Lys Lys Val Glu Arg Glu Thr Glu Thr Asp Pro Leu Asp Tyr Thr 20 25 30 Asp Ser His 35 (2) INFORMATION FOR SEQ ID NO:637: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:637: Pro Thr Ser Gin Pro Arg Arg Asp Pro Thr Gly Gin Lys Glu Ser Lys 1 5 10 15 Lys Lys Val Glu Arg Glu Thr Glu Ala Ala Pro Leu Asp Cys Thr 20 25 30 Asp Ser His 35 (2) INFORMATION FOR SEQ ID NO:638: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:638: Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gin Ala Arg Arg Asn Arg 1 5 10 15 Arg Arg Arg Trp Arg Glu Arg Gin Arg Gin Ile His Ser Ile Ser Glu 20 25 30 Arg Ile Leu Ser Thr Tyr Leu Gly Arg Ser Ala Glu Pro Val Pro Leu 35 40 45 Gin Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys 50 55 60 Gly Thr Ser Gly Thr Gin Gly Val Gly Ser Pro Gin Ile Leu Val Glu • 65 70 75 80 Ser Pro Thr Val Leu Glu Ser Gly Thr Lys Glu Cys Cys Leu 85 90 95 Ala Gin Cys His Ser His Ser Ser Ser Gly Asp Arg 100 105 110 (2) INFORMATION FOR SEQ ID NO:639: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:639: Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gin Ala Arg Arg Asn Arg 1 5 10 15 Arg Arg Arg Trp Arg Glu Arg Gin Arg Gin Ile His Ser Ile Ser Thr 20 25 30 Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Pro Val Pro Leu 35 40 45 Pro Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Lys Asp Cys 50 55 60 Gly Thr Ser Gly Thr Gin Gly Met Gly Ser Pro Gin Ile Leu Val Glu 65 70 75 80 Pro Pro Lys Val Leu Glu Pro Gly Thr Ala Glu Glu Cys Cys Tyr Leu 85 90 95 Ala Gin Cys His Arg His Ser Ser Ser Gly Asp Arg 100 105 110 (2) INFORMATION FOR SEQ ID NO:640: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:640: Asp Pro Pro Pro Asn Pro Glu Gly Thr Arg Gin Ala Arg Arg Asn Arg 1 5 10 15 Arg Arg Arg Trp Arg Glu Arg Gin Arg Gin Leu His Ser Ile Ser Ala 20 25 30 Arg Ile Leu Ser Thr Phe Leu Gly Arg Pro Glu Glu Ser Val Pro Leu 35 40 45 Gin Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp Cys Asn Glu Asp Cys 50 55 60 Gly Thr Ser Gly Thr Gin Gly Met Gly Ser Pro Gin Ile Leu Val Glu 65 70 75 80 Ser Pro Ala Val Leu Glu Ala Gly Thr Thr Glu Glu Cys Cys Leu 85 90 95 Val Gin Trp His Gly His Ser Ser Ser Gly Asp Arg 100 105 110 (2) INFORMATION FOR SEQ ID NO:6 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:641: Glu Gin Ile Trp Asn Asn Met Thr Trp Met Glu Trp Asp Arg Glu Ile 1 5 10 15 Asn Asn Tyr Thr Ser Leu Ile His Ser Leu Ile Glu Glu Ser Gin Asn 20 25 30 Gin Gin Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Lys Trp Ala 35 40 45 Ser Leu Trp Asn Trp Phe Asn Ile Thr Asn Trp Leu Trp Tyr Ile Lys 50 55 60 Leu Phe Ile Met Ile Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe 65 70 75 80 Ala Val Leu Ser Ile Val Asn Arg Val Arg Gin Gly Tyr Ser Pro Leu 85 90 95 Ser Phe Gin Thr His Leu Pro Ile Pro Arg Gly Pro Asp Arg Pro Glu 100 105 110 Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Asp Arg Ser Ile Arg 115 120 125 Leu Val Asn Gly Ser Leu Ala Leu Ile Trp Asp Asp Leu Arg Ser Leu 130 135 140 Cys Leu Phe Ser Tyr His Arg Leu Arg Asp Leu Leu Leu Ile Val Thr 145 150 155 160 Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr 165 170 175 Trp Trp Asn Leu Leu Gin Tyr Trp Ser Gin Glu Leu Lys Asn Ser Ala 180 185 190 Val Asn Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp 195 200 205 Arg Val Ile Glu Val Leu Gin Ala Ala Tyr Arg Ala Ile Arg His Ile 210 215 220 Pro Arg Arg Ile Arg Gin Gly Leu Glu Arg Ile Leu Leu 225 230 235 (2) INFORMATION FOR SEQ ID NO:642: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:642: Glu Glu Ile Trp Glu Asn Met Thr Trp Met Gin Trp Glu Lys Glu Ile 1 5 10 15 His Asn His Thr Lys Tyr Ile Tyr Ser Leu Leu Glu Lys Ser Gin Asn 20 25 30 Gin Gin Glu Lys Asn Glu Gin Glu Leu Leu Glu Leu Asp Gin Trp Ala 35 40 45 Ser Leu Trp Asn Trp Phe Asp Ile Thr Lys Trp Leu Trp Tyr Ile Lys 50 55 60 Ile Phe Ile Met Val Val Gly Gly Leu Ile Gly Leu Arg Ile Val Phe 65 70 75 80 Ala Val Leu Ser Ile Val Asn Arg Val Arg Gin Gly Tyr Ser Pro Leu 85 90 95 Ser Phe Gin Thr Leu Leu Pro Thr Pro Arg Gly Pro Asp Arg Pro Glu 100 105 110 Gly Ile Glu Glu Met Gly Gly Glu Arg Asp Arg Asp Arg Ser Thr Arg 115 120 125 Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu 130 135 140 Cys Leu Phe Leu Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr 145 150 155 160 Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr 165 170 175 Trp Trp Asn Leu Leu Lys Tyr Trp Ser Gin Glu Leu Gin Lys Ser Ala 180 185 190 Val Ile Leu Leu Asn Ala Thr Ala Ile Ala Val Ala Glu Gly Thr Asp 195 200 205 Arg Val Leu Glu Val Leu Gin Arg Ala Tyr Arg Ala Ile Leu His Ile 210 215 220 Pro Arg Arg Ile Arg Gin Gly Leu Glu Met Ala Leu Leu 225 230 235 (2) INFORMATION FOR SEQ ID NO:643: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 237 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:643: Glu Thr Ile Trp Asp Asn Met Thr Trp Met Gin Trp Glu Arg Glu Ile 1 5 10 15 Asp Asn Tyr Thr Asn Ile Ile Tyr Thr Leu Ile Glu Glu Ser Gin Asn 20 25 30 Gin Gin Glu Lys Asn Glu Leu Glu Leu Leu Glu Leu Asp Lys Trp Ala 35 40 45 Asn Leu Trp Asn Trp Phe Ser Ile Ser Asn Trp Leu Trp Tyr Ile Lys 50 55 60 Leu Phe Ile Met Val Val Gly Gly Leu Val Gly Leu Arg Ile Val Phe 65 70 75 80 Thr Val Leu Ser Ile Val Asn Arg Val Arg Gin Gly Tyr Ser Pro Leu 85 90 95 Ser Phe Gin Thr His Leu Pro Thr Pro Lys Gly Pro Asp Arg Pro Glu 100 105 110 Gly Ile Glu Glu Glu Gly Gly Glu Arg Asp Arg Gly Ser Ser Thr Arg 115 120 125 Leu Val His Gly Phe Leu Ala Leu Phe Trp Asp Asp Leu Arg Ser Leu 130 135 140 Cys Leu Phe Ser Tyr His His Leu Arg Asp Leu Leu Leu Ile Val Thr 145 150 155 160 Arg Ile Val Glu Leu Leu Gly Arg Arg Gly Trp Glu Ala Leu Lys Tyr 165 170 175 Trp Trp Asn Leu Leu Gin Tyr Trp Arg Gin Glu Leu Gin Lys Ser Ala 180 185 190 Val Ser Leu Phe Asn Gly Thr Ala Ile Ala Val Ala Glu Gly Thr Asp 195 200 205 Arg Val Ile Glu Ala Leu Arg Arg Ala Tyr Arg Ala Ile Leu His Ile 210 215 220 Pro Arg Arg Ile Arg Gin Gly Leu Glu Arg Ala Leu Leu 225 230 235 (2) INFORMATION FOR SEQ ID NO:644: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 207 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein ( i) SEQUENCE DESCRIPTION: SEQ ID NO:644: Met Gly Gly Lys Trp Ser Lys Ser Ser Val Ile Gly Trp Pro Ala Val 1 5 10 15 Arg Glu Arg Met Arg Arg Ala Glu Pro Ala Ala Asp Gly Val Gly Ala 20 25 30 Val Ser Arg Asp Leu Glu Lys His Gly Ala Ile Thr Ser Ser Asn Thr 35 40 45 Ala Ala Asn Asn Ala Ala Cys Ala Trp Leu Glu Ala Gin Glu Glu Glu 50 55 60 Glu Val Gly Phe Pro Val Thr Pro Gin Val Pro Leu Arg Pro Met Thr 65 70 75 80 Tyr Lys Ala Ala Val Asp Leu Ser His Phe Leu Lys Glu Lys Gly Gly 85 90 95 Leu Glu Gly Leu Ile His Ser Gin Arg Arg Gin Asp Ile Leu Asp Leu 100 105 110 Trp Ile Tyr His Thr Gin Gly Tyr Phe Pro Asp Trp Gin Asn Tyr Thr 115 120 125 Pro Gly Pro Gly Val Arg Tyr Pro Leu Thr Phe Gly Trp Cys Tyr Lys 130 135 140 Leu Val Pro Val Glu Pro Asp Lys Val Glu Glu Ala Asn Lys Gly Glu 145 150 155 160 Asn Thr Ser Leu Leu His Pro Val Ser Leu His Gly Met Asp Asp Pro 165 170 175 Glu Arg Glu Val Leu Glu Trp Arg Phe Asp Ser Arg Leu Ala Phe His 180 185 190 His Val Ala Arg Glu Leu His Pro Glu Tyr Phe Lys Asn Cys 195 200 205 (2) INFORMATION FOR SEQ ID NO:645: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:645: Met Gly Gly Lys Ala Lys Ser Ser Val Val Arg His Ala Ser 1 5 10 15 Gly Val Gly Ala Asn Asn Gin Cys 20 25 (2) INFORMATION FOR SEQ ID NO:646: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:646: Met Gly Gly Lys Trp Ser Glu Ser Ser Val Val Arg Arg His Val Pro 1 5 10 15 Leu Arg Gin Gly Ser Tyr Arg Ser Pro Leu 20 25 (2) INFORMATION FOR SEQ ID NO:647: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 74 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:647: CTACAAGGGA CTTTCCGCTG GGGACTTTCC AGGGAGGCGT GGCCTGGGCG GGACTGGGGA 60 GTGGCGAGCC CTCA 74 (2) INFORMATION FOR SEQ ID NO:648: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 78 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO-.648: CTGTTGGGGA CTTTCCATCC GTTGGGGACT TTCCAAGGCG GCGTGGCCTG GGTGACTAGT 60 TCCGGTGGGG ACTTTCCA 78 (2) INFORMATION FOR SEQ ID NO:649: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 67 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:649: CCGTTTGTTC CGTTGGGGAC TTTCCAGGAG ACGTGGCCTG AGTGACTAAG CCGCTGGGGA 60 CTTTCCG 67 (2) INFORMATION FOR SEQ ID NO:650: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 621 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:650: ATGGGTGGCA AGTGGTCAAA AAGTAGTGTG ATTGGATGGC CTGCTGTAAG GGAAAGAATG 60 AGACGAGCTG AGCCAGCAGC AGATGGGGTG GGAGCAGTAT CTCGAGACCT AGAAAAACAT 120 GGAGCAATCA CAAGTAGCAA TACAGCAGCT AACAATGCTG CTTGTGCCTG GCTAGAAGCA 180 CAAGAGGAGG AAGAGGTGGG TTTTCCAGTC ACACCTCAGG TACCTTTAAG ACCAATGACT 240 TACAAGGCAG CTGTAGATCT TAGCCACTTT TTAAAAGAAA AGGGGGGACT GGAAGGGCTA 300 ATTCACTCCC AAAGAAGACA AGATATCCTT GATCTGTGGA TCTACCACAC ACAAGGCTAC 360 TTCCCTGATT GGCAGAACTA CACACCAGGG CCAGGGGTCA GATATCCACT GACCTTTGGA 420 TGGTGCTACA AGCTAGTACC AGTTGAGCCA GATAAGGTAG AAGAGGCCAA TAAAGGAGAG 480 AACACCAGCT TGTTACACCC TGTGAGCCTG CATGGAATGG ATGACCCTGA GAGAGAAGTG 540 TTAGAGTGGA GGTTTGACAG CCGCCTAGCA TTTCATCACG TGGCCCGAGA GCTGCATCCG 600 GAGTACTTCA AGAACTGCTG A 621 (2) INFORMATION FOR SEQ ID NO:651: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1596 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 651: GAACAGATTT GGAATAACAT GACCTGGATG GAGTGGGACA GAGAAATTAA CAATTACACA 60 AGCTTAATAC ACTCCTTAAT TGAAGAATCG CAAAACCAGC AAGAAAAGAA TGAACAAGAA 120 TTATTGGAAT TAGATAAATG GGCAAGTTTG TGGAATTGGT TTAACATAAC AAATTGGCTG 180 TGGTATATAA AATTATTCAT AATGATAGTA GGAGGCTTGG TAGGTTTAAG AATAGTTTTT 240 GCTGTACTTT CTATAGTGAA TAGAGTTAGG CAGGGATATT CACCATTATC GTTTCAGACC 300 CACCTCCCAA TCCCGAGGGG ACCCGACAGG CCCGAAGGAA TAGAAGAAGA AGGTGGAGAG 360 AGAGACAGAG ACAGATCCAT TCGATTAGTG AACGGATCCT TAGCACTTAT CTGGGACGAT 420 CTGCGGAGCC TGTGCCTCTT CAGCTACCAC CGCTTGAGAG ACTTACTCTT GATTGTAACG 480 AGGATTGTGG AACTTCTGGG ACGCAGGGGG TGGGAAGCCC TCAAATATTG GTGGAATCTC 540 CTACAGTATT GGAGTCAGGA ACTAAAGAAT AGTGCTGTTA ACTTGCTCAA TGCCACAGCC 600 ATAGCAGTAG CTGAGGGGAC AGATAGGGTT ATAGAAGTAT TACAAGCAGC TTATAGAGCT 660 ATTCGCCACA TACCTAGAAG AATAAGACAG GGCTTGGAAA GGATTTTGCT ATAAGATGGG 720 TGGCAAGTGG TCAAAAAGTA GTGTGATTGG ATGGCCTGCT GTAAGGGAAA GAATGAGACG 780 AGCTGAGCCA GCAGCAGATG GGGTGGGAGC AGTATCTCGA GACCTAGAAA AACATGGAGC 8 0 AATCACAAGT AGCAATACAG CAGCTAACAA TGCTGCTTGT GCCTGGCTAG AAGCACAAGA 900 GGAGGAAGAG GTGGGTTTTC CAGTCACACC TCAGGTACCT TTAAGACCAA TGACTTACAA 960 GGCAGCTGTA GATCTTAGCC ACTTTTTAAA AGAAAAGGGG GGACTGGAAG GGCTAATTCA 1020 CTCCCAAAGA AGACAAGATA TCCTTGATCT GTGGATCTAC CACACACAAG GCTACTTCCC 1080 TGATTGGCAG AACTACACAC CAGGGCCAGG GGTCAGATAT CCACTGACCT TTGGATGGTG 1140 CTACAAGCTA GTACCAGTTG AGCCAGATAA GGTAGAAGAG GCCAATAAAG GAGAGAACAC 1200 CAGCTTGTTA CACCCTGTGA GCCTGCATGG AATGGATGAC CCTGAGAGAG AAGTGTTAGA 1260 GTGGAGGTTT GACAGCCGCC TAGCATTTCA TCACGTGGCC CGAGAGCTGC ATCCGGAGTA 1320 CTTCAAGAAC TGCTGACATC GAGCTTGCTA CAAGGGACTT TCCGCTGGGG ACTTTCCAGG 1380 GAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC 1440 TGCTTTTTGC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG 1500 GCTAACTAGG GAACCCACTG CTTAAGCCTC AATAAAGCTT GCCTTGAGTG CTTCAAGTAG 1560 TGTGTGCCCG TCTGTTGTGT GACTCTGGTA ACTAGA 1596 (2) INFORMATION FOR SEQ ID NO:652: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:656: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTGCCTGTA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:657: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:652: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTTTTTGCC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:653: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:657: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTGCCTGTAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:658: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (XI) SEQUENCE DESCRIPΗON: SEQ ID NO:653: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTTΠTGCCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:654: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:658: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGCCTGTACT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:659: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:654: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTTTGCCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt ) NO:655: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:659: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCTGTACTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:660: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:655: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTTTGCCTGT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:656: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:660: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTGTACTGG (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:661: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:665: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACTGGGTCTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:666: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:661: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGTACTGGG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:662: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:666: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGGGTCTCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:667: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:662: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTACTGGGT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:663: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:667: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGGTCTCTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:668: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ IDNO:663: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTACTGGGTC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:664: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ TD NO:668: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGTCTCTCT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:669: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ED NO:664: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TACTGGGTCT ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:665: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTTON: SEQ ffi) NO:669: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTCTCTCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:670: (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:674: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTCTGGTTAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:675: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:670: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTCTCTCTGG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:671: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:675: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTCTGGTTA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:676: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ H5 NO:671: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTCTCTGGT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:672: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:676: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGGTTAGAC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:677: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:672: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTCTCTGGTT (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:673: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:677: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGTTAGACC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:678: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ H5 NO:673: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTCTGGTTA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ED NO:674: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:678: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGTTAGACCA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:679: (ii) MOLECULE TYPE: DNA (i) SEQUENCE C ~ -ARACTERISΗCS: (A) LENGTH: 10 base pairs GACCAGATCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:684: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:679: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTTAGACCAG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:680: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:684: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACCAGATCTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:685: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:680: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTAGACCAGA (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:681: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:685: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CCAGATCTGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:686: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:681: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAGACCAGAT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:682: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:686: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CAGATCTGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ DD NO:687: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:682: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGACCAGATC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:683: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:687: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGATCTGAGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:688: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ffi ) NO:683: (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:693: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:688: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GATCTGAGCC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:689: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:693: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GAGCCTGGGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) " ^FORMATION FOR SEQ TD NO:694: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:689: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ATCTGAGCCT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:690: (xi) SEQUENCE DESCRIPTION: SEQ ED NO:694: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGCCTGGGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:695: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:690: (B) TYPE: nucleic acid (Q STRANDEDNESS: single TCTGAGCCTG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:691: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:695: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GCCTGGGAGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ DD NO:696: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:691: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTGAGCCTGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:692: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:696: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CCTGGGAGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:697: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:692: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGAGCCTGGG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:697: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTGGGAGCTC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:698: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:702: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGCTCTCTGG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:703: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:698: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGGGAGCTCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ DD NO:699: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:703: (i) SEQUENCE (.HARACTERISTICS: (A) LENGTH: 10 base pairs GCTCTCTGGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:704: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:699: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGGAGCTCTC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ffi) NO:700: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:704: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTCTCTGGCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:705: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ tt) NO:700: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GGAGCTCTCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:701: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:705: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TCTCTGGCTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:706: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:701: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGCTCTCTG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:702: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:706: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTCTGGCTAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:707: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:711: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCTAACTAGG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:712: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:707: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTGGCTAAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:708: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:712: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTAACTAGGG ( STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:713: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ IDNO:708: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGGCTAACT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:709: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID N0.713: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAACTAGGGA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ED NO:714: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:709: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGGCTAACTA ( STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:710: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:714: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AACTAGGGAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:715: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ tt> NO:710: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGCTAACTAG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:711: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ ED NO:715: ACTAGGGAAC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) DEFORMATION FOR SEQ ID NO:716: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:720: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGAACCCACT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:721: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ H5 NO:716: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTAGGGAACC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ TD NO:717: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:721: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GAACCCACTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:722: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:717: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TAGGGAACCC (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:718: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:722: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AACCCACTGC ( STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:723: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:718: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGGGAACCCA (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:719: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:723: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ACCCACTGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:724: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ _D NO:719: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GGGAACCCAC (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:720: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:724: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCCACTGCTT (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:725: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:729: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGCTTAAGCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:730: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ID NO:725: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCACTGCTTA P) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:726: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:730: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GCTTAAGCCT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) " FORMATION FOR SEQ ID NO:731: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:726: (B) TYPE: nucleic acid ( STRANDEDNESS: single CACTGCTTAA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:727: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:731: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTTAAGCCTC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:732: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:727: (B) TYPE: nucleic acid (C) STRANDEDNESS: single ACTGCTTAAG (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:728: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:732: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TTAAGCCTCA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:733: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:728: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTGCTTAAGC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:729: (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:733: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs TAAGCCTCAA (B) TYPE: nucleic acid . (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:734: (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:738: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTCAATAAAG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:739: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:734: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AAGCCTCAAT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:735: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:739: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCAATAAAGC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:740: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:735: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AGCCTCAATA (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ tt) NO:736: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ TD NO:740: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CAATAAAGCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:741: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:736: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCTCAATAA (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ DD NO:737: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:74I: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid AATAAAGCTT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:742: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ IDNO:737: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCTCAATAAA (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:738: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:742: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid ATAAAGCTTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:743: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTTGCCTTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR S1.Q ID NO:748: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:743: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TAAAGCTTGC 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:744: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:748: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs CTTGCCTTGA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:749: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ tt) NO:744: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAAGCTTGCC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:745: (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:749: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TTGCCTTGAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:750: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:745: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AAGCTTGCCT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:746: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:750: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGCCTTGAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi ) NO:751: 00 MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt) NO:746: (B) TYPE: nucleic acid (C) STRANDEDNESS: single AGCTTGCCTT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:747: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:751: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCCTTGAGTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:752: (ii) MOLECULE TYPE: DNA fi) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:747: (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) ~ ~ ORMATION FOR SEQ ID NO:757: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:752: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CCTTGAGTGC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:753: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:757: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTGCTTCAA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:758: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ IDNO:753: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTTGAGTGCT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:754: (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:758: (0 SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GTGCTTCAAG (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:759: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ tt>NO:754: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TΓGAGTGCTT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:755: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:759: (I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TGCTTCAAGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ED NO:760: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ IDNO:755: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGAGTGCTTC (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:756: (xi) SEQUENCE DESCRIPTION: SEQ ED NO:760: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GCTTCAAGTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:761: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffTlON: SEQ ffi) NO:756: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GAGTGCTTCA 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:761: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CTTCAAGTAG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ ID NO:762: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:766: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs AGTAGTGTGT (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:767: (ii) MOLECULE TYPE: DNA (0 SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:762: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TTCAAGTAGT 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ TD NO:763: (xi) SEQUENCE DESCRIPTION: SEQ ffi) NO:767: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs GTAGTGTGTG (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:768: (ii) MOLECULE TYPE: DNA (0 SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ tt) NO:763: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TCAAGTAGTG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ tt) NO:764: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:768: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs TAGTGTGTGC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID N0. 69: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:764: (B) TYPE: nucleic acid (C) STRANDEDNESS: single CAAGTAGTGT (D) TOPOLOGY: linear fu) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:765: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:769: 0) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs AGTGTGTGCC (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:770: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:765: (B) TYPE: nucleic acid ( STRANDEDNESS: single AAGTAGTGTG 05) TOPOLOGY: linear fii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ffi) NO:766. (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:770: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGTGTGCCC (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:771: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ tt ) NO:775: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGCCCGTCTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:776: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:771: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTGTGCCCG (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:772: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPΗON: SEQ TD NO:776: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GCCCGTCTGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:777: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΉCS: (xi) SEQUENCE DESCRffΗON: SEQ ffi>NO:772: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGTGCCCGT (O STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:773: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ tt ) NO:777: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCCGTCTGTT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ffi) NO:778: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:773: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTGCCCGTC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ED NO:774: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:778: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CCGTCTGTTG (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:779: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ffi>NO:774: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGCCCGTCT (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ TD NO:775: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffΗON: SEQ ffi) NO:779: CGTCTGTTGT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:780: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:784: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTTGTGTGAC (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ~ 5 NO:785: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRffTlON: SEQ ID NO:780: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTCTGTTGTG (C) STRANDEDNESS: single 0>) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:781: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:785: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TTGTGTGACT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:786: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (xi) SEQUENCE DESCRIPTION: SEQ H NO:781: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TCTGTTGTGT (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:782: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:786: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTGTGACTC (C) STRANDEDNESS: single D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:787: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRffΗON: SEQ ID NO:782: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid CTGTTGTGTG (Q STRANDEDNESS: single 0>) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ffi) NO:783: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ffi) NO:787: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid GTGTGACTCT (C) STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ tt) NO:788: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:783: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTTGTGTGA (Q STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:784: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISTICS: (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:788: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid TGTGTGACTC (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:789: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:793: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs GACTCTGGTA (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:794: (ii) MOLECULE TYPE: DNA (0 SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (xi) SEQUENCE DESCRIPTION: SEQ ID NO:789: (B) TYPE: nucleic acid (C) STRANDEDNESS: single GTGTGACTCT (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ ID NO:790: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:794: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs ACTCTGGTAA (B) TYPE: nucleic acid (Q STRANDEDNESS: single (D) TOPOLOGY: linear (2) INFORMATION FOR SEQ ID NO:795: (ii) MOLECULE TYPE: DNA (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH 10 base pairs (xi) SEQUENCE DESCRffΗON: SEQ ID NO:790: (B) TYPE: nucleic acid (C) STRANDEDNESS: single TGTGACTCTG 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ BD NO:791: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:795: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs CTCTGGTAAC (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMAΗON FOR SEQ tt) NO:796: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ ID NO:791: (C) STRANDEDNESS: single 05) TOPOLOGY: linear GTGACTCTGG (ii) MOLECULE TYPE: DNA (2) INFORMAΗON FOR SEQ TD NO:792: (xi) SEQUENCE DESCRIPTION: SEQ TD NO:796: (i) SEQUENCE CHARACTERISΉCS: TCTGGTAACT (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (2) INFORMAΗON FOR SEQ ID NO:797: (D) TOPOLOGY: linear (i) SEQUENCE CHARACTERISΗCS: (ii) MOLECULE TYPE: DNA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (xi) SEQUENCE DESCRIPTION: SEQ TD NO:792: ( STRANDEDNESS: single (D) TOPOLOGY: linear TGACTCTGGT (ii) MOLECULE TYPE: DNA (2) INFORMATION FOR SEQ tt) NO:793: (xi) SEQUENCE DESCRffTlON: SEQ tt) NO:797: (i) SEQUENCE CHARACTERISΗCS: CTGGTAACTA (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (2) INFORMAΗON FOR SEQ ID NO:798: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPΗON: SEQ ID NO:798: TGGTAACTAG (2) INFORMATION FOR SEQ ID NO:799: (i) SEQUENCE CHARACTERISΗCS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single 05) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRffΗON: SEQ ID NO:799: GGTAACTAGA (2) INFORMATION FOR SEQ ID NO:800: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9207 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:800: TGGAAGGGCT AATTCACTCA CGGAAAAGAC CAGTTGAACC AGAAGAAGAT AGAAGAGGCC 60 ATGAAGAAGA AAACAACAGA TTGTTCTGCT TGCTCAGCTG GGGACTTTCC AGAAGGCGCG 120 GCCTGAGTGA CTAAGCCCCG TTGGGGACTT TCCGAAGAGG CATGAAGGGA CTTTCCAAGG 180 CAGGCGTGGC CTGGGCGGGA CTGGGGAGTG GCGAGCCCTC AGATGCTGCA TATAAGCAGC 2 0 TGCTTTCTGC CTGTACTGGG TCTCTCTGGT TAGACCAGAT CTGAGCCTGG GAGCTCTCTG 300 GCTAGCTAGG GAACCCACTG CTTAAGCCTC AATAAAGCTT GCCTTGAGTG CTTCAAGTAG 360 TGTGTGCCCG TCTGTTGTGT GACTCTGGTA TCTAGAGATC CCTCAGACCA TTTTAGTCCG 420 TGTGGAAAAT CTCTAGCAGT GGCGCCCGAA CAGGGACTTG AAAGCGAAAG GAAAACCAGA 480 GGAGCTCTCT CGACGCAGGA CTCGGCTTGC TGAAGCGCGC ACGGCAAGAG GCGAGGGGCG 540 GCGACTGGTG AGTACGCCGA AAATTTTGAC TAGCGGAGGC TAGAAGGAGA GAGATGGGTG 600 CGAGAGCGTC AATATTAAGC GGGGGAAAAT TAGATAGATG GGAGAAAATT CGGTTAAGGC 660 CAGGAGGAAA GAAAAAGTAT AAATTAAAAC ATATAGTATG GGCAAGCAGG GAGCTAGAAC 720 GATTCGCAGT CAATCCTGGC CTGTTGGAAA CATCAGAAGG CTGTAGACAA ATACTGGGAC 780 AGTTACACCC GTCCCTTCAG ACAGGATCAG AAGAACTTAA ATCAGTATAT AATGCAGTAG 840 CAGTCCTCTA TTGTGTGCAT CAAAACATAG ACATAAAGGA CACCAAGGAA GCTTTAGAAA 900 AGATAGAGGA AGAGCAAAAC AAATGTAAGA AAAAAGCACA GCAAGCAGCA GCACAGCAAG 960 CAGCAGCTGG CACAGGAAAC AGCAACCCGG TCAGCCAAAA TTACCCTATA GTACAGAACA 1020 TGCAGGGGCA AATGGTACAT CAGGCCATAT CACCTAGAAC TTTAAATGCA TGGGTAAAAG 1080 TAATAGAAGA GAAGGCTTTC AGCCCAGAGG TAATACCCAT GTTTTCAGCA TTATCAGAAG 1140 GAGCCACCCC ACAAGATTTA AACACCATGC TAAACACAGT C_~GGGGACAT CAAGCAGCTA 1200 TGCAAATGTT AAAAGAGACC ATCAATGAGG AAGCTGCAGA ATGGGATAGA TTACATCCAG 1260 CGCAGGCAGG GCCTGTTGCA CCAGGCCAGA TGAGAGACCC AAGGGGAAGT GACATAGCAG 1320 GAACTACTAG TACCCTTCAG GAACAAATAG GATGGATGAC AGGTAATCCA GCTATCCCAG 1380 TAGGAGAAAT CTATAAAAGA TGGATAATCC TGGGATTAAA TAAAATAGTA AGGATGTATA 1440 GCCCTATCAG CATTCTGGAC ATAAAACAAG GACCAAAGGA ACCCTTTAGA GACTATGTAG 1500 ACCGGTTCTA TAAAACTCTA AGAGCCGAGC AAGCTACACA GGAGGTAAAA AATTGGATGA 1560 CAGAAACCTT GTTGGTCCAA AATGCAAACC CAGATTGTAA GACTATTTTA AAAGCATTGG 1620 GACCAGCAGC TACACTAGAA GAAATGATGA CAGCATGTCA GGGAGTGGGA GGACCCAGCC 1680 ATAAAGCAAG AGTTTTGGCA GAAGCAATGA GCCAAGCAAC AAATGCAGCT ACTGTAATGA 1740 TGCAGAGAAG CAATTTTAGA AACCAAAGAA AGAATGTTAA GTGTTTCAAT TGTGGCAAAG 1800 AAGGGCACAT AGCCAGAAAT TGCAGGGCTC CTAGGAAAAG GGGCTGTTGG AAATGTGGAA 1860 AGGAAGGACA CCAAATGAAA GATTGTACTG AGAGACAGGC TAATTTTTTA GGGAAAATCT 1920 GGCCTTCCCA CAAGGGGAGG CCAGGGAACT TTCTTCAGAG CAGGCCAGAA CCAACAGCCC 1980 CTCTCCAGGG CAGGCCGGAG CCATCAGCCC CGCCAGAAGA GAGCTTCAGG TTTGGGGAGG 2040 AGACAACAAC TCCCTCTCAG AAGCAGGAGC CGATAGACAG GGACAGGGAT CTGTATCCTT 2100 TAGCTTCCCT CAGATCACTC TTTGGCAACG ACCCCTCGTC ACAATAAAGA TAGGGGGGCA 160 GCTGAAGGAA GCTCTATTAG ATACAGGAGC AGATGATACA GTATTAGAAG ACATGCATTT 2220 GCCAGGAAAA TGGAAACCAA AAATGATAGG GGGAATTGGA GGTTTTATCA AAGTAAAACA 2280 ATATGATGAA ATTCTTGTAG AAATCTGTGG ACATAAAGCT ATAGGTACAG TATTAGTAGG 2340 ACCTACACCT GTCAACATAA TTGGAAGAAA TCTGTTGACT CAGATTGGTT GCACTTTAAA 2400 TTTTCCCATT AGTCCTATTG AAACTGTACC AGTACAATTA AAGCCAGGAA TGGATGGCCC 2460 AAAGGTTAAA CAATGGCCAT TGACAGAAGA GAAAATAAAA GCATTAGTAG AAATTTGTAC 2520 AGAAATGGAA AAGGAAGGAA AGATTTCAAA AATTGGGCCT GAAAATCCAT ACAATACTCC 2580 AGTATTTGCC ATAAAGAAAA AAGATGGTAC TAAATGGAGA AAATTAGTAG ATTTCAGAGA 2640 CCTTAATAAG AGAACTCAAG ACTTCTGGGA AGTTCAATTA GGAATACCAC ATCCCTCAGG 2700 ATTAAAAAAG AAAAAATCAG TAACAGTACT GGATGTGGGT GATGCATACT TTTCAGTTCC 2760 CTTAGATGAA AACTTCAGGA AGTATACTGC ATTTACCATA CCTAGTATAA ATAATGAGAC 2820 ACCAGGGATT AGATATCAGT ACAATGTGCT TCCACAGGGA TGGAAAGGAT CACCAGCAAT 2880 ATTCCAAAGT AGCATGACAA GAATCTTAGA GCCTTTTAGA AGACAAAATC CAGACATAGT 2940 TATCTATCAA TACATGGATG ACTTGTATGT AGGATCTGAT TTAGAAATAG GACAGCATAG 3000 AATAAAAATA GAGGAACTGA GACAACATCT GTTGAAGTGG GGATTTACCA CACCAGACAA 3060 AAAGCATCAG AAAGAACCCC CATTCCTTTG GATGGGTTAT GAACTCCATC CTGATAAATG 3120 GACAGTGCAA CCTATAGTAC TGCCAGAAAA AGACAGCTGG ACTGTCAATG ACATACAGAA 3180 GTTAGTGGGT AAATTAAATT GGGCAAGTCA GATTTACCCA GGAATTAAAG TAAGGCAATT 3240 ATGTAAACTC CTTAGGGGAA CCAAAGCACT AACAGAAGTA ATACCACTAA CAGAAGAAGC 3300 AGAGCTAGAA CTGGCAGAAA ACAGGGAAAT TCTAAGAGAA CCAGTACATG GAGTGTATTA 3360 TGACCCATCA AAAGACTTAA TAGCAGAAAT ACAGAAGCAG GAGCAAGGCC AATGGACATA 3420 TCAAATTTAT CAAGATCAAT TTAAAAATCT AAAAACAGGA AAGTATGCAA GATTGAGGGG 3480 TGCCCACACT AATGATGTAA AACAATTTCC AGAGGCAGTG CAAAAAATAG CCACAGAAAG 3540 CATAGTAATA TGGGGAAAGA CTCCTAAATT TAGACTACCC ATACAAAAAG AAACATGGGA 3600 CGCATGGTGG ACAGAGTATT GGCAAGCCAC CTGGATTCCT GAGTGGGAGT TTGTCAATAC 3660 CCCTCCCCTA GTAAAATTAT GGTACCAGTT AGAAAAAGAA CCCATAATAG GAGCAGAAAC 3720 TTTCTATGTA GATGGGGCAG CTAACAGAGA GACTAAATTA GGAAAAGCAG GATATGTTAC 3780 TGACAGAGGA AGACAAAAAG TTGTCTCCCT AACTGACACA ACAAATCAGA AGACTGAGTT 3840 ACAAGCAATT CATCTAGCTT TGCAGGATTC AGGATTAGAA GTAAACATAG TAACAGACTC 3900 ACAGTATGCA TTAGGAATCA TTCAAGCACA ACCAGATAAA AGTGAATCAG AAATAGTCAA 3960 TCAAATAATA GAGCAATTAA TAAAAAAGGA AAAGGTCTAC CTGGCATGGG TACCAGCACA 4020 CAAAGGAATT GGAGGGAATG AACAAGTAGA TAAATTAGTC AGTGCTGGAA TCAGGAAAAT 4080 ACTATTTTTA GATGGAATAG ATAAGGCACA AGAAGGCCAT GAGAAATATC ACAGTAATTG 4140 GAGAGCAATG GCTAGTGGTT TTAACCTGCC ACCTATAGTA GCAAAAGAAA TAGTAGCCAG 4200 CTGTGATAAA TGTCAGCTAA AAGGAGAAGC CATGCATGGA CAAGTAGACT GTAGTCCAGG 4260 AATATGGCAA CTAGATTGTA CACATCTAGA AGGAAAAATT ATCCTGGTAG CAGTTCATGT 4320 AGCCAGTGGA TATATAGAAG CAGAAGTTAT TCCAGCAGAG ACAGGGCAGG AAACAGCATA 4380 CTTTATCTTA AAATTAGCAG GAAGGTGGCC AGTAAACACA ATACATACAG ACAATGGCGG 4440 CAATTTCATC AGTACCACGG TTAAGGCCGC CTGTTGGTGG GCAGGGATCA AGCAGGAATT 4500 TGGCATTCCC TACAATCCCC AAAGCCAAGG AGTAGTGGAA TCTATGAATA GAGAATTAAA 4560 GAAAATTATA GGACAGGTAA GAGATCAGGC TGAACATCTT AAGACAGCAG TACAAATGGC 4620 AGTATTCATC CACAATTTTA AAAGAAAAGG GGGGATTGGG GGATACAGTG CAGGGGAAAG 4680 AATAGTAGAC ATAATAGCAA CAGACATACA AACTAAAGAA TTACAAAAGC AAATTACAAA 4740 AATTCAAAAT TTTCGGGTTT ATTACAGGGA CAGCAGAGAT CCACTTTGGA AAGGACCAGC 4800 AAAACTTCTC TGGAAAGGCG AAGGGGCAGT AGTAATACAA GATAATAGTG ACATAAAAGT 4860 AGTGCCAAGA AGAAAAGTAA AGATCATTAG GGATTATGGA AAACAGATGG CAGGTGATGA 4920 TTGTGTGGCA AGTAGACAGG ATGAGGATTA GAACATGGAA CAGTTTAGTG AAACACCATA 4980 TGTATGTTTC AAAGAAAGCT AAGGGATGGA TTTATAGACA TCACTATGAA AACACTCATC 5040 CAAAAATAAG CTCAGAAGTA CACATCCCAC TAGGGGAAGC TAGATTGGTA ATAACAACAT 5100 ATTGGGGTCT ACATACAGGA GAAAGAGACT GGCATTTGGG TCAGGGAGTC TCCATAGAAT 5160 GGAGGGAAAG GACATATAGA ACACAAGTAG ACCCCGAACT AGCAGACCAA CTAATTCATA 5220 TACATTACTT TGATTGTTTT TCAGAATCTG CCATAAGAAG TGCCATATTA GGATATAGAG 5280 TTAGGCATAG GTGTGAATAT CAAGCAGGAC ATAACAAGGT AGGATCTCTA CAGTACTTGG 5340 CACTAACAGC ATTAATAACA CCAAAGAAGA TAAAGCCACC TTTGCCTAGT GTTGCGAAAC 5400 TGACAGAGGA TAGATGGAAC AAGCCCCAGA AGACCAAGGG CCACAGAGGC AGCCATACAA 5460 TGAATGGACA CTAGAACTTT TAGAGGAGCT TAAGAATGAA GCTGTTAGGC ATTTTCCTAG 5520 GGTATGGCTC CATGGCTTAG GGCAACATAT CTATGAAACT TATGGGGATA CTTGGGAAGG 5580 AGTGGAGGCC ATAACAAGAA CTCTGCAACA ACTGCTGTTT ATTCATTTCA GAATTGGGTG 5640 TCAAC-ATAGC AGAATAGGCA TTATTCGACA GAGGAGAGCA AGAAATGGAG CCAGTAGATC 5700 CTAGACTAGA GCCCTGGAAG CATCCAGGAA GTCAGCCTAA GACTGCGTGT ACCACTTGCT 5760 ATTGTAAAAA GTGCTGCTTT CATTGCCAAG TTTGTTTTAT GACAAAAGGC TTAGGCATCT 5820 CCTATGGCAG GAAGAAGCGG AGACAGCGAC GAAGAGCTCC TCAAGACAGT CAGACTCATC 5880 AAGCTTATCT ATCAAAGCAG TAAGTAATAT ATGTAATGCA ACCTTTACAA ATAGTAGCAA 5940 TAGTAGCATT AGTAGTAGCA GGAATAATAG CAATAGTTGT GTGGACCATA GTATTCATAG 6000 AATATAAGAA AATATTAAGA CAAAGAAAAA TAGACAGGTT GATTGATAGA ATAAGAGAAA 6060 GAGCAGAAGA CAGTGGCAAT GACAGTGAAG GGGATCAGGA AGAATTATCG GCACTTGTGG 6120 ACATGGGGCA CCATGATCCT TGGGATATTA ATGATCTGTA GAGCTGCAAA CAATTTGTGG 6180 GTCACAGTCT ATTATGGGGT ACCTGTGTGG AGAGAAGCAA CCACCACTCT ATTTTGTGCA 6240 TCAGATGCCA AGGCATATGA TGCAGAGGTA CATAATGTTT GGGCCACACA TGCCTGTGTA 6300 CCCACAGACC CTAACCCACA AGAAGTAGAA TTGAAAAATG TGACAGAAAA TTTTAACATG 6360 TGGAAAAATA ACATGGTAGA ACAGATGCAT GAGGATATAA TCAGTTTATG GGATCAAAGC 6420 CTGAAGCCAT GTGTAAAATT AACCCCACTC TGTGTTTCTT TAAATTGCAC TGATGCTACT 6480 AATACCACTA ATAGTAATAC CACTAGCAGC AGCGAGAAAC CGAAGGGGAC AGGGGAAATA 6540 AAAAACTGCT CTTTCAATAT CACCACAAGC ATAAGAGATA AGGTGCAGAA ACAATATGCA 6600 CTTTTTTATA GCCTTGATGT AGTACCAATG GATGATAATG ATAATAGTAC AAGCTATAGG 6660 TTAATAAGTT GTAACACCTC AATCATTACA CAGGCCTGTC CAAAGATATC CTTTGAGCCA 6720 ATTCCCATAC ATTATTGTGC CCCGGCTGGT TTTGCGATTC TAAAGTGTAA AGATAAAAGG 6780 TTCAATGGAA AAGGACCATG TACAAGTGTC AGCACAGTAC AGTGTACACA TGGAATTAGG 6840 CCAGTAGTAT CAACTCAACT GTTGTTAAAT GGCAGTCTAG CAGAAGAAGA GGTAGTAATT 6900 AGATCTGACA ATTTTACGAA CAATGCTAAA ACCATAATAG TACAGCTGAG CAAATCTGTA 6960 GAAATTACTT GTGTAAGACC CAACAACAAT ACAAGAAAAA GTATAAGTAT GGGACCAGGG 7020 AGAGCATTTT ATACAACAGA AATAATAGGA GATATAAGAC AAGCATATTG TAACATTAGT 7080 AAAGCAAACT GGACTGACAC TTTAGAACAG ATAGCTAGAA AATTAAGAGA ACAATTTGAG 7140 AATAAAACAA TAGTCTTTAA GCCATCCTCA GGAGGGGACC CAGAAATTGT AACACAGTTT 7200 TACAGTTTTA ATTGTGGAGG GGAATTTTTC TACTGTAATT CAACACAACT GTTTAATGGT 7260 ACTTGGAATG GTACTTGGGT TAATGGTACT TGGAGTAGTA ATAATACGAC TGATACTGCA 7320 AATATCACAC TCCCATGCAG AATAAAACAA TTTATAAACA TGTGGCAGGA AGTAGGAAAA 7380 GCAATGTATG CCCCTCCCAT CAAAGGACAA ATTAAATGTA CATCAAATAT TACAGGGCTG 7440 ATATTAACAA GAGATGGTGG TAACAATAAC ACCACGAACG ACAACGAGAC CGAGACCTTC 7500 AGACCTGGAG GAGGAGATAT GAGGGACAAT TGGAGAAGTG AATTATATAA ATATAAAGTA 7560 GTACAAGTTG AACCATTAGG AGTAGCACCC ACCAAGGCAA AGAGAAGAGT GGTGCAAAGA 7620 GAAAAAAGAG CAGTGGGAAT AGGAGCTATG TTCCTTGGGT TCTTAGGAGC AGCAGGAAGC 7680 ACTATGGGCG CAGCGTCAGT GACGCTGACG GTACAAGCCA GACAATTATT GTCTGGTATA 7740 GTGCAGCAGC AGAACAATCT GCTGAGGGCT ATTGAGGCGC AACAGCATCT GTTGCAACTC 7800 ACAGTCTGGG GCATCAAACA GCTCCAGGCA AGAGTCCTGG CTGTGGAAAG ATACCTAAGG 7860 GATCAACAGC TCCTGGGACT TTGGGGTTGC TCTGGAAAAC TCATTTGCAC CACTACTGTG 7920 CCTTGGAACA ATAGCTGGAG TAATAAATCT CTGGAAACAA TTTGGGATAA CATGACCTGG 7980 ATGCAGTGGG AAAGAGAAAT TGACAATTAC ACAAACATAA TATACACCTT AATTGAAGAA 8040 TCGCAGAACC AACAAGAAAA AAATGAACTA GAATTATTGG AATTGGATAA ATGGGCAAAT 8100 TTGTGGAATT GGTTTAGTAT ATCAAACTGG CTATGGTATA TAAAATTATT CATAATGGTA 8160 GTAGGAGGCT TGGTAGGTTT AAGAATAGTT TTTACTGTAC TTTCTATAGT TAATAGAGTT 8220 AGGCAGGGAT ACTCACCATT ATCGTTTCAG ACCCACCTCC CAACCCCGAA GGGACCCGAC 8280 AGGCCAGAAG GAATCGAAGA AGAAGGTGGA GAGAGAGACA GAGGCAGCTC CACTCGATTA 8340 GTGCACGGAT TCTTAGCACT TTTCTGGGAC GACCTGAGGA GTCTGTGCCT CTTCAGCTAC 8400 CACCACTTGA GAGACTTACT CTTGATTGTA ACGAGGATTG TGGAACTTCT GGGACGCAGG 8460 GGATGGGAAG CCCTCAAATA CTGGTGGAAT CTCCTGCAGT ATTGGAGGCA GGAACTACAG 8520 AAGAGTGCTG TTAGCTTGTT CAATGGCACG GCCATAGCAG TAGCTGAGGG GACAGATAGA 8580 GTTATAGAAG CTTTACGAAG GGCTTATAGA GCTATTCTCC ACATACCTAG AAGAATAAGA 8640 CAGGGCTTAG AAAGGGCTTT GCTATAAAAT GGGTGGCAAG TGGTCAGAAA GTAGTGTGGT 8700 TAGAAGGCAT GTACCTTTAA GACAAGGCAG CTATAGATCT TAGCCGCTTT TTAAAAGAAA 8760 AGGGGGGACT GGAAGGGCTA ATTCACTCAC GGAAAAGACC AGTTGAACCA GAAGAAGATA 8820 GAAGAGGCCA TGAAGAAGAA AACAACAGAT TGTTCTGCTT GCTCAGCTGG GGACTTTCCA 8880 GAAGGCGCGG CCTGAGTGAC TAAGCCCCGT TGGGGACTTT CCGAAGAGGC ATGAAGGGAC 8940 TTTCCAAGGC AGGCGTGGCC TGGGCGGGAC TGGGGAGTGG CGAGCCCTCA GATGCTGCAT 9000 ATAAGCAGCT GCTTTCTGCC TGTACTGGGT CTCTCTGGTT AGACCAGATC TGAGCCTGGG 9060 AGCTCTCTGG CTAGCTAGGG AACCCACTGC TTAAGCCTCA ATAAAGCTTG CCTTGAGTGC 9120 TTCAAGTAGT GTGTGCCCGT CTGTTGTGTG ACTCTGGTAT CTAGAGATCC CTCAGACCAT 9180 TTTAGTCCGT GTGGAAAATC TCTAGCA 9207

Claims: CLAIMS: 1. An isolated HIV-1 strain or a component, part, fragment or derivative thereof which is substantially non-pathogenic 2. A strain of HIV-1 according to claim 1 wherein said strain is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject. 3. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1 or results in reduced synthesis of said polypeptide or protein. 4. A strain of HIV-1 according to claim 2 which carries one or more mutations in its genome resulting in the said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1. 5. A strain of HIV-1 according to claim 3 or 4 wherein said strain carries a mutation in its nef gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome. 6. A strain of HIV-1 according to claim 5 wherein said strain is reactive to antibodies to gp41-45, gpl20 and/or gpl60 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the nef gene and/or LTR region of pathogenic HIV-1. 7. A strain of HIV- 1 according to claim 6 wherein said strain is capable of inducing an immune response to at least one of gag, pol and/or env. 8. A strain of HIV-1 according to claim 7 wherein said strain carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3. 9. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (i) 8830-8862; (ii) 9009-9035; (iii) 9019-9029; and (iv) 9033-9049. 10. A strain of HTV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (vii) 9105-9224; and (viii) 9271-9370. 11. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. 12. A strain of HIV-1 according to claim 8 wherein said strain carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (xiii) 9105-9224 (xiv) 9389-9395; and (xv) 9281-9366. 13. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL4-3: ATGGGTGGCA TGGGTGGCAA (SEQ ID NO:3); GGGTGGCAAG GGTGGCAAGT (SEQ ID NO:5); GTGGCAAGTG TGGCAAGTGG (SEQ ID NO:7); GGCAAGTGGT GCAAGTGGTC (SEQ ID NO:9) ; CAAGTGGTCA AAGTGGTCAA (SEQ ID NO:11) AGTGGTCAAA GTGGTCAAAA (SEQ ID NO:13) TGGTCAAAAA GGTCAAAAAG (SEQ ID NO:15) GTCAAAAAGT TCAAAAAGTA (SEQ ID NO:17) CAAAAAGTAG AAAAAGTAGT (SEQ ID NO:19); AAAAGTAGTG AAAGTAGTGT (SEQ ID NO:21); AAGTAGTGTG AGTAGTGTGA (SEQ ID NO:23); GTAGTGTGAT TAGTGTGATT (SEQ ID NO:25); AGTGTGATTG GTGTGATTGG (SEQ ID NO:27) TGTGATTGGA TGATTGGATG ATTGGATGGC TGGATGGCCT GATGGCCTGC TGGCCTGCTG GCCTGCTGTA CTGCTGTAAG GCTGTAAGGG TGTAAGGGAA TAAGGGAAAG AGGGAAAGAA GGAAAGAATG AAAGAATGAG AGAATGAGAC AATGAGACGA TGAGACGAGC GACGAGCTGA (SEQ ID NO:63) CGAGCTGAGC (SEQ ID NO:65) AGCTGAGCCA (SEQ ID NO:67) CTGAGCCAGC (SEQ ID NO:69) GAGCCAGCAG (SEQ ID NO:71) GCCAGCAGCA (SEQ ID NO:73) CAGCAGCAGA (SEQ ID NO:75) GCAGCAGATG (SEQ ID NO:77) AGCAGATGGG (SEQ ID NO:79) CAGATGGGGT (SEQ ID NO:81) GATGGGGTGG (SEQ ID NO:83) TGGGGTGGGA (SEQ ID NO:85) GGGTGGGAGC (SEQ ID NO:87) GTGGGAGCAG (SEQ ID NO:89) GGGAGCAGTA (SEQ ID NO:91) GAGCAGTATC (SEQ ID NO:93) GCAGTATCTC (SEQ ID NO:95) AGTATCTCGA (SEQ ID NO:97) TATCTCGAGA (SEQ ID NO:99) TCTCGAGACC TCGAGACCTA GAGACCTAGA GACCTAGAAA CCTAGAAAAA TAGAAAAACA GAAAAACATG AAAACATGGA AACATGGAGC CATGGAGCAA TGGAGCAATC GAGCAATCAC GCAATCACAA AATCACAAGT TCACAAGTAG ACAAGTAGCA AAGTAGCAAT GTAGCAATAC AGCAATACAG 138 140 142 144 146 148 150 152 154 156 158 160 162 164 166 168 170 172 174 176 178 180 182 184 186 188 190 192 194 196 198 200 202 204 206 208 210 212 443 445 447 449 451 453 455 457 459 461 463 465 467 469 471 473 475 477 479 481 483 485 487 489 491 493 495 497 499 501 503 505 507 509 511 513 515 517 14. A strain of HIV-1 according to claim 8 wherein said deletion encompasses at least one of the fol owing decanucleotides from the LTR region of HIV-1 strain NL4-3: GCTTTTTGCC CTTTTTGCCT TTTTTGCCTG TTTTGCCTGT TTTGCCTGTA TTGCCTGTAC TGCCTGTACT GCCTGTACTG CCTGTACTGG CTGTACTGGG TGTACTGGGT GTACTGGGTC TACTGGGTCT ACTGGGTCTC CTGGGTCTCT TGGGTCTCTC GGGTCTCTCT GGTCTCTCTG GTCTCTCTGG TCTCTCTGGT CTCTCTGGTT TCTCTGGTTA CTCTGGTTAG TCTCTGGTTA CTGGTTAGAC TGGTTAGACC GGTTAGACCA GTTAGACCAG TTAGACCAGA TAGACCAGAT AGACCAGATC GACCAGATCT ACCAGATCTG CCAGATCTGA CAGATCTGAG AGATCTGAGC GATCTGAGCC ATCTGAGCCT TCTGAGCCTG CTGAGCCTGG TGAGCCTGGG GAGCCTGGGA AGCCTGGGAG GCCTGGGAGC CCTGGGAGCT CTGGGAGCTC TGGGAGCTCT GGGAGCTCTC 15. A strain of HIV-1 according to claim 8 having the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number . 16. An isolated strain of HIV-1 which is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response to at least one of gag, pol and/or env and which is incapable of directing synthesis of a nef gene product or a full length nef gene product. 17. An isolated strain of HIV-1 according to claim 16 wherein the glycoprotein is at least one of gp41-45, gpl20 and/or gpl60. 18. A nucleic acid molecule or a part, fragment or derivative thereof from an HIV-1 isolate defined in any one of claims 1 to 16. 19. A molecular infectious clone comprising a nucleic acid molecule according to claim 18. 20. A method for inhibiting or reducing productive infection of an individual by a pathogenic strain of HIV-1, said method comprising administering to a subject a non- pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying DNA derived from said non-pathogenic HIV-1. 21. A method according to claim 20 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject. 22. A method according to claim 21 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1. 23. A method according to claim 17 wherein said isolate carries one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1. 24. A method according to claim 22 or 23 wherein said HIV-1 isolate carries a mutation in its nef gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome. 25. A method according to claim 24 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gpl20 and/or gpl60 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the nef gene and/or LTR region of pathogenic HIV-1. 26. A method according to claim 25 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of gag, pol and/or env. 27. A method according to claim 26 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3. 28. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (i) 8830-8862; (ii) 9009-9035; (iii) 9019-9029; and (iv) 9033-9049. 29. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (vii) 9105-9224; and (viii) 9271-9370. 30. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. 31. A method according to claim 27 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. 32. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43: ATGGGTGGCA (SEQ ID NO:2) TGGGTGGCAA (SEQ ID NO:3) GGGTGGCAAG (SEQ ID NO:4) GGTGGCAAGT (SEQ ID NO:5) GTGGCAAGTG (SEQ ID NO:6) TGGCAAGTGG (SEQ ID NO:7) GGCAAGTGGT (SEQ ID NO:8) GCAAGTGGTC (SEQ ID NO:9) ID NO:163) ID NO:165) ID NO:167) ID NO:169) ID NO:171) ID NO:173) ID NO:175) ID NO:177) ID NO:179) ID NO:181) ID NO:183) ID NO:185) ID NO:187) ID NO:189) ID NO:191) ID NO:193) ID NO:195) ID NO:197) ID NO:199) ID NO:201) ID NO:203) ID NO:205) ID NO:207) ID NO:209) ID NO:211) ID NO:213) ID NO:215) ID NO:217) ID NO:219) ID NO:221) ID NO:223) ID NO:225) ID NO:227) ID NO:229) ID NO:231) ID NO:233) ID NO:235) ID NO:237) 314 316 318 320 322 324 326 328 330 332 334 336 338 340 342 344 346 348 350 352 354 356 358 360 362 364 366 368 370 372 374 376 378 380 382 384 386 388 542 544 546 548 550 552 554 556 558 560 562 564 566 568 570 572 574 576 578 580 582 584 586 588 590 592 594 596 598 600 602 604 606 608 610 612 33. A method according to claim 27 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3: GCTTTTTGCC (SEQ ID NO:652) CTTTTTGCCT (SEQ ID NO:653) TTTTTGCCTG (SEQ ID NO:654) TTTTGCCTGT (SEQ ID NO:655) TTTGCCTGTA (SEQ ID NO:656) TTGCCTGTAC (SEQ ID NO:657) TGCCTGTACT (SEQ ID NO:658) GCCTGTACTG (SEQ ID NO:659) CCTGTACTGG (SEQ ID NO:660) CTGTACTGGG (SEQ ID NO:661) TGTACTGGGT (SEQ ID NO:662) GTACTGGGTC (SEQ ID NO:663) TACTGGGTCT (SEQ ID NO:664) ACTGGGTCTC (SEQ ID NO:665) CTGGGTCTCT (SEQ ID NO:666) TGGGTCTCTC (SEQ ID NO:667) GGGTCTCTCT (SEQ ID NO:668) GGTCTCTCTG (SEQ ID NO:669) GTCTCTCTGG (SEQ ID NO:670) TCTCTCTGGT (SEQ ID NO:671) CTCTCTGGTT (SEQ ID NO:672) TCTCTGGTTA (SEQ ID NO:673) CTCTGGTTAG (SEQ ID NO:674) TCTCTGGTTA (SEQ ID NO:675) CTGGTTAGAC (SEQ ID NO:676) TGGTTAGACC (SEQ ID NO:677) GGTTAGACCA (SEQ ID NO:678) GTTAGACCAG (SEQ ID NO:679) TTAGACCAGA (SEQ ID NO:680) TAGACCAGAT (SEQ ID NO:681) AGACCAGATC (SEQ ID NO:682) GACCAGATCT (SEQ ID NO:683) ACCAGATCTG (SEQ ID NO:684) CCAGATCTGA (SEQ ID NO:685) CAGATCTGAG (SEQ ID NO:686) AGATCTGAGC (SEQ ID NO:687) GATCTGAGCC (SEQ ID NO:688) ATCTGAGCCT (SEQ ID NO:689) TCTGAGCCTG (SEQ ID NO:690) CTGAGCCTGG (SEQ ID NO:691) TGAGCCTGGG (SEQ ID NO:692) GAGCCTGGGA (SEQ ID NO:693) AGCCTGGGAG (SEQ ID NO:694) GCCTGGGAGC (SEQ ID NO:695) CCTGGGAGCT (SEQ ID NO:696) CTGGGAGCTC (SEQ ID NO:697) TGGGAGCTCT (SEQ ID NO:698) GGGAGCTCTC (SEQ ID NO:699) GGAGCTCTCT (SEQ ID NO:700) GAGCTCTCTG (SEQ ID NO:701) AGCTCTCTGG (SEQ ID NO:702) GCTCTCTGGC (SEQ ID NO:703) CTCTCTGGCT (SEQ ID NO:704) TCTCTGGCTA (SEQ ID NO:705) CTCTGGCTAA (SEQ ID NO:706) TCTGGCTAAC (SEQ ID NO:707) CTGGCTAACT (SEQ ID NO:708) TGGCTAACTA (SEQ ID NO:709) GGCTAACTAG (SEQ ID NO:710) GCTAACTAGG (SEQ ID NO:711) CTAACTAGGG (SEQ ID NO:712) TAACTAGGGA (SEQ ID NO:713) AACTAGGGAA (SEQ ID NO:714) ACTAGGGAAC (SEQ ID NO:715) CTAGGGAACC (SEQ ID NO:716) TAGGGAACCC (SEQ ID NO:717) AGGGAACCCA (SEQ ID NO:718) GGGAACCCAC (SEQ ID NO:719) TCTGGTAACT (SEQ ID NO:796); CTGGTAACTA (SEQ ID NO:797) ; TGGTAACTAG (SEQ ID NO:798); GGTAACTAGA (SEQ ID NO:799) . 34. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number . 35. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of gag, pol and/or env and which is incapable of directing synthesis of a nef gene product or a full length nef gene product. 36. A method according to claim 35 wherein the glycoprotein is at least one of gp41- 45, gpl20 and/or gpl60. 37. A method for vaccinating an individual against the development of AIDS or AIDS related diseases, said method comprising administering to said individual a non- pathogenic isolate of HIV-1 in an amount effective to infect target cells and to generate target cells carrying DNA derived from said non-pathogenic HIV-1. 38. A method according to claim 37 wherein said isolate is capable of stimulating an immune response in a human or primate against at least one glycoprotein on HIV-1 whilst not substantially reducing proliferative responses and cytokine production to a mitogen in said human or primate compared to a healthy, non-infected human or primate subject. 39. A method according to claim 38 wherein said isolate carries one or more mutations in its genome resulting in the inability to direct synthesis of at least one polypeptide or protein from a pathogenic strain of HIV-1. 40. A method according to claim 17 wherein said isolate carried one or more mutations in its genome resulting in said genome directing synthesis of a truncated form of a polypeptide or protein from a pathogenic strain of HIV-1. 41. A method according to claim 39 or 40 wherein said HIV-1 isolate carries a mutation in its nef gene and/or long terminal repeat (LTR) region or in a functionally equivalent location in the HIV-1 genome. 42. A method according to claim 40 wherein said HIV-1 isolate is reactive to antibodies to gp41-45, gpl20 and/or gpl60 of HIV-1 and carries a deletion of at least ten contiguous nucleotides in a region corresponding to the nef gene and/or LTR region of pathogenic HIV-1. 43. A method according to claim 42 wherein said HIV-1 isolate is capable of inducing an immune response to at least one of gag, pol and/or ewv. 44. A method according to claim 43 wherein said HIV-1 isolate carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3. 45. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (i) 8830-8862; (ii) 9009-9035; (iii) 9019-9029; and (iv) 9033-9049. 46. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (Vii) 9105-9224; and (viii) 9271-9370. 47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. 47. A method according to claim 44 wherein said isolate carries a deletion in its genome of at least 10 nucleotides within a region selected from the list consisting of: nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. 48. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL43: ATGGGTGGCA TGGGTGGCAA (SEQ ID NO:3); GGGTGGCAAG GGTGGCAAGT (SEQ ID NO:5); GTGGCAAGTG TGGCAAGTGG (SEQ ID NO:7) ; GGCAAGTGGT GCAAGTGGTC (SEQ ID NO:9); CAAGTGGTCA AAGTGGTCAA (SEQ ID NO:11) AGTGGTCAAA GTGGTCAAAA (SEQ ID NO:13) TGGTCAAAAA GGTCAAAAAG (SEQ ID NO:15) GTCAAAAAGT TCAAAAAGTA (SEQ ID NO:17) CAAAAAGTAG AAAAAGTAGT (SEQ ID NO:19) ; AAAAGTAGTG AAAGTAGTGT (SEQ ID NO:21); AAGTAGTGTG AGTAGTGTGA (SEQ ID NO:23) ; GTAGTGTGAT TAGTGTGATT (SEQ ID NO:25) ; AGTGTGATTG GTGTGATTGG (SEQ ID NO:27) TGTGATTGGA GTGATTGGAT (SEQ TGATTGGATG GATTGGATGG (SEQ ATTGGATGGC TTGGATGGCC (SEQ TGGATGGCCT GGATGGCCTG (SEQ 112 114 116 118 120 122 124 126 128 130 132 134 136 138 140 142 144 146 148 150 152 154 156 158 160 162 164 166 168 170 172 174 176 178 180 182 184 186 340 342 344 346 348 350 352 354 356 358 360 362 364 366 368 370 372 374 376 378 380 382 384 386 388 390 392 394 396 398 400 402 404 406 408 410 412 414 49. A method according to claim 44 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3: GCTTTTTGCC CTTTTTGCCT TTTTTGCCTG TTTTGCCTGT TTTGCCTGTA TTGCCTGTAC TGCCTGTACT GCCTGTACTG CCTGTACTGG CTGTACTGGG TGTACTGGGT GTACTGGGTC TACTGGGTCT ACTGGGTCTC CTGGGTCTCT TGGGTCTCTC GGGTCTCTCT GGTCTCTCTG GTCTCTCTGG TCTCTCTGGT CTCTCTGGTT TCTCTGGTTA :674 :675 :676 :677 :678 :679 :680 :681 :682 :683 :684 :685 :686 :687 :688 :689 :690 :691 :692 :693 :694 :695 :696 :697 :698 :699 :700 :701 :702 :703 :704 :705 :706 :707 :708 :709 ;710 :711 712 713 :714 715 :716 717 718 719 :720 :721 :722 :723 :724 :725 :726 :727 :728 :729 :730 :731 :732 :733 :734 :735 :736 :737 738 :739 :740 :741 742 :743 744 :745 746 :747 748 :749 50. A method according to claim 24 wherein said HIV-1 isolate has the identifying characteristics of HIV-1 isolate ECACC V94101706 or HIV-1 isolate ECACC V941031169 or isolate C54 deposited at ECACC on 14 February, 1995 under Accession Number 51. A method according to claim 20 wherein the HIV-1 isolate is reactive to antibodies to a glycoprotein of HIV-1, is capable of inducing an immune response of gag, pol and or ewv and which is incapable of directing synthesis of a nef gene product or a full length nef gene product. 52. A method according to claim 51 wherein the glycoprotein is at least one of gp41 - 45, gpl20 and/or gpl60. 53. A method for obtaining a preparation of non-pathogenic HIV- 1 from a biological sample, said method comprising co-culturing PBMCs from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid. 54. A method according to claim 53 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication. 55. A method according to claim 54 wherein the cytokine is M-CSF. 56. A method according to claim 53 or 54 or 55 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2. 57. A method according to claim 53 wherein the PBMCs from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs. 58. A method according to claim 53 or 57 wherein the cocultured cells are subjected to UV irradiation. 59. A method for obtaining a preparation of non-pathogenic HIV-1 from a biological sample, said method comprising co-culturing monocytes from said biological sample from an individual putatively infected with said non-pathogenic HIV-1 with HIV-1 seronegative donor PBMCs depleted for CD8+ cells, harvesting the monocytes and PBMCs and supernatant fluid every from about 5 to about 10 days and adding fresh medium with CD8+ depleted PBMCs with said fresh medium and isolating said virus from the supernatant fluid. 60. A method according to claim 59 wherein the seronegative PBMCs are pretreated with a cytokine for a time and under conditions sufficient to enhance HIV-1 replication. 61. A method according to claim 60 wherein the cytokine is M-CSF. 62. A method according to claim 59 or 60 or 61 wherein the HIV-1 seronegative donor PBMCs are first stimulated with PHA and/or IL-2. 63. A method according to claim 59 wherein the monocytes from a putative infected individual are also CD8+ depleted prior to coculturing with seronegative donor PBMCs. 64. A method according to claim 59 or 63 wherein the cocultured cells are subjected to UV irradiation. 65. A method for identifying or screening for compounds capable of reducing or otherwise interfering with HIV-1 replication, said method comprising contacting a compound to be tested with a cell or cell extract containing or capable of containing a nef gene product fused to a reporter molecule capable of giving an identifiable signal and screening for a compound which inhibits said signal. 66. A method according to claim 65 wherein the compound is an antibody to nef gene product or a part thereof. 67. A method according to claim 65 wherein the compound is a DNA targeting agent and inhibits transcription of the nef gene. 68. A compound capable of inhibiting nef gene product function or nef gene transcription. 69. A compound capable of inhibiting nef gene product function or nef gene transcription identified according to the method of claim 65 or 66 or 67. 70. A therapeutic composition useful for inhibiting or reducing productive infection by a pathogenic strain of HIV-1 and/or for vaccinating an individual against the development of AIDS or AIDS-related diseases, said composition comprising a non- pathogenic strain of HIV-1 according to any one of claims 1 to 16 and one or more pharmaceutical acceptable carriers and/or diluents. 71. A therapeutic composition according to claim 70 wherein said HIV-1 isolate comprises genetic material that directs expression of antisense or ribozyme nucleotide sequences which inhibit production of one or more proteins encoded by a pathogenic strain of HIV-1. 72. A viral isolate which: (i) is genetically or immunologically related to a pathogenic strain of HIV- 1 ; (ii) is substantially non-pathogenic in human subjects; (iii) comprises a first nucleotide sequence constituting its genome which is capable of hybridising under medium stringency conditions to SEQ ID NO: 1 or a complementary form thereof; and (iv) comprises a second nucleotide sequence within said first nucleotide sequence and which second nucleotide sequence directs expression of a mRNA molecule capable of inhibiting, reducing or otherwise down- regulating translation of a protein or polypeptide encoded by a pathogenic strain of HIV-1 or inhibit, reduce or otherwise down regulate operation of a non-protein encoding a region of a pathogenic strain of HIV-1. 73. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of gag or pol. 74. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of ewv or tat. 75. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of rev or vpu. 76. A viral isolate according to claim 72 wherein the targeted protein or polypeptide is selected from the list consisting of vpr, vz/or nef. 11. A viral isolate according to claim 72 wherein the targeted protein is nef 78. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in the genome of said HIV-1 wherein said deletion mutation results in said genome being unable to synthesise a polypeptide or protein from a pathogenic strain of HIV-1 or directing the synthesis of a truncated form of said polypeptide or protein wherein the presence of a such a mutation is indicative of the presence of a non-pathogenic strain of HIV-1. 79. The method according to claim 78 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3. 80. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (i) 8830-8862; (ii) 9009-9035; (iii) 9019-9029; and (iv) 9033-9049. 81. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (vii) 9105-9224; and (viii) 9271-9370. 82. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: and 83. A strain of HIV-1 according to claim 79 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. 84. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL4-3: ATGGGTGGCA TGGGTGGCAA (SEQ ID NO:3) ; GGGTGGCAAG GGTGGCAAGT (SEQ ID NO:5) ; GTGGCAAGTG TGGCAAGTGG (SEQ ID NO:7) ; GGCAAGTGGT GCAAGTGGTC (SEQ ID NO:9) ; CAAGTGGTCA AAGTGGTCAA (SEQ ID NO:11) AGTGGTCAAA GTGGTCAAAA (SEQ ID NO:13) TGGTCAAAAA GGTCAAAAAG (SEQ ID NO:15) GTCAAAAAGT TCAAAAAGTA (SEQ ID NO:17) CAAAAAGTAG AAAAAGTAGT (SEQ ID NO:19); AAAAGTAGTG AAAGTAGTGT (SEQ ID NO:21); AAGTAGTGTG AGTAGTGTGA (SEQ ID NO:23) ; GTAGTGTGAT TAGTGTGATT (SEQ ID NO:25); AGTGTGATTG GTGTGATTGG (SEQ ID NO:27) TGTGATTGGA GTGATTGGAT (SEQ TGATTGGATG GATTGGATGG (SEQ ATTGGATGGC TTGGATGGCC (SEQ TGGATGGCCT GGATGGCCTG (SEQ GATGGCCTGC ATGGCCTGCT (SEQ 418 420 422 424 426 428 430 432 434 436 438 440 442 444 446 448 450 452 454 456 458 460 462 464 466 468 470 472 474 476 478 480 482 484 486 488 490 492 85. A strain of HIV-1 according to claim 79 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3: GCTTTTTGCC CTTTTTGCCT TTTTTGCCTG TTTTGCCTGT TTTGCCTGTA TTGCCTGTAC TGCCTGTACT GCCTGTACTG CCTGTACTGG CTGTACTGGG TGTACTGGGT GTACTGGGTC TACTGGGTCT ACTGGGTCTC CTGGGTCTCT TGGGTCTCTC GGGTCTCTCT GGTCTCTCTG GTCTCTCTGG TCTCTCTGGT CTCTCTGGTT TCTCTGGTTA CTCTGGTTAG TCTCTGGTTA :676 :678 :680 :682 :684 :686 :688 :690 :692 694 696 698 700 702 704 706 708 710 712 714 716 718 720 722 724 726 728 730 732 734 736 :738 ;740 :742 :744 :746 :748 :750 86. A method for determining the pathogenicity of an HIV-1 strain after said HIV-1 strain infects cells of an individual, said method comprising determining the presence of a deletion mutation in its genome of at least 10 nucleotides within the region from nucleotide 8787 to nucleotide 9709 using the nucleotide numbering of HIV-1 strain NL4-3 wherein the presence of said deletion mutation is indicative of the presence of a non-pathogenic strain of HIV-1. 87. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: 88. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (v) 9281-9371; (vi) 9281-9362; (vii) 9105-9224; and (viii) 9271-9370. 89. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (ix) 8882-8928; (x) 8850-9006; (xi) 8792-9041; and (xii) 9112-9204. 90. A method according to claim 86 wherein said non-pathogenic HIV-1 carries a deletion in its genome of at least 10 nucleotides from within a region selected from the list consisting of: nucleotide (xiii) 9105-9224; (xiv) 9389-9395; and (xv) 9281-9366. 91. A strain of HIV-1 according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the nef gene of HIV-1 strain NL4-3: ATGGGTGGCA (SEQ ID NO:2); TGGGTGGCAA (SEQ ID NO:3); GGGTGGCAAG (SEQ ID NO:4) ; GGTGGCAAGT (SEQ ID NO:5) ; 158 160 162 164 166 168 170 172 174 176 178 180 182 184 186 188 190 192 194 196 198 200 202 204 206 208 210 212 214 216 218 220 222 224 226 228 230 232 538 540 542 544 546 548 550 552 554 556 558 560 562 564 566 568 570 572 574 576 578 580 582 584 586 588 590 592 594 596 598 600 602 604 606 608 610 612 92. A method according to claim 86 wherein said deletion encompasses at least one of the following decanucleotides from the LTR region of HIV-1 strain NL4-3: GCTTTTTGCC CTTTTTGCCT (SEQ ID NO: 653) TTTTTGCCTG TTTTGCCTGT (SEQ ID NO: 655) TTTGCCTGTA TTGCCTGTAC (SEQ ID NO: 657) TGCCTGTACT GCCTGTACTG (SEQ ID NO: 659) CCTGTACTGG CTGTACTGGG (SEQ ID NO: 661) TGTACTGGGT GTACTGGGTC (SEQ ID NO: 663) TACTGGGTCT ACTGGGTCTC (SEQ ID NO: 665) CTGGGTCTCT TGGGTCTCTC (SEQ ID NO: 667) GGGTCTCTCT GGTCTCTCTG (SEQ ID NO: 669) GTCTCTCTGG TCTCTCTGGT (SEQ ID NO: 671) CTCTCTGGTT TCTCTGGTTA (SEQ ID NO: 673) CTCTGGTTAG TCTCTGGTTA (SEQ ID NO: 675) CTGGTTAGAC TGGTTAGACC (SEQ ID NO: 677) GGTTAGACCA GTTAGACCAG (SEQ ID NO: 679) TTAGACCAGA TAGACCAGAT (SEQ ID NO: 681) AGACCAGATC GACCAGATCT (SEQ ID NO: 683) ACCAGATCTG CCAGATCTGA (SEQ ID NO: 685) CAGATCTGAG AGATCTGAGC (SEQ ID NO: 687) GATCTGAGCC ATCTGAGCCT (SEQ ID NO: 689) TCTGAGCCTG CTGAGCCTGG (SEQ ID NO: 691) TGAGCCTGGG GAGCCTGGGA (SEQ ID NO: 693) AGCCTGGGAG GCCTGGGAGC (SEQ ID NO: 695) CCTGGGAGCT CTGGGAGCTC (SEQ ID NO: 697) TGGGAGCTCT GGGAGCTCTC (SEQ ID NO: 699) GGAGCTCTCT GAGCTCTCTG (SEQ ID NO: 701) AGCTCTCTGG GCTCTCTGGC (SEQ ID NO: 703) CTCTCTGGCT TCTCTGGCTA (SEQ ID NO: 705) CTCTGGCTAA TCTGGCTAAC (SEQ ID NO: 707) CTGGCTAACT TGGCTAACTA (SEQ ID NO: 709) GGCTAACTAG GCTAACTAGG (SEQ ID NO: 711) CTAACTAGGG TAACTAGGGA (SEQ ID NO: 713) AACTAGGGAA ACTAGGGAAC (SEQ ID NO; 715) CTAGGGAACC TAGGGAACCC (SEQ ID NO: 717) AGGGAACCCA GGGAACCCAC (SEQ ID NO: 719) :720 :722 :724 :726 :728 730 :732 :734 :736 :738 :740 ;742 :744 :746 :748 :750 :752 754 756 758 760 762 764 :766 :768 :770 :772 :774 :776 :778 :780 :782 :784 :786 :788 :790 TGACTCTGGT (SEQ ID NO:792) GACTCTGGTA (SEQ ID NO:793) ACTCTGGTAA (SEQ ID NO:794) CTCTGGTAAC (SEQ ID NO:795) TCTGGTAACT (SEQ ID NO:796) CTGGTAACTA (SEQ ID NO:797) TGGTAACTAG (SEQ ID NO:798) GGTAACTAGA (SEQ ID NO:799)

Inventors: COOPER DAVID, CROWE SUZANNE, DEACON NICHOLAS JOHN, LEARMONT JENNIFER CATHERINE, MCPHEE DALE ALAN, COOPER, DAVID, CROWE, SUZANNE, DEACON, NICHOLAS, JOHN, LEARMONT, JENNIFER, CATHERINE, MCPHEE, DALE, ALAN
Applicants: AUSTRALIAN RED CROSS, COOPER DAVID, CROWE SUZANNE, DEACON NICHOLAS JOHN, LEARMONT JENNIFER CATHERINE, MACFARLANE BURNET CTRE MED RES, MCPHEE DALE ALAN, AUSTRALIAN RED CROSS SOCIETY (NSW DIVISION), COOPER, DAVID, CROWE, SUZANNE, DEACON, NICHOLAS, JOHN, LEARMONT, JENNIFER, CATHERINE, MCPHEE, DALE, ALAN, THE MACFARLANE BURNET CENTRE FOR MEDICAL RESEARCH
Application year: 1995
Main classification: C12N7
IPC codes: A61K31, A61K39, A61P31, C07H21, C07K14, C12N7, C12N15, C12Q1, G01N33